Search by Journal
- HOME
- > Search by Journal
- > Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences
Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences
Volume , Issue suppl.1 / 2019
English Article 
Japanese Article- Please note that metadata of J-type articlesare generated by machine-translation and the original texts are written in Japanese.
|
CPL. It is concentration ... of the wisdom of ... pharmacy from this of the clinical pharmacy to take the new times on 武田泰生1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1-1, 2019. |
|---|
|
|
SL1. Expect it of hospital pharmacist 安川孝志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2-2, 2019. |
|---|
|
SL2. A global perspective on the future of pharmaceutical healthcare in hospital related settings Robert J. Moss1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 3-3, 2019. |
|---|
|
|
Medical seminar 1. How the pharmacist should be concerned with oral anticancer agent-treated patients; is ... MS01-1 led by ... Abemaciclib-treated patients 伊藤充矢1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 4-4, 2019. |
|---|
|
|
Medical seminar 1. How the pharmacist should be concerned with oral anticancer agent-treated patients; is ... MS01-2 led by ... Abemaciclib-treated patients 阪田安彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 5-5, 2019. |
|---|
|
|
Symposium 1. The evaluation of drug interactions, the condition of a patient time change that a drug transporter and a metabolism enzyme are involved in: Inflection of the biomarker 杉山雄一, 吉門崇 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 6-6, 2019. |
|---|
|
|
2-01-S01-1. Drug interaction (DDI) risk assessment based on the internal biomarker, Introduction 杉山雄一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 7-7, 2019. |
|---|
|
|
2-01-S01-2. Endogenous biomarker search to predict kidney transporter-mediated drug interactions 楠原洋之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 8-8, 2019. |
|---|
|
|
2-01-S01-3. Prediction based on the internal biomarker of DDI through the liver transporter 吉門崇1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 9-9, 2019. |
|---|
|
|
2-01-S01-4. Evaluation of the CYP3A activity at impaired renal function that assumed 4β-Hydroxycholesterol an index 鈴木陽介1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 10-10, 2019. |
|---|
|
|
Symposium 2. - pharmacist knows it for cancer genomic medicine new age 縄田修一, 櫻井洋臣 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 11-11, 2019. |
|---|
|
|
2-01-S02-1. The current situation of the cancer genomic medicine and future problem 四十物絵理子1, 西原広史1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 12-12, 2019. |
|---|
|
|
2-01-S02-2. Role of a cancer genomic medicine coordinator in the cancer genomic medicine core base Hospital and the pharmacist 竹野美沙樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 13-13, 2019. |
|---|
|
|
2-01-S02-3. To snuggle up to patients and the family who choose possible side effect - treatment by knowing the genetic information; - 鈴木美慧1, 深野智華1, 大川恵1,2, 出森彩乃1,2, 金井久子1,2, 山内英子1,3, 山中美智子1,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 14-14, 2019. |
|---|
|
|
2-01-S02-4. Efforts for the personnel training of the pharmacist concerned with cancer genomic medicine 櫻井洋臣1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 15-15, 2019. |
|---|
|
|
2-01-S02-5. It is ... mainly on the making of role - system of the pharmacist to refer patients in hope of an examination for cancer genome panel to a testable medical institution, education 縄田修一1,2,3, 西川徹3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 16-16, 2019. |
|---|
|
|
Symposium 3. Precaution and point - based on the example of advice - observational study of the study to be able to be carried out by clinical practice 百賢二, 城田幹生 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 17-17, 2019. |
|---|
|
|
2-02-S03-1. About clinical studies about Antimicrobial Stewardship Program (we work on antimicrobial proper use support) 村上修太郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 18-18, 2019. |
|---|
|
|
2-02-S03-2. Example of the observational study in the blood-forming organ tumor domain 安武夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 19-19, 2019. |
|---|
|
|
2-02-S03-3. Experience an observational study for the proper use of the pharmaceutical products that safe breaking news was delivered 石田耕太1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 20-20, 2019. |
|---|
|
|
2-02-S03-4. Research activities in the civilian Hospital thinking from the position of the young pharmacist 上野栞1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 21-21, 2019. |
|---|
|
|
2-02-S03-5. Observational study - about the medication adherence evaluation that added advice observational study - dosage form of medicine 百賢二1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 22-22, 2019. |
|---|
|
|
Symposium 4. Pharmaceutical approach through the example to a pregnant woman, a nursing mother with a mental disorder 赤嶺由美子, 伊差川サヤカ, 香西祥子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 23-23, 2019. |
|---|
|
|
2-02-S04-1. Fact-finding of the psychotropic drug medical treatment for a pregnant woman, the nursing mother 伊差川サヤカ1, 諸見牧子1, 与那覇房子1, 中村克徳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 24-24, 2019. |
|---|
|
|
2-02-S04-2. Antipsychotics and pregnant woman, nursing mother 山根律子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 25-25, 2019. |
|---|
|
|
2-02-S04-3. An antiepileptic drug (mood stabilizer) and pregnant woman, nursing mother 赤嶺由美子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 26-26, 2019. |
|---|
|
|
2-02-S04-4. To protect a pregnant woman and a baby; is ... about ... benzodiazepine system medicine 前田雅之1, 宮原芽久美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 27-27, 2019. |
|---|
|
|
2-02-S04-5. Luxury goods and pregnant woman, nursing mother with antidepressant and pregnant woman, nursing mother/mentation 香西祥子1,2,3, 河西邦浩1, 加藤育子3, 岡田仁3, 日下隆3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 28-28, 2019. |
|---|
|
|
Symposium 5. Dispatch ... from ... convalescent bed to test a role of the hospital pharmacist in the local inclusion care system 島田美樹, 菅原満 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 29-29, 2019. |
|---|
|
|
2-02-S05-1. The academic first subcommittee final report "participation of the hospital pharmacist in medical therapy in the convalescence and research of the usefulness in the local inclusion care system" 岸本真1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 30-30, 2019. |
|---|
|
|
2-02-S05-2. Role of the pharmacist in the local inclusion care ward 三澤貴美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 31-31, 2019. |
|---|
|
|
2-02-S05-3. Role - medication support of the pharmacist in the convalescence and at-home support ... 茂木徹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 32-32, 2019. |
|---|
|
|
2-02-S05-4. Prescription suggestion ... to medical care, the care environment after role - discharge of the pharmacist in the convalescence 藤原久登1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 33-33, 2019. |
|---|
|
|
Medical seminar 2. Antimicrobial proper use MS02 in 80% of GE pharmaceutical products posts era 北原隆志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 34-34, 2019. |
|---|
|
|
Symposium 1. The roles of pharmacists in the quality, efficacy, and safety of pharmaceuticals Yoshikazu Tasaki, Ryuji Ikeda, Bo Yu, Jung-Tae Kim, Hisashi Urushihara Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 35-35, 2019. |
|---|
|
|
2-03-IS01-1. The role of hospital pharmacists in ensuring the quality, efficacy, and safety of pharmaceutical therapy in Japan Atsumi Nishikori1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 36-36, 2019. |
|---|
|
|
2-03-IS01-2. Information technology helps the safety of medication during pregnancy Yong Yang1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 37-37, 2019. |
|---|
|
|
2-03-IS01-3. The evaluation of drug utilization review on potentially inappropriate medications for elderly patients in a tertiary hospital Yeo Hyang Cho1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 38-38, 2019. |
|---|
|
|
2-03-IS01-4. Transforming the Pharmacy Landscape in Singapore Lita Chew1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 39-39, 2019. |
|---|
|
|
Symposium 2. The roles of pharmacists in the quality, efficacy, and safety of pharmaceuticals Yoshikazu Tasaki, Ryuji Ikeda, Takeshi Akiyoshi, Makiko Iwasawa Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 40-40, 2019. |
|---|
|
|
2-03-IS02-1. Retrospective analysis of the correlation between tacrolimus whole blood concentrations and variations in blood cell counts in patients undergoing allogeneic haematopoietic stem cell transplantation Naoki Yoshikawa1, Shuhei Urata1, Kazuya Yasuda1, Hiroshi Sekiya1, Yasutoshi Hirabara1, Manabu Okumura1, Ryuji Ikeda1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 41-41, 2019. |
|---|
|
|
2-03-IS02-2. Study of Exposures to Pharmaceutical Dust After Grinding Tablets Takenori Tamaki1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 42-42, 2019. |
|---|
|
|
2-03-IS02-3. The role and meaning of Japanese pharmacist working in Developing country for UHC and SDGs Mitsuru Otsuka1, Kouji Okahashi1, Kanji Tomogane1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 43-43, 2019. |
|---|
|
|
2-03-IS02-4. Certified pharmacists in U.S.A., and training programs and certified pharmacists in Thailand Shinichi Masuda1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 44-44, 2019. |
|---|
|
|
2-03-IS02-5. Pharmacist-driven clinical studies on chemotherapy-induced nausea and vomiting Toshinobu Hayashi1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 45-45, 2019. |
|---|
|
|
Symposium 6. I want to go home even if I have medical care - Now is the time for pediatric home medical care where the true value of drug-drug cooperation is questioned - 串田一樹, 廣原正宜 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 46-46, 2019. |
|---|
|
|
2-04-S06-1. The current situation and problems of the childhood treatment at home 森脇浩一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 47-47, 2019. |
|---|
|
|
2-04-S06-2. Role of the hospital pharmacist in the childhood treatment at home 丹沢彩乃1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 48-48, 2019. |
|---|
|
|
2-04-S06-3. About relation of the childhood treatment at home 長谷川寛1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 49-49, 2019. |
|---|
|
|
2-04-S06-4. Problem of the childhood treatment at home 串田一樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 50-50, 2019. |
|---|
|
|
Medical seminar 3. It is ... MS03 based on relation ... medical institution of the pharmacist to the outpatient department chemotherapy that is safer, and is reliable and the cooperation between health insurance pharmacies 松井礼子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 51-51, 2019. |
|---|
|
|
Symposium 7. Replacement ... one or ... that what will occur in the drug section then of an electronic medical chart and the formulations system which cannot go when we avoid it 小枝伸行, 若林進 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 52-52, 2019. |
|---|
|
|
2-04-S07-1. Electronic medical chart not to be able to be accepted when we avoid it and ... to learn from replacement - success example of the formulations system, a failure example 若林進1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 53-53, 2019. |
|---|
|
|
2-04-S07-2. Do the function, truth need it? Approach ... at ... system update 岡橋孝侍1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 54-54, 2019. |
|---|
|
|
2-04-S07-3. As it is not used for update example - system of the drug section system in the AI era 佐藤弘康1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 55-55, 2019. |
|---|
|
|
2-04-S07-4. The system update is a chance of new duties construction and the problem rearranging 木村好伸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 56-56, 2019. |
|---|
|
|
2-04-S07-5. Is it the pharmaceutical products order that you do for what? ... single dose, advice ... of the use standardization 池田和之1,2, 和田良浩1,2, 川崎裕貴1, 小林慎治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 57-57, 2019. |
|---|
|
|
Symposium 8. Prepare for a disaster! Let's think about the role of pharmacists and their education in the event of a disaster - BRIDGE OVER TROUBLED WATER - 高山和郎, 小林政彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 58-58, 2019. |
|---|
|
|
2-04-S08-1. Disaster medical care and pharmacist support to spread 渡邉暁洋1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 59-59, 2019. |
|---|
|
|
2-04-S08-2. A role and cooperation of the pharmacist at disaster [efforts of Osaka] 若井聡智1, 辻野悦次2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 60-60, 2019. |
|---|
|
|
2-04-S08-3. Efforts from a time of peace when a pharmacist should do it for a disaster 谷大輔1, 小林政彦1, 中出雅治2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 61-61, 2019. |
|---|
|
|
2-04-S08-4. Refuge administration simulation education to specialty and a pharmacy student, a pharmacist of the disaster medical care education 安原智久1, 永田実沙1, 串畑太郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 62-62, 2019. |
|---|
|
|
Symposium 9. Proposal ... from ... pharmaceutical products proper use study to rise in the scientific viewpoint, and to ride out the perioperative period safely 畝井浩子, 北村佳久 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 63-63, 2019. |
|---|
|
|
2-05-S09-1. Pharmaceutical intervention point 畝井浩子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 64-64, 2019. |
|---|
|
|
2-05-S09-2. Perioperative infection measures 矢野貴久1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 65-65, 2019. |
|---|
|
|
2-05-S09-3. What a pharmacist can do for perioperative delirium - Past efforts and future considerations - 吉川明良1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 66-66, 2019. |
|---|
|
|
2-05-S09-4. Pharmacoepidemiology study in the perioperative domain utilizing the large-scale medical information database 座間味義人1,2, 石澤有紀3, 新村貴博1, 小山敏広4, 濱野裕章2, 岡田直人2, 合田光寛2, 武智研志5, 中馬真幸5, 堀ノ内裕也6, 桐野靖2, 中村敏己2, 寺岡和彦2, 石澤啓介1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 67-67, 2019. |
|---|
|
|
2-05-S09-5. Promotion ... of mentation change in the inflammatory state associated with the perioperative period and efficacy change - pharmaceutical products proper use of the central nerve agent 北村佳久1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 68-68, 2019. |
|---|
|
|
Medical seminar 4. Current situation of the cancer cachexia practice and fine-view MS04 高山浩一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 69-69, 2019. |
|---|
|
|
Symposium 10. ... which reconsiders central charge and crosstalk - efficiency and the cooperation with the ward charge pharmacist 赤嶺由美子, 三浦昌朋 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 70-70, 2019. |
|---|
|
|
2-05-S10-1. Purpose explanation 三浦昌朋1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 71-71, 2019. |
|---|
|
|
2-05-S10-2. The thing which the collaboration of a dispensary charge pharmacist and the ward charge pharmacist brings 大本暢子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 72-72, 2019. |
|---|
|
|
2-05-S10-3. Cooperation - with dispensary, efficiency in anticancer agent preparation duties and safe reinforcement - ward pharmacist 濱口直美1, 杉本浩子1, 世古口典子1, 岩本卓也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 73-73, 2019. |
|---|
|
|
2-05-S10-4. Therapeutic drug monitoring in the ward drug duties that a study laboratory supports 尾田一貴1, 岩村耕次1, 片野田朋美1, 成田勇樹1, 田上直美1, 城野博史1, 齋藤秀之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 74-74, 2019. |
|---|
|
|
2-05-S10-5. Cooperation with the central in the ward charge pharmacist viewpoint 加賀谷英彰1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 75-75, 2019. |
|---|
|
|
2-05-S10-6. It is the efforts of the institution mainly on operation ground or an injection, and the like 清川真美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 76-76, 2019. |
|---|
|
|
Symposium 11. It is not finished without knowing it globalization ... of the use of pharmaceutical products. How is opposite to carrying out travel and the regulation pharmaceutical products of the drug for the medical care; ... 石原千春, 橋本直弥 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 77-77, 2019. |
|---|
|
|
2-05-S11-1. About reporting of the pharmaceutical products regulation that we saw from a correspondence example to the carrying out travel of the drug for the medical care in the health insurance pharmacy and problems 石原千春1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 78-78, 2019. |
|---|
|
|
2-05-S11-2. With invention at drug carrying import and export permission application in our hospital, actually 橋本直弥1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 79-79, 2019. |
|---|
|
|
2-05-S11-3. About a system of the export by the carrying of drug for the medical care and medical psychotropic drugs and the import 坂西義史1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 80-80, 2019. |
|---|
|
|
2-05-S11-4. Regulation by the international treaty of the sleeping drug 鈴木勉1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 81-81, 2019. |
|---|
|
|
Symposium 12. Efforts and fusion by the basics, the clinical practice that aimed at the countermeasure of peripheral neuropathy with the cancer chemotherapy 江頭伸昭, 川尻雄大 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 82-82, 2019. |
|---|
|
|
2-06-S12-1. Clinical on-site problem and countermeasure 川上和宜1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 83-83, 2019. |
|---|
|
|
2-06-S12-2. The onset mechanism analysis and drug repositioning study of peripheral neuropathy with the cancer chemotherapy 中川貴之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 84-84, 2019. |
|---|
|
|
2-06-S12-3. Fundamental researches and the future prospects aiming at reduction, inhibition of peripheral neuropathy with oxaliplatin 川尻雄大1, 小林大介1, 牛尾聡一郎2, 江頭伸昭3, 島添隆雄1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 85-85, 2019. |
|---|
|
|
2-06-S12-4. Preventive preparation search for oxaliplatin-induced peripheral neuropathy utilizing the large-scale medical information database 合田光寛1,2, 座間味義人1,2, 新村貴博2, 川尻雄大3, 武智研志4, 中馬真幸4, 萱野純史1, 濱野裕章1, 岡田直人1, 小林大介3, 島添隆雄3, 石澤有紀5, 桐野靖1, 中村敏己1, 寺岡和彦1, 石澤啓介1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 86-86, 2019. |
|---|
|
|
2-06-S12-5. Inhibition of anticancer agent-induced peripheral neuropathy with the renin-angiotensin system inhibitor 高取真吾1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 87-87, 2019. |
|---|
|
|
Medical seminar 5. Bottom line MS05 of heart failure practice guidelines that a pharmacist knows it and is helpful 筒井裕之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 88-88, 2019. |
|---|
|
|
SL3. Change and security risk and mental attitude ... which the healthcare worker of thing - all whom DX brings in the medical settings should recognize 小屋松美佳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 89-89, 2019. |
|---|
|
|
SL4. Medical care of the AI era 木村通男1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 90-90, 2019. |
|---|
|
|
Symposium 13. Clinical pharmacy study to take the new times utilizing medical big data on 千堂年昭, 石澤啓介 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 91-91, 2019. |
|---|
|
|
2-06-S13-1. The study general remarks using medical big data 樋之津史郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 92-92, 2019. |
|---|
|
|
2-06-S13-2. Study example by the data inflection of the National level 小山敏広1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 93-93, 2019. |
|---|
|
|
2-06-S13-3. The database analysis study that started from the true clinical practice 今井徹1, 鈴木慎一郎1, 鷲巣晋作1, 木村高久1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 94-94, 2019. |
|---|
|
|
2-06-S13-4. From a viewpoint of attempt - psychiatry medical therapy of the application to pharmacist duties of large-scale side effect database - 江角悟1, 牛尾聡一郎1, 北村佳久1, 千堂年昭1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 95-95, 2019. |
|---|
|
|
2-06-S13-5. The mechanism elucidation of the drug-related side effect that fused with medical big data analysis in fundamental researches and development of the therapeutic drug 新村貴博1, 座間味義人1,2, 石澤有紀3, 合田光寛2, 武智研志4, 中馬真幸4, 福島圭穣5, 堀ノ内裕也6, 池田康将6, 藤野裕道5, 土屋浩一郎7, 石澤啓介1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 96-96, 2019. |
|---|
|
|
Medical seminar 6. It is MS06 about a factor and the prevention of the quality drop of the biomedicine 内山進1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 97-97, 2019. |
|---|
|
|
Medical seminar 7. Medical therapy MS07 of the Reiwa era 竹屋泰1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 98-98, 2019. |
|---|
|
|
Medical seminar 8. Latest medical treatment and drug proper use MS08-1. for the progress recurrence breast cancer The latest medical treatment for the progress recurrence breast cancer 徳永えり子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 99-99, 2019. |
|---|
|
|
Medical seminar 8. Latest medical treatment and drug proper use MS08-2. for the progress recurrence breast cancer Efforts for the drug proper use in the Kyushu cancer center 衛藤智章1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 100-100, 2019. |
|---|
|
|
Medical seminar 9. Local formula reenforcement and methodology MS09 今井博久1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 101-102, 2019. |
|---|
|
|
Medical seminar 10. Proper use - MS10-1. of challenge - thrombomodulin alfa to septicemic death ZERO We think about optimal treatment of the sepsis-related DIC 鈴木泰1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 103-103, 2019. |
|---|
|
|
Medical seminar 10. Proper use - MS10-2. of challenge - thrombomodulin alfa to septicemic death ZERO Contribution to proper use of genetically-modified thrombomodulin (rTM) in the sepsis-related DIC 安藝敬生1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 104-104, 2019. |
|---|
|
|
Symposium 14. Suggestion from the clinical pharmacy for the clinical application of the examination for pharmacogenomics 寺田智祐, 斎藤嘉朗 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 105-105, 2019. |
|---|
|
|
2-12-S14-1. Personalized medicine and pharmacogenomics - current situation and problem ... 斎藤嘉朗1, 塚越絵里1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 106-106, 2019. |
|---|
|
|
2-12-S14-2. Prediction of the side effect of examination for HLA expression risk 莚田泰誠1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 107-107, 2019. |
|---|
|
|
2-12-S14-3. The latest PGx study: Side effect of STAT3 genetic polymorphism and the molecular target type anticancer medicine 山本和宏1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 108-108, 2019. |
|---|
|
|
2-12-S14-4. Sensitivity to NUDT15 genetic polymorphism and thiopurine preparation 田中庸一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 109-109, 2019. |
|---|
|
|
2-12-S14-5. The inflection situation of the examination for pharmacogenomics in the true clinical practice 平大樹1, 辻大樹2, 齋藤嘉朗3, 莚田泰誠4, 三浦昌朋5, 寺田智祐6 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 110-110, 2019. |
|---|
|
|
Medical seminar 11. Proper use of transfusion and the plasma derivative and future fine-view MS11 米村雄士1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 111-111, 2019. |
|---|
|
|
Symposium 15. What a pharmacist should really send him out for for optimal antithrombotic therapy in consideration of risk benefit? 石井伊都子, 土岐真路 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 112-112, 2019. |
|---|
|
|
2-12-S15-1. Adherence aid of the blood rustle to have liked to ask a pharmacist for from a physician 南圭祐1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 113-113, 2019. |
|---|
|
|
2-12-S15-2. Key to solution that "a pharmacist" regards as a current problem over the antithrombotic therapy 土岐真路1, 横溝綾子1, 北山知里1, 浅海夕貴1, 前田幹広1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 114-114, 2019. |
|---|
|
|
2-12-S15-3. Proper use of DOAC in consideration of PK / PD - Thoroughly DOAC and PK / PD - 山口洪樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 115-115, 2019. |
|---|
|
|
2-12-S15-4. How should the pharmacist step into the combination of antithrombocytic agent and anticoagulant? What changes by ... guidelines revision? ... 芦川直也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 116-116, 2019. |
|---|
|
|
2-12-S15-5. How do you think about new problem of the DOAC era, Overdose/Underdose? 堀内望1, 野崎歩1, 小林由佳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 117-117, 2019. |
|---|
|
|
2-12-S15-6. Term ... of the magic that fact/pharmacist of the understanding degree of ... patients hangs local power aiming at the adherence improvement of the antithrombotic drug 宮崎元康1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 118-118, 2019. |
|---|
|
|
Symposium 16. The revision of "the duties manual for use of security of pharmaceutical products" and the utilization 小枝伸行, 岸本真 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 119-119, 2019. |
|---|
|
|
2-12-S16-1. Point to keep in mind about the use and application of "the duties manual making manual revised edition" on the basis of revisions, and the like of the medicine machine method, the Pharmacist Law 土屋文人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 120-120, 2019. |
|---|
|
|
2-12-S16-2. Visualization - of the duties manual with inflection - process flowchart of the medical safe manual in the small and medium size hospital 酒向幸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 121-121, 2019. |
|---|
|
|
2-12-S16-3. Duties manual revision work for safe use of the pharmaceutical products which we performed in cooperation with medical safe Management Department and future problem 高橋弘充1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 122-122, 2019. |
|---|
|
|
2-12-S16-4. About the simplification that suppressed the key point of the pharmaceutical products safety management manual in the cottage-hospital in the medical treatment type 近藤幸男1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 123-123, 2019. |
|---|
|
|
Symposium 17. A role and the future prospects of the current pharmaceutical products source of information in the objective pharmaceutical products evaluation 後藤伸之, 冨田隆志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 124-124, 2019. |
|---|
|
|
2-13-S17-1. The revision point of the package insert mention point and utilization method to expect 後藤伸之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 125-125, 2019. |
|---|
|
|
2-13-S17-2. The revision point of the interview form mention point and utilization method to expect 冨田隆志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 126-126, 2019. |
|---|
|
|
2-13-S17-3. It is ... from ... pharmaceutical products evaluation making use of RMP to patients care 川名真理子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 127-127, 2019. |
|---|
|
|
2-13-S17-4. We read and untie a report by a deliberative committee, an application material summary some other time 荒義昭1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 128-128, 2019. |
|---|
|
|
Medical seminar 12. How to use front line - palonosetron and aprepitant - MS12 of the supportive care for Chemotherapy Induced Nausea and Vomiting 吉田直久1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 129-129, 2019. |
|---|
|
|
Symposium 18. The leading viewpoint that a study leader should have to solve a clinical problem in the cancer chemotherapy 橋本浩伸, 河添仁 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 130-130, 2019. |
|---|
|
|
2-13-S18-1. Encounter with the study leader before pharmacy school life making a clinical problem the article 内田真美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 131-131, 2019. |
|---|
|
|
2-13-S18-2. As the education person in charge, obtained it by the study instruction for the young pharmacist; learn 橋本浩伸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 132-132, 2019. |
|---|
|
|
2-13-S18-3. Strategy to publish a rearward observational study in the learned journal with high impact factor 河添仁1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 133-133, 2019. |
|---|
|
|
2-13-S18-4. Point ... of know-how - manuscript making of the article contribution and the revice 大谷壽一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 134-134, 2019. |
|---|
|
|
Symposium 19. It is ... from the discovery of extract - side effect to manage an allergy, the side effect of patients well to management, a report 小枝伸行, 関谷泰明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 135-135, 2019. |
|---|
|
|
2-13-S19-1. Side effects, and the like about the use, and the like of the summary of the report system and the reported information 岩崎麻美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 136-136, 2019. |
|---|
|
|
2-13-S19-2. What kind of side effect should you report? Inflection method in the clinical practice of the side effect report 土屋雅美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 137-137, 2019. |
|---|
|
|
2-13-S19-3. About the inflection of collection and data of the information on adverse drug reactions 望月伸夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 138-138, 2019. |
|---|
|
|
2-13-S19-4. A collection activity of the information on adverse drug reactions for the early detection and future efforts 男全昭紀1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 139-139, 2019. |
|---|
|
|
2-13-S19-5. Problems in uniform management and the system management of the side effect in the pharmacy 高橋正明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 140-140, 2019. |
|---|
|
|
Symposium 20. How do you confront the needs of the pharmacist that the future of the international contribution of the pharmacist is required word no hearing - disaster relief and development cooperation? 小林政彦, 折井孝男 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 141-141, 2019. |
|---|
|
|
2-14-S20-1. In the case of change - Medecins Sans Frontieres of the medical assistance settings for the urgent humanitarian crisis 黒崎伸子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 142-142, 2019. |
|---|
|
|
2-14-S20-2. Than experience in role - Middle East and Africa as venture management and the health coordinator in the humanitarian support of the International Red Cross 五十嵐真希1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 143-143, 2019. |
|---|
|
|
2-14-S20-3. An example of the carrier management of the small and medium size scale hospital pharmacist participating in an overseas medical assistance activity 榊原英朗1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 144-144, 2019. |
|---|
|
|
2-14-S20-4. Work work balance in a challenge and personnel training - normal business routine and international relief duties to medical logistics in the disaster relief 小林映子1, 石田耕太2, 細谷治2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 145-145, 2019. |
|---|
|
|
Medical seminar 13. One or ... MS13 where there is what as - pharmacist in the cancer genomic medicine first year 寺田智祐1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 146-146, 2019. |
|---|
|
|
Symposium 21. Development of the hospitalization and release support task by all pharmacists connecting to the living of patients 室井延之, 荒木隆一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 147-147, 2019. |
|---|
|
|
2-14-S21-1. Role of medical therapy and the pharmacist connecting to the area from a hospital 室井延之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 148-148, 2019. |
|---|
|
|
2-14-S21-2. Way of thinking, process of role - medical care cooperation ... of the hospital pharmacist supporting community medical care 荒木隆一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 149-149, 2019. |
|---|
|
|
2-14-S21-3. From Hyogo to the whole country, we think about new cooperation from drugstore vision business 吉田昌弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 150-150, 2019. |
|---|
|
|
2-14-S21-4. ... to tie medical care, care cooperation - pharmaceutical support by the inflection of the drug control summary at a discharge, and to tie to the living of patients 澁田憲一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 151-151, 2019. |
|---|
|
|
Symposium 22. Examination modality ... necessary for an evaluation of competency - medical therapy that went step further sought by the pharmacist of the circulatory organ domain 柴田啓智, 志賀剛 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 152-152, 2019. |
|---|
|
|
2-14-S22-1. Pharmacist activity brought about by Modality - Echo possibility - 柴田啓智1, 甲斐光1, 大山亜梨沙1, 西村知晃1, 田上治美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 153-153, 2019. |
|---|
|
|
2-14-S22-2. An electrocardiogram evaluation and the arrhythmic pharmaceutical management that are demanded from a pharmacist 梶原洋文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 154-154, 2019. |
|---|
|
|
2-14-S22-3. The condition of a patient evaluation of patients to arrest from a medical history, physical examination, vital sign generally and the pharmaceutical management 北原加奈之1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 155-155, 2019. |
|---|
|
|
2-14-S22-4. Competency of the circulatory organ medical therapy to expect of a pharmacist 志賀剛1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 156-156, 2019. |
|---|
|
|
Symposium 23. [cure association arts and sciences Committee] Upbringing of the ability for drug interactions management in the healthcare setting 米澤淳, 伊藤清美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 157-157, 2019. |
|---|
|
|
2-15-S23-1. Making - academic first subcommittee activity report ... of "the relation guide to the drug interactions in the healthcare setting" 伊藤清美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 158-158, 2019. |
|---|
|
|
2-15-S23-2. Activity plan ... of the upbringing - clinical pharmacy academic fourth subcommittee of the ability for drug interactions management in the healthcare setting 米澤淳1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 159-159, 2019. |
|---|
|
|
2-15-S23-3. Inflection method of PISCS in the drug interactions management 大野能之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 160-160, 2019. |
|---|
|
|
2-15-S23-4. Utilization and problem of the drug interactions evidence in clinical settings 木村丈司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 161-161, 2019. |
|---|
|
|
2-15-S23-5. The management utilizing the DDI database 増田純一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 162-162, 2019. |
|---|
|
|
Medical seminar 14. Dr. Efficiency MS14-1 of the JOY X intelligence 村松博1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 163-163, 2019. |
|---|
|
|
Symposium 24. Basic medical treatment in the intensive care that we want to hold down now 加藤隆寛, 原直己 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 164-164, 2019. |
|---|
|
|
2-15-S24-1. Basic medical treatment in patients with cerebral hemorrhage 若杉和美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 165-165, 2019. |
|---|
|
|
2-15-S24-2. Is the evidence usable? Medical treatment of acute myocardial infarction 奥川寛1, 馬橋美由季1, 堀内望1, 野崎歩1, 小林由佳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 166-166, 2019. |
|---|
|
|
2-15-S24-3. Mainly on prophylactic medical therapy - stress ulcer, deep vein thrombosis - 川邊一寛1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 167-167, 2019. |
|---|
|
|
2-15-S24-4. A pharmacist can do it; with evidence of the nourishment management, actually! 川口奈奈子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 168-168, 2019. |
|---|
|
|
2-15-S24-5. With the viewpoint of the pharmacist who is necessary for PADIS management? 勝綾香1, 中薗健一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 169-169, 2019. |
|---|
|
|
2-15-S24-6. Where is the medical treatment in the intensive care standardized to? 加藤隆寛1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 170-170, 2019. |
|---|
|
|
Symposium 25. Art to write a record to be handed down to offer better medical treatment 寺沢匡史, 坂野昌志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 171-171, 2019. |
|---|
|
|
2-15-S25-1. From a viewpoint of thing - medical care security sought by a record to be handed down definitely - 高野秀仁1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 172-172, 2019. |
|---|
|
|
2-15-S25-2. Art of mention of "A" (assessment) not to be troubled with anymore 寺沢匡史1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 173-173, 2019. |
|---|
|
|
2-15-S25-3. Art - to tell DI and cooperation and mention - necessary information of the ward pharmacist of the record at reporting to a physician precisely 佐村優1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 174-174, 2019. |
|---|
|
|
2-15-S25-4. With the art of the record to be able to make use of in ward drug duties? 眞継賢一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 175-175, 2019. |
|---|
|
|
2-15-S25-5. It is ... based on the intervention example to patients with ... outpatient department cancer that a book asks for seamless records from hospitalization to the outpatient department 菅野雄太1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 176-176, 2019. |
|---|
|
|
2-15-S25-6. Drug control summary for cooperation between institutions to tell him/her about from the southernmost tip 小杉卓大1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 177-177, 2019. |
|---|
|
|
Symposium 26. What would you do at such time? The blood sugar control that a specialized pharmacist thinks about 厚田幸一郎, 竹内裕紀 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 178-178, 2019. |
|---|
|
|
2-16-S26-1. Of duties for the safety management of the blood glucose level is annual, and consider - aging; and ... 藤井博之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 179-179, 2019. |
|---|
|
|
2-16-S26-2. Diabetes and cancer Aiming for a well-balanced therapeutic relationship 根本真記1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 180-180, 2019. |
|---|
|
|
2-16-S26-3. Advice of the blood sugar control practice depending on renal function to change 堀井剛史1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 181-181, 2019. |
|---|
|
|
2-16-S26-4. What would you do at such time? Blood sugar control in the perioperative period 柴田啓智1, 吉田愛1, 北岡朋子1, 田中忠宏1, 田上治美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 182-182, 2019. |
|---|
|
|
Symposium 27. It is ... by the intervention that one step stepped into for hypogonadism with contribution ... treatment of the pharmacist to patients with AYA generation cancer 米村雅人, 日置三紀 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 183-183, 2019. |
|---|
|
|
2-16-S27-1. Team approach in medical care of AYA generation cancer 清水千佳子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 184-184, 2019. |
|---|
|
|
2-16-S27-2. Contribution of the pharmacist to the male AYA patients 小室雅人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 185-185, 2019. |
|---|
|
|
2-16-S27-3. Contribution of the pharmacist to the female AYA patients 日置三紀1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 186-186, 2019. |
|---|
|
|
2-16-S27-4. Simulated patient (SP) participation type education for medication support in deference to communication ... patients including sensitive contents 有田悦子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 187-187, 2019. |
|---|
|
|
Symposium 28. Wide achievement of the pharmacist in the pediatric domain 冨家俊弥, 小高賢一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 188-188, 2019. |
|---|
|
|
2-16-S28-1. In the settings of AMR measures 由留部圭伍1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 189-189, 2019. |
|---|
|
|
2-16-S28-2. The team approach in medical care that an NICU ward pharmacist aims at 灘谷直実1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 190-190, 2019. |
|---|
|
|
2-16-S28-3. Relation of the pharmacist in the childhood palliative care 坂田和佳子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 191-191, 2019. |
|---|
|
|
2-16-S28-4. A pharmacist can do it through allergic disease for children 上荷裕広1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 192-192, 2019. |
|---|
|
|
Symposium 29. It is each role for/Precision Medicine from this of the hospital pharmacist taking cancer personalized medicine 野村久祥, 辻大樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 193-193, 2019. |
|---|
|
|
3-01-S29-1. Experience of the examination for gene panel in the national cancer research center east Hospital 向原徹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 194-194, 2019. |
|---|
|
|
3-01-S29-2. As a pharmaceutical support cancer genomic medicine coordinator to personalized medicine 上本剛1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 195-195, 2019. |
|---|
|
|
3-01-S29-3. Personalized medicine of the pharmaceutical viewpoint by the clinical pharmacist 野村久祥1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 196-196, 2019. |
|---|
|
|
3-01-S29-4. It is ... for a case by a risk factor search of individualization - neutropenia of the side effect management in the cancer chemotherapy 矢野良一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 197-197, 2019. |
|---|
|
|
3-01-S29-5. Individualization for the supportive care of the cancer medical therapy 辻大樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 198-198, 2019. |
|---|
|
|
Medical seminar 15. Development MS15 of innovative antibody pharmaceutical products by the evolution of the antibody engineering technique and the adaptation 根津淳一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 199-199, 2019. |
|---|
|
|
Symposium 30. Secret ... which intervenes in the multidrug therapy of patients in polypharmacy - CKD to cut in "kidney" 平田純生, 浦田元樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 200-200, 2019. |
|---|
|
|
3-01-S30-1. Overview: Are the patients in CKD polypharmacy? 浦田元樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 201-201, 2019. |
|---|
|
|
3-01-S30-2. The secret of the need and the management of the multidrug therapy of the preservation period CKD patients to think about from evidence 鈴木大介1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 202-202, 2019. |
|---|
|
|
3-01-S30-3. The secret to learn in an example, and to intervene in the polypharmacy of patients with CKD for the preservation period 小林豊1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 203-203, 2019. |
|---|
|
|
3-01-S30-4. The secret to learn in an example, and to intervene in the polypharmacy of patients on dialysis 早川兼司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 204-204, 2019. |
|---|
|
|
3-01-S30-5. It is a topic and the phosphate binder that it is in the polypharmacy of patients on dialysis re-inspection 吉田拓弥1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 205-205, 2019. |
|---|
|
|
Symposium 31. Foundations of antiinfection medicine which a pharmacist should know and practical how to use antimicrobial proper use support team 松元一明, 西圭史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 206-206, 2019. |
|---|
|
|
3-01-S31-1. Antimicrobiogram and anti-VAIO gram 浦上宗治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 207-207, 2019. |
|---|
|
|
3-01-S31-2. Use and administration plan of the MRSA infection therapeutic drug 植田貴史1, 竹末芳生1, 中嶋一彦1, 一木薫1, 石川かおり1, 高井喜子1, 和田恭直1, 山田久美子1, 土田敏恵1, 高橋佳子2, 石原美佳2, 木村健2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 208-208, 2019. |
|---|
|
|
3-01-S31-3. ESBL-producing infection treatment up to date 松元一明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 209-209, 2019. |
|---|
|
|
3-01-S31-4. Practice of CDI infection treatment 茂見茜里1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 210-210, 2019. |
|---|
|
|
3-01-S31-5. Mainly on a spectrum and the use - azole system medicine of the antifungal agent - 浜田幸宏1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 211-211, 2019. |
|---|
|
|
Symposium 32. Drug discovery, Ikuyaku study - image of future pharmacist ... which solves the problems that we found in the viewpoint of the pharmacist building evidence by oneself 松元一明, 永田将司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 212-212, 2019. |
|---|
|
|
3-02-S32-1. The pharmacist image that is sought in the future from the present by a hospital, a drugstore pharmacist 安川孝志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 213-213, 2019. |
|---|
|
|
3-02-S32-2. Consideration through the activity by the pharmaceutical viewpoint with the drugstore in the area as a base 手嶋無限1,2,4, 中嶋幹郎2,4, 徳永仁3,4, 狭間研至4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 214-214, 2019. |
|---|
|
|
3-02-S32-3. Clinical pharmacy study in the drugstore 堀里子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 215-215, 2019. |
|---|
|
|
3-02-S32-4. Mission of the hospital pharmacist contributing to medical therapy 永田将司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 216-216, 2019. |
|---|
|
|
3-02-S32-5. ... that clinical pharmacy study - package insert in the hospital becomes the hint of the study 高田龍平1, 山梨義英1, 伊藤(松岡)紗代1, 豊田優1, 山本武人1, 鈴木洋史1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 217-217, 2019. |
|---|
|
|
Medical seminar 16. Device MS16 of the medication counseling of the Chinese medicine 船戸元子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 218-218, 2019. |
|---|
|
|
Symposium 33. It is ... for role - seamless pharmaceutical intervention of the pharmacist corresponding to the drugstore with the extensive pharmaceutical function in the cancer domain 松井礼子, 安原眞人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 219-219, 2019. |
|---|
|
|
3-02-S33-1. ... which looks back on the cooperation with the drugstore than the purpose of ... symposium than position of the hospital pharmacist 松井礼子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 220-220, 2019. |
|---|
|
|
3-02-S33-2. Than an administrative viewpoint "the pharmacist of a drugstore and the hospital coping by the revisions such as the medicine machine methods, and the like" 三山由芙子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 221-221, 2019. |
|---|
|
|
3-02-S33-3. Than position of the hospital pharmacist is ... around medical cooperation - PBPM in the cancer chemotherapy with the neighborhood ethical pharmacy 縄田修一1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 222-222, 2019. |
|---|
|
|
3-02-S33-4. Than the position of the health insurance pharmacy pharmacist 久田健登1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 223-223, 2019. |
|---|
|
|
Symposium 34. ... which thinks about pharmaceutical care of role - cardiovascular disease of the pharmacist in the heart rehabilitation 吉国健司, 神村英利 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 224-224, 2019. |
|---|
|
|
3-02-S34-1. About the role of the pharmacist whom the role physician of the pharmacist in the heart rehabilitation expects 折口秀樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 225-225, 2019. |
|---|
|
|
3-02-S34-2. A role and exercise drug linkage of the physical therapist in the heart rehabilitation 花田智1, 岩切弘直2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 226-226, 2019. |
|---|
|
|
3-02-S34-3. "Pharmacist of medical treatment and heart rehabilitation and the bedside" - ward pharmacist and collaboration - that the heart rehabilitation is wonderful 土岐真路1, 武市尚也2, 木田圭亮3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 227-227, 2019. |
|---|
|
|
3-02-S34-4. Adjustment ... of the medicine about relation ... coronary risk factor of the pharmacist to foreign heart rehabilitation 向井一樹1, 無漏田香穂1, 大原由希子1, 橋本佳浩1, 本間智明2, 小林平2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 228-228, 2019. |
|---|
|
|
Symposium 35. We will consider the optimal direction for uses of the inhalant as multidirectional approach - pharmacist aiming at proper use of the inhalant 長井紀章, 平大樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 229-229, 2019. |
|---|
|
|
3-03-S35-1. Respiratory illness that inhalation therapy plays a key role of the medical therapy 福岡和也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 230-230, 2019. |
|---|
|
|
3-03-S35-2. Role of the hospital pharmacist in the inhalational instruction 尾上雅英1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 231-231, 2019. |
|---|
|
|
3-03-S35-3. Inhalational cooperation "Shiga inhalation therapy cooperation forum" in Shiga 永井智宏1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 232-232, 2019. |
|---|
|
|
3-03-S35-4. Practice of the inhalant study aiming at clinical on-site utilization 平大樹1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 233-233, 2019. |
|---|
|
|
3-03-S35-5. Transpulmonary applied - of the recent transpulmonary DDS development status - drug carrier 田原耕平1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 234-234, 2019. |
|---|
|
|
Medical seminar 17. New stem cell preparation (products such as regenerative therapy, and the like) MS17 for patients with spinal cord injury 佐々木祐典1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 235-235, 2019. |
|---|
|
|
Symposium 36. Importance of the moisturizing preparation in clinical settings and transdermal application preparation 内野智信, 徳留嘉寛 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 236-236, 2019. |
|---|
|
|
3-03-S36-1. Importance of the moisture retention in the skin physiology 正木仁1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 237-237, 2019. |
|---|
|
|
3-03-S36-2. How to use right moisturizer forming strong skin 大谷道輝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 238-238, 2019. |
|---|
|
|
3-03-S36-3. Efforts for the dry skin care in EGFR tyrosine kinase inhibitor (EGFR-TKI) 瀧口友美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 239-239, 2019. |
|---|
|
|
3-03-S36-4. Dosage form design of the moisturizing preparation which a pharmaceutical company thinks about 小澤洋介1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 240-240, 2019. |
|---|
|
|
3-03-S36-5. A moisturizing product and the design that cosmetics company thinks about 坂田修1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 241-241, 2019. |
|---|
|
|
3-03-S36-6. Coming percutaneous absorption type preparation (containing the moisturizing preparation) 杉林堅次1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 242-242, 2019. |
|---|
|
|
Symposium 37. Should do what to provide relief, safe medical therapy at rebuilding - small scale hospital of the drug duties in the small hospital; or ... 賀勢泰子, 荒木隆一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 243-243, 2019. |
|---|
|
|
3-03-S37-1. Some viewpoints that hospital pharmacist in the future should face each other 小枝伸行1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 244-244, 2019. |
|---|
|
|
3-03-S37-2. Cottage-hospital pharmacist being able to do it as making match to being at home ... from the duties revolution acute phase of the cottage-hospital duty pharmacist, the thing that you should do 園田利広1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 245-245, 2019. |
|---|
|
|
3-03-S37-3. The future of the medical therapy support for elderly people 森直樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 246-246, 2019. |
|---|
|
|
3-03-S37-4. Evidence construction ... from efforts - clinical duties, study to offer safe medical therapy to the seriously disabled child person 森本真仁1, 浜田茂明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 247-247, 2019. |
|---|
|
|
3-03-S37-5. The future of the small hospital pharmacist judging from drug section management 上野山周雄1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 248-248, 2019. |
|---|
|
|
3-03-S37-6. Message to small scale hospital pharmacist taking community medical care 荒木隆一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 249-249, 2019. |
|---|
|
|
Symposium 38. To bring up the young person who can play an active part in the clinical duties 安武夫, 伊藤佳織 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 250-250, 2019. |
|---|
|
|
3-04-S38-1. Young upbringing of the ward pharmacist using the Step-up system 伊藤佳織1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 251-251, 2019. |
|---|
|
|
3-04-S38-2. "Advice" for upbringing of a student and the young pharmacist 柏倉康治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 252-252, 2019. |
|---|
|
|
3-04-S38-3. Foreign cancer medical therapy: Yell from a mom pharmacist 藤堂真紀1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 253-253, 2019. |
|---|
|
|
3-04-S38-4. Clinical questions found in clinical practice 百賢二1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 254-254, 2019. |
|---|
|
|
3-04-S38-5. Let's review On-the-Job Training 土手賢史1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 255-255, 2019. |
|---|
|
|
Medical seminar 18. Have a pharmacist know it by short statue treatment; drum and - short stature and problem of the heart, Biosimilar - MS18 堀川玲子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 256-256, 2019. |
|---|
|
|
Symposium 39. It is ... expecting the development of a TDM study, the clinical application by solution to clinical question - clinical pharmacist utilizing the TDM 尾田一貴, 三浦昌朋 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 257-257, 2019. |
|---|
|
|
3-04-S39-1. Usefulness of the TDM in the oral molecular target anticancer agent of the blood-forming organ tumor domain 鐙屋舞子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 258-258, 2019. |
|---|
|
|
3-04-S39-2. Solution to clinical question by the clinical operation of the TDM enforcement system utilizing the HPLC 尾田一貴1,2, 岩村耕次1, 片野田朋美1,2, 成田勇樹1, 野坂生郷2, 城野博史1, 齋藤秀之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 259-259, 2019. |
|---|
|
|
3-04-S39-3. The example that deepened understanding to the pharmacokinetics of the patients individual by TDM, and was able to contribute to treatment strategy decision 八島秀明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 260-260, 2019. |
|---|
|
|
3-04-S39-4. Practice of the TDM which intended the medical treatment management 潮平英郎1, 伊差川サヤカ1, 諸見牧子1, 与那覇房子1, 中村克徳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 261-261, 2019. |
|---|
|
|
3-04-S39-5. The clinical question and consideration which were found by a case of the acute drug intoxication 榎屋友幸1, 今井寛2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 262-262, 2019. |
|---|
|
|
Symposium 40. Do you not feel anxiety for correspondence to the foreign patients? To step forward to initial one step? What should I do? 高田勝利, 吉山友二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 263-263, 2019. |
|---|
|
|
3-04-S40-1. The concentration of the wisdom for the correspondence to the foreign patients who will be helpful from now on 吉山友二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 264-264, 2019. |
|---|
|
|
3-04-S40-2. The foreign patients correspondence in the national international medical research center hospital and efforts of the pharmacy 坂本治彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 265-265, 2019. |
|---|
|
|
3-04-S40-3. Even if only Japanese is possible, let's use the help item, and and, at first, OK will step forward one step happily! 池浦恵1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 266-266, 2019. |
|---|
|
|
3-04-S40-4. Because a foreign player receives medical care in Japan, have a pharmacist 笠師久美子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 267-267, 2019. |
|---|
|
|
3-04-S40-5. Intellect understands a medical interpreter. We help with the potentially serious medical errors cancellation of the workplace. 森田直美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 268-268, 2019. |
|---|
|
|
Symposium 41. Pharmaceutical products safety measures: - to think about the use and application of - big data "from now on" because "we came to here" 折井孝男, 高田敦史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 269-269, 2019. |
|---|
|
|
3-05-S41-1. About the situation of administration, the management of MID-NET 金子明依1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 270-270, 2019. |
|---|
|
|
3-05-S41-2. Evaluation of a pharmacoepidemiology study and the pharmacist duties using the medical database 小原拓1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 271-271, 2019. |
|---|
|
|
3-05-S41-3. Expectation ... from data mapping to need of the standardization that we were able to see and process - big data use and application 横山威一郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 272-272, 2019. |
|---|
|
|
3-05-S41-4. Possibility and expectation of the common understanding and same method of the person concerned concerned with "the next-generation medical base method" 佐々木正大1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 273-273, 2019. |
|---|
|
|
Medical seminar 19. Merit - MS19 of treatment strategy - Biosimilar medicine for HER2-positive breast cancer 新田吉陽1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 274-274, 2019. |
|---|
|
|
Symposium 42. Viewpoint of the pharmacist of the intensive care domain for the yew logic emergency and the pharmacist of the cancer domain 土手賢史, 前田幹広 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 275-275, 2019. |
|---|
|
|
3-05-S42-1. Approach to patients with solid carcinoma of sepsis 東加奈子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 276-276, 2019. |
|---|
|
|
3-05-S42-2. Cardiotoxicity of the anticancer medicine becoming a cause, the precipitants for heart failure 土手賢史1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 277-277, 2019. |
|---|
|
|
3-05-S42-3. Patients with cancer are ... from the situation of septic shock - intensive care to meet 安藝敬生1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 278-278, 2019. |
|---|
|
|
3-05-S42-4. Acute heart failure to develop in anticancer medicine-treated patients 原直己1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 279-279, 2019. |
|---|
|
|
Symposium 43. Measures to immune-mediated adverse event (irAE) with the immune checkpoint inhibitor and medical cooperation 渡邊裕之, 林祐一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 280-280, 2019. |
|---|
|
|
3-05-S43-1. Immune-mediated adverse event (irAE) and the measures 池末裕明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 281-281, 2019. |
|---|
|
|
3-05-S43-2. It is ... from practice of the team approach in medical care in efforts - Gifu University faculty of medicine hospital of the pharmacist to the immune-mediated adverse event management 飯原大稔1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 282-282, 2019. |
|---|
|
|
3-05-S43-3. The irAE management by regional alliances 南晴奈1, 渡邊裕之1, 池田宗彦1, 秦晃二郎1, 増田智先1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 283-283, 2019. |
|---|
|
|
3-05-S43-4. Diagnosis, treatment for medical understanding about irAE and serious irAE 林祐一1, 飯原大稔2, 鈴木昭夫2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 284-284, 2019. |
|---|
|
|
PL. Efforts and problem for the further development of the Japanese cure association 奥田真弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 285-285, 2019. |
|---|
|
|
About the review of authorization, the specialized pharmacist system in the Japanese cure association and a new system design 寺田智祐1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 286-286, 2019. |
|---|
|
|
Medical seminar 20. Characteristic and how to use MS20 of the antiparkinsonism drug 橋口昭大1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 287-287, 2019. |
|---|
|
|
SL5. Cerebral cortex neural circuit reorganization at the condition of a patient due to the glia cells: Mainly on chronic pain 鍋倉淳一1,2, 竹田育子1, 江藤圭1,2, 和氣弘明3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 288-288, 2019. |
|---|
|
|
SL6. Medication Safety in a Complex Oncology Landscape Stephen Harnicar1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 289-290, 2019. |
|---|
|
|
SL7. History and the future of the lung cancer medical therapy 中西洋一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 291-291, 2019. |
|---|
|
|
Medical seminar 21. Effect MS21 that a deglutition adjuvant product gives to the disintegration of various tablets 富田隆1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 292-292, 2019. |
|---|
|
|
Medical seminar 22. New development MS22 of the HER2-positive breast cancer medical therapy 高野利実1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 293-293, 2019. |
|---|
|
|
Medical seminar 23. Thing - MS23 to think of as ... pharmacist about use of magnesium oxide 堀美智子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 294-294, 2019. |
|---|
|
|
Medical seminar 24. It is ... MS24-1 mainly on real - standard treatment and adverse event management of the digestive organ cancer medical therapy 山崎健太郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 295-295, 2019. |
|---|
|
|
Medical seminar 24. It is ... MS24-2 mainly on real - standard treatment and adverse event management of the digestive organ cancer medical therapy 石川寛1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 296-296, 2019. |
|---|
|
|
Symposium 44. Pharmaceutical products safe sexological advice - pharmacist playing a clinical role on the site is ... from this aiming 佐藤光利, 宇野勝次 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 297-297, 2019. |
|---|
|
|
3-12-S44-1. We aim at the social contribution through pharmacist (DSSP) specialized in pharmaceutical products safety 宇野勝次1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 298-298, 2019. |
|---|
|
|
3-12-S44-2. Medical therapy support in consideration of pharmacokinetics 前田頼伸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 299-299, 2019. |
|---|
|
|
3-12-S44-3. Drug-related nephropathic assessment 平田純生1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 300-300, 2019. |
|---|
|
|
3-12-S44-4. Side effect measures of pharmaceutical products using PK/PD/PGx analysis 北市清幸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 301-301, 2019. |
|---|
|
|
3-12-S44-5. Because a drugstore pharmacist secures safety of medicine, can do it 近藤悠希1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 302-302, 2019. |
|---|
|
|
Medical Seminar 25. Formulary - A New Role for Pharmacists - MS25 神村英利1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 303-303, 2019. |
|---|
|
|
Symposium 45. We think about a theory of the multidrug therapy across a disease from a pharmaceutical point of view 竹内裕紀, 井上岳 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 304-304, 2019. |
|---|
|
|
3-12-S45-1. - to think about application to usefulness - immunologic renal disease of the multidrug therapy of the immunosuppressive drug in the kidney transplantation 竹内裕紀1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 305-305, 2019. |
|---|
|
|
3-12-S45-2. Way of thinking of the multidrug therapy of the anticancer medicine 石川寛1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 306-306, 2019. |
|---|
|
|
3-12-S45-3. Multidrug therapy in the diabetes therapeutic drug 井上岳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 307-307, 2019. |
|---|
|
|
3-12-S45-4. The Chinese medicine is the origin of the multidrug therapy 山田陽城1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 308-308, 2019. |
|---|
|
|
3-12-S45-5. Problems of the multidrug therapy in the mental disorder 赤嶺由美子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 309-309, 2019. |
|---|
|
|
Symposium 46. It is ... for duties development with ... added value to think about improvement in efficiency, productivity of pharmacist duties 吉村知哲, 外山聡 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 310-310, 2019. |
|---|
|
|
3-12-S46-1. Efforts for efficiency and the improvement by the pharmacy tissue management in productivity 吉村知哲1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 311-311, 2019. |
|---|
|
|
3-12-S46-2. Efficiency of pharmacist duties in the Hokkaido area 粟屋敏雄1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 312-312, 2019. |
|---|
|
|
3-12-S46-3. Streamline pharmacist work and improve productivity through task sharing and task shifting 舟越亮寛1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 313-313, 2019. |
|---|
|
|
3-12-S46-4. For the effectiveness of hospital pharmacist duties by the other types of job cooperation, value-added improvement 萱野勇一郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 314-314, 2019. |
|---|
|
|
3-12-S46-5. Utilization and duties efficiency of the medical information using IT 下堂薗権洋1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 315-315, 2019. |
|---|
|
|
Medical seminar 26. Antiepileptic drug MS26 to regard as the mechanism of action from a side effect 花谷亮典1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 316-316, 2019. |
|---|
|
|
Symposium 47. Ergonomy and cooperation - of a hospital, the health insurance pharmacy in line with cooperation and pharmacy management - local fact in the community medical care 赤瀬朋秀, 金田昌之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 317-317, 2019. |
|---|
|
|
3-14-S47-1. We drop the strategy of the hospital into the pharmacy 植木哲也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 318-318, 2019. |
|---|
|
|
3-14-S47-2. Practice of the pharmacy management in the university-affiliated drugstore to contribute to a local inclusion care system 寺町ひとみ1,2,3, 井口和弘3,4, 伊野陽子3,4, 野口義紘1,3, 玉木啓文3,4, 山下修司3,5, 舘知也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 319-319, 2019. |
|---|
|
|
3-14-S47-3. Balun strike scorecard ... which new attempt - hospital pharmacist for the sustainable medicine medicine cooperation and a local pharmacist conduct by collaboration 須賀宏之1, 内田隆通1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 320-320, 2019. |
|---|
|
|
3-14-S47-4. Practice of the regional pharmacy management in the local construction 舟越亮寛1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 321-321, 2019. |
|---|
|
|
3-14-S47-5. The pursuit of the sustainability in the community medical care and role of the pharmacist 赤瀬朋秀1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 322-322, 2019. |
|---|
|
|
Medical Seminar 27. Wimins Health and Female Hormones - Potential for Equol - MS27 中村隆文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 323-323, 2019. |
|---|
|
|
Symposium 48. The basics and practice to work on a clinical pharmacy study 伊藤清美, 田崎嘉一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 324-324, 2019. |
|---|
|
|
3-14-S48-1. For the first clinical pharmacy study Japanese alphabet - of - study plan and the article making 池田龍二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 325-325, 2019. |
|---|
|
|
3-14-S48-2. A point and precaution of the study ethic to work on clinical studies 渡邉達也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 326-326, 2019. |
|---|
|
|
3-14-S48-3. As we are not confused by statistics mind - p value necessary for a clinical pharmacy study 山村重雄1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 327-327, 2019. |
|---|
|
|
3-14-S48-4. Need - pharmacy education of clinical studies and clinical mediation - with settings 園田純一郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 328-328, 2019. |
|---|
|
|
3-14-S48-5. Significance and the prospects of the clinical studies in the drugstore 恩田光子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 329-329, 2019. |
|---|
|
|
Symposium 49. "How do you addicted to an acute poison in medicine thing cope?" 堀寧, 峯村純子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 330-330, 2019. |
|---|
|
|
3-14-S49-1. Drug-related arrhythmia in the acute drug intoxication! We think about pharmaceutical approach from a case 今井徹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 331-331, 2019. |
|---|
|
|
3-14-S49-2. About poison in medicine thing analysis duties carried out now 波多野亘1, 五十嵐大輝1, 寺島達也1, 平良木由布1, 島田祐子1, 堀寧1, 広瀬由和2, 廣瀬保夫2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 332-332, 2019. |
|---|
|
|
3-14-S49-3. Relation of the pharmacist to the patients whom colchicine poisoning developed in by a Colchicum autumnale false meal 矢内一成1, 鈴木博也1, 小林正和2, 赤坂和俊1, 山口浩明3, 眞野成康1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 333-333, 2019. |
|---|
|
|
3-14-S49-4. The early diagnosis that is addicted to distigmine bromide by the ER permanent residence pharmacist 齋藤靖弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 334-334, 2019. |
|---|
|
|
3-14-S49-5. A poisoning case of our hospital and the correspondence 佐藤智人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 335-335, 2019. |
|---|
|
|
Symposium 50. From the viewpoint of problems and measures - eating deglutition of the subnutrition in the community medical care, infusion management, pressure sore, cancer care - 倉田なおみ, 小原道子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 336-336, 2019. |
|---|
|
|
3-15-S50-1. Purpose of this symposium 倉田なおみ1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 337-337, 2019. |
|---|
|
|
3-15-S50-2. The intraoral situation that is an entrance of the dietary intake and the improvement 戸原玄1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 338-338, 2019. |
|---|
|
|
3-15-S50-3. What the current situation and a pharmacist of a quantity of nourishment in the infusion nourishment, the nourishment composition should do 東敬一朗1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 339-339, 2019. |
|---|
|
|
3-15-S50-4. We know the onset cause of the pressure sore, and let's collaborate by the multi-type of job 塚田邦夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 340-340, 2019. |
|---|
|
|
3-15-S50-5. Viewpoint of the caring at home that we were able to see from subnutrition and intraoral environment 小原道子1,2, 林秀樹2,3, 生木庸寛2,4, 松川泰治5, 加藤梨那5, 池野隆光1, 鈴木大7, 古島大資6, 山田浩6, 杉山正2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 341-341, 2019. |
|---|
|
|
Medical seminar 28. Dr. JOY X valuable MR MS28-1 若林進1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 342-342, 2019. |
|---|
|
|
Symposium 51. Skill ... which looks at the patients in ... anticancer treatment to think about the side effect management of the pharmacist carrying the new times 松尾宏一, 川上和宜 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 343-343, 2019. |
|---|
|
|
3-15-S51-1. Diagnosis of exclusion ... not to make significance - easiness to conduct the side effect management that a pharmacist conducts be associated with medicine 松尾宏一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 344-344, 2019. |
|---|
|
|
3-15-S51-2. How do consider whether is judgment - side effect of the side effect of pharmacist; ... 川口崇1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 345-345, 2019. |
|---|
|
|
3-15-S51-3. Point - of the adverse event evaluation that a tumor physician conducts on cancer medical therapy and the observation to expect of differential diagnosis - pharmacist 柴田伸弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 346-346, 2019. |
|---|
|
|
3-15-S51-4. Adverse event evaluation for the medical staff 山口拓洋1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 347-347, 2019. |
|---|
|
|
3-15-S51-5. Example introduction 川上和宜1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 348-348, 2019. |
|---|
|
|
Symposium 52. Art of the summary of a viewpoint and the case summary of the pharmaceutical intervention of the pharmacist specialized in a cancer 河原昌美, 濱敏弘 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 349-349, 2019. |
|---|
|
|
3-15-S52-1. About the pharmacist examination situation and a trend specialized in a cancer of 2018 河原昌美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 350-350, 2019. |
|---|
|
|
3-15-S52-2. The case that was involved in the supportive care for the malignant lymphoma with suspected merger of the SIADH がけ晋太郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 351-351, 2019. |
|---|
|
|
3-15-S52-3. The case that was involved in a regimen choice in consideration of the overall status of patients with pancreatic cancer 藺上圭子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 352-352, 2019. |
|---|
|
|
3-15-S52-4. Pharmaceutical intervention for patients with liposarcoma 山口恭平1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 353-353, 2019. |
|---|
|
|
3-15-S52-5. The case that intervened that is prophylactic for the VTE becoming severe of patients with lung cancer 西部星来1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 354-354, 2019. |
|---|
|
|
3-15-S52-6. Pharmaceutical intervention for the diarrhea symptom of patients with recurrent stomach cancer 松井裕典1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 355-355, 2019. |
|---|
|
|
Symposium 53. Scientific approach for proper use of the Chinese medicine 礒濱洋一郎, 本間真人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 356-356, 2019. |
|---|
|
|
3-16-S53-1. The Chinese medicine which contributes to improvement of the quality of life of patients with cancer: Appropriate prescription choice based on the basics, clinical studies 上園保仁1,2, 宮野加奈子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 357-357, 2019. |
|---|
|
|
3-16-S53-2. Immunodepression cells (MDSC) derived from an immunostimulation effect and marrow of the Chinese medicine 礒濱洋一郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 358-358, 2019. |
|---|
|
|
3-16-S53-3. Effect of the Chinese medicine on decrease in quantity of muscle 大澤匡弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 359-359, 2019. |
|---|
|
|
3-16-S53-4. Adverse event of herbal medicinal products 本間真人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 360-360, 2019. |
|---|
|
|
Receiving a prize -1. Study on pharmaceutical intervention for the clinical problem solution and outcome evaluation 橋田亨1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 361-361, 2019. |
|---|
|
|
Receiving a prize -2. Evidence creation and clinical application about the use of perinatal pharmaceutical products, supplement 小原拓1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 362-362, 2019. |
|---|
|
|
Receiving a prize -3. Study on evaluation of the usefulness of the pharmacist intervention aiming at pharmaceutical products proper use 木村丈司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 363-363, 2019. |
|---|
|
|
Receiving a prize -4. The development of the inhalational instruction tool which pointed to individualization inhalation therapy and clinical usefulness evaluation 平大樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 364-364, 2019. |
|---|
|
|
Medical seminar 29. It is - MS29-1. making use of ICI by the cooperation of combo X combo - pharmacist and the physician Wanting a pharmacist to know it being the current situation of ICI 岩澤俊一郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 365-365, 2019. |
|---|
|
|
Medical seminar 29. It is - MS29-2. making use of ICI by the cooperation of combo X combo - pharmacist and the physician For the ICI cooperation that we saw from a pharmacist 今井千晶1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 366-366, 2019. |
|---|
|
|
Medical seminar 29. It is - MS29-3-1. making use of ICI by the cooperation of combo X combo - pharmacist and the physician Real examination that we maintain a case 今井千晶1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 367-367, 2019. |
|---|
|
|
Symposium 54. It is ... for the active treatment participation of practice - pharmacist of PBPM (medical treatment management based on the protocol) in the clinical nutrition 井上真, 伊東弘樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 368-368, 2019. |
|---|
|
|
4-01-S54-1. We regard PBPM as the change of the pharmacist duties in the clinical nutrition domain 井上真1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 369-369, 2019. |
|---|
|
|
4-01-S54-2. What can a pharmacist do now? Thing - that it is seen in the point of - work-style reform by an original action now 鶴知光1, 小野沙織2, 長嶋フクヱ2, 高瀬麻衣3, 阿部浩子3, 上坂英二3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 370-370, 2019. |
|---|
|
|
4-01-S54-3. Of PBPM in the clinical nutrition therapy to give on the site, actually 野崎歩1, 堀内望1, 奥川寛1, 馬橋美由季1, 小林由佳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 371-371, 2019. |
|---|
|
|
4-01-S54-4. PBPM for the purpose of the clinical department cross-sectional intervention in the electrolyte management 梶原洋文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 372-372, 2019. |
|---|
|
|
Symposium 55. Relation to hospitalization and release support and medical cooperation - perioperative patients security and high quality medical care 舟越亮寛, 柴田ゆうか Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 373-373, 2019. |
|---|
|
|
4-02-S55-1. The perioperative care team member training business of Japanese Society of Anesthesiologists 齋藤繁1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 374-374, 2019. |
|---|
|
|
4-02-S55-2. Adjustment ... that in front of efforts ... art discontinuation standard review and a clinical department characteristic in the outpatient department in front of the art were considered 石塚良子1, 尾崎淳子1, 松原和夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 375-375, 2019. |
|---|
|
|
4-02-S55-3. The bringing medicine center operation in the local core hospital and good use of perioperative duties check seat 日江井和英1, 土本暁斗1, 安田翔1, 武冨佳那子1, 水野楓子1, 佐藤和也1, 塚原民夫1, 宇佐見文隆1, 堀内正1, 加納久美子2, 山崎潤二3, 梶川真樹4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 376-376, 2019. |
|---|
|
|
4-02-S55-4. It is ... from efforts - medicine support center about the perioperative medical security in the Kyoto second Red Cross hospital to the hospitalization and release support center 福田喬士1, 野口裕介1, 堀内あす香1, 神田英一郎1, 友金幹視1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 377-377, 2019. |
|---|
|
|
Medical seminar 30. It is ... MS30 mainly on current situation - dementia, Parkinson's disease of a problem and the development of the neurodegenerative disease therapeutic drug 野元正弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 378-378, 2019. |
|---|
|
|
PA-1. Development of the quantitative evaluation model of the adverse drug reaction expression risk using the data mining technique 今井俊吾1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 379-379, 2019. |
|---|
|
|
PA-2. Examination of the daptomycin (DAP) loading dose using the femoral MRSA infection mouse model 加藤秀雄1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 380-380, 2019. |
|---|
|
|
PA-3. Basic study on elucidation of the injury risk based on the pathological evaluation of the extravasation of thiopental and the propofol and effect of the application of a poultice 柴田ゆうか1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 381-381, 2019. |
|---|
|
|
PA-4. Identification of new EGFR-TKI acquisition of resistance factor eIF3c and elucidation of the clinical significance 新谷拓也1,2, 東阪和馬2,3, 前田真貴子2, 濱田将矢2, 辻亮介2, 川崎桂輔4, 山本智也1, 前田真一郎1,2, 森井英一4, 熊ノ郷敦5, 堤康央2, 長友泉5, 藤尾慈2, 奥田真弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 382-382, 2019. |
|---|
|
|
PA-5. Study on blood poison-related expression mechanism with antipsychotics 鳥居綾1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 383-383, 2019. |
|---|
|
|
PA-6. Study on risk factor of the hiccups using the clinical information and treatment 細谷龍一郎1,2, 田中一平1, 石坂範子1, 永村陽一郎1, 野澤(石井)玲子3, 網野猛4, 鎌田智幸4, 日野斉一1, 加賀谷肇5, 植沢芳広2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 384-384, 2019. |
|---|
|
|
PA-7. Search of the new preventive preparation for anticancer medicine oxaliplatin-induced peripheral neuropathy 山本将大1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 385-385, 2019. |
|---|
|
|
Medical seminar 31. Treatment strategy for the unresectable progress, recurrent gastric cancer to read from evidence and true clinical practice and in the future fine-view MS31 有上貴明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 386-386, 2019. |
|---|
|
|
Medical seminar 32. Of rheumatoid arthritis treatment will be MS32 from now on until now 押領司健介1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 387-387, 2019. |
|---|
|
|
Symposium 56. For improvement of the infection with pharmacist practice support 塩田有史, 三鴨廣繁 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 388-388, 2019. |
|---|
|
|
4-05-S56-1. Infection practice support of the pharmacist in the university hospital (there is an infection department) 塩田有史1,2, 浅井信博1,3, 小泉祐介1,3, 山岸由佳1,3, 三鴨廣繁1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 389-389, 2019. |
|---|
|
|
4-05-S56-2. Infection practice support of the pharmacist in the university hospital (there is no infection department) 茂見茜里1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 390-390, 2019. |
|---|
|
|
4-05-S56-3. Infection practice support of the pharmacist in the large-scale hospital 奥平正美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 391-391, 2019. |
|---|
|
|
4-05-S56-4. Infection practice support of the pharmacist in the middle scale hospital 木村匡男1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 392-392, 2019. |
|---|
|
|
4-05-S56-5. University pharmacy school 継田雅美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 393-393, 2019. |
|---|
|
|
Medical seminar 33. Drug choice - MS33 which we saw from a new positioning - fruit clinical viewpoint of the bony formation accelerant 中條悟1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 394-395, 2019. |
|---|
|
|
Symposium 57. For practice and the development of the TDM study after the revised medical law enforcement 谷川原祐介, 増田智先 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 396-396, 2019. |
|---|
|
|
4-05-S57-1. Practice of the TDM precision management in conformity with the revised medical law 谷川原祐介1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 397-397, 2019. |
|---|
|
|
4-05-S57-2. Precision management and standardization in the laboratory study 滝野寿1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 398-398, 2019. |
|---|
|
|
4-05-S57-3. TDM precision management whole country survey: Immunosuppressive drug 増田智先1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 399-399, 2019. |
|---|
|
|
4-05-S57-4. The thing which TDM standardization and a Japanese TDM association aim at 栄田敏之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 400-400, 2019. |
|---|
|
|
Symposium 58. A medical guidepost to tie safely in the mild medical care! 高瀬久光, 井手口直子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 401-401, 2019. |
|---|
|
|
4-06-S58-1. National fact-finding about the intervention of the pharmacist for the polypharmacy in the mild medical domain 内田まやこ1,9, 鈴木真也2,9, 菅幸生3,9, 菅原英輝4,9, 国分秀也5,9, 植沢芳広6,9, 中川貴之7,9, 高瀬久光8,9 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 402-402, 2019. |
|---|
|
|
4-06-S58-2. Observational, prospective study about the pharmacist intervention effect in the polypharmacy 鈴木真也1,9, 内田まやこ2,9, 菅幸生3,9, 菅原英輝4,9, 国分秀也5,9, 植沢芳広6,9, 中川貴之7,9, 高瀬久光8,9 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 403-403, 2019. |
|---|
|
|
4-06-S58-3. Contribution to medical safety from the perspective of pre-avoid reports 金子健1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 404-404, 2019. |
|---|
|
|
4-06-S58-4. From the position of medical safe ... pharmacist 鷲山厚司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 405-405, 2019. |
|---|
|
|
4-06-S58-5. From the situation of medical safe ... physician 岡村知直1, 皆元文恵2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 406-406, 2019. |
|---|
|
|
4-06-S58-6. Communication for medical security 井手口直子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 407-407, 2019. |
|---|
|
|
Medical seminar 34. - MS34 which is like - efficiency, and thinks about the way of high drug duties of the productivity from the current situation analysis of pharmacist duties to be able to employ according to hospital functions 武田泰生1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 408-408, 2019. |
|---|
|
|
Medical seminar 35. Medical treatment MS35. of the retinopathy Medical treatment of the retinopathy 寺崎寛人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 409-409, 2019. |
|---|
|
|
Medical seminar 36. Dr. Work-style reform MS36-1 of a utilization method and the pharmacist of the efficiency JADER side effect search of the JOY X intelligence 萱野勇一郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 410-410, 2019. |
|---|
|
|
Symposium 59. [cure association health insurance pharmacy WG] In the interval of - generalist and the specialist thinking about the specialty of the drugstore pharmacist - 宮崎長一郎, 出石啓治 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 411-411, 2019. |
|---|
|
|
4-10-S59-1. Expect the medicine machine methods, and the like in the specialty of the pharmacist in the revision 境啓満1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 412-412, 2019. |
|---|
|
|
4-10-S59-2. About the specialty of the drugstore pharmacist in the local inclusion care 吉田力久1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 413-413, 2019. |
|---|
|
|
4-10-S59-3. With the specialist whom a drugstore pharmacist aims at 伊藤譲1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 414-414, 2019. |
|---|
|
|
4-10-S59-4. With the authorized pharmacist, specialized pharmacist demanded from a drugstore pharmacist 竹内尚子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 415-415, 2019. |
|---|
|
|
4-10-S59-5. Performing PBPM of the oral anticancer medicine medical therapy, and having thought about specialty acquisition of the anticancer medicine medical therapy in the drugstore pharmacist 中村優1,2, 天本耕一郎1,2, 手嶋無限1,2, 池田理恵1, 中村忠博1,3, 山形浩介1,2, 井手陽一1,2, 水崎直文1, 宮崎彰宣1, 秋吉隆治1, 有澤賢二4, 宮崎長一郎4, 安原眞人5, 佐々木均1,3, 田代浩幸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 416-416, 2019. |
|---|
|
|
4-10-S59-6. Role of clinical pharmacy and the pharmacy education which a drugstore pharmacist carries 吉山友二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 417-417, 2019. |
|---|
|
|
Medical seminar 37. Not medication counseling the medication support? ... MS37-1. to think about from ... HIV infection team approach in medical care Medication support by the pharmacist in the foreign team approach in medical care 矢倉裕輝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 418-418, 2019. |
|---|
|
|
MS37-2. The medication support that a change and a pharmacist of the medication awareness in the long-term medication patients are available for 大石裕樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 419-419, 2019. |
|---|
|
|
Symposium 60. The change, needs, the prospects of the pharmacist authorization system in the infection domain to think about now 北原隆志, 村木優一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 420-420, 2019. |
|---|
|
|
4-10-S60-1. The participation in infection control foundation period of the pharmacist 白石正1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 421-421, 2019. |
|---|
|
|
4-10-S60-2. The specialized pharmacist birth period 継田雅美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 422-422, 2019. |
|---|
|
|
4-10-S60-3. What should the pharmacist practice in the hospital infection measures team? 中川博雄1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 423-423, 2019. |
|---|
|
|
4-10-S60-4. Participation in AMR era AST 橋本麻衣子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 424-424, 2019. |
|---|
|
|
4-10-S60-5. Role, the prospects of the authorized system and pharmacist in the infection domain 北原隆志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 425-425, 2019. |
|---|
|
|
Symposium 61. Term of the organizer regarding pregnancy treatment and the safety assessment of the drug as rheumatism 中島研, 山根律子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 426-426, 2019. |
|---|
|
|
4-11-S61-1. How do you examine patients with rheumatoid arthritis of the request for fertility? 後藤美賀子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 427-427, 2019. |
|---|
|
|
4-11-S61-2. The pregnancy and rheumatic medicine 中島研1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 428-428, 2019. |
|---|
|
|
4-11-S61-3. It is mainly ... about a biological drug safe information and evaluation ... in the use during the pregnancy of the antirheumatic drug 村岡香代子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 429-429, 2019. |
|---|
|
|
4-11-S61-4. The effect on children of the new antirheumatic drug and efforts in our country 八鍬奈穂1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 430-430, 2019. |
|---|
|
|
Medical seminar 38. Outline MS38 of the Fabry's disease judging from circulatory organ medicine 上原吉就1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 431-431, 2019. |
|---|
|
|
Symposium 62. How does the pharmacist face each other for a disease without relation ... definitive therapy of the pharmacist in intractable disease treatment? Term of ... organizer 池田龍二, 城野博史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 432-432, 2019. |
|---|
|
|
4-11-S62-1. Applied development from the development of the Alzheimer's disease model mouse 斉藤貴志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 433-433, 2019. |
|---|
|
|
4-11-S62-2. It is ... for treatment of contribution - Gaucher's disease to the clinical department as the pharmacist by system of measurement establishment of the intractable disease diagnosis 寺薗英之1,2, 日高朋1, 高橋毅行1,2, 奥津果優3, 吉満誠4, 武田泰生1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 434-434, 2019. |
|---|
|
|
4-11-S62-3. Effect of the STAT3 antagonist on hereditary renal disease Alport's syndrome 横田翼1,2, Suico Maryann2, 首藤剛2, 甲斐広文2, 池田龍二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 435-435, 2019. |
|---|
|
|
4-11-S62-4. How should you face each other as a pharmacist (pharmacy researcher) to overcome an inborn character lipid dysbolism Niemann-Pick disease C type? 石塚洋一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 436-436, 2019. |
|---|
|
|
4-11-S62-5. Analysis of a foresight, the prophylaxis hard to hear that environmental factors influence 大神信孝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 437-437, 2019. |
|---|
|
|
Symposium 63. We conduct the affairs, and how is it helpful? Fix the eyes on the evaluation for ... medical service fees, the reflection to a policy with the demanded outcome; and the term of ... organizer 林稔展, 松尾宏一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 438-438, 2019. |
|---|
|
|
4-12-S63-1. It is ... for the new role of clinical studies - pharmacist beginning with usual duties 川田敬1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 439-439, 2019. |
|---|
|
|
4-12-S63-2. Efforts and outcome evaluation of the pharmacist outpatient department for the oral anticancer medicine 郷真貴子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 440-440, 2019. |
|---|
|
|
4-12-S63-3. For the achievement of the pharmacist in the life 100 years times 中井清人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 441-441, 2019. |
|---|
|
|
4-12-S63-4. A hospital, medical office pharmacist duties and medical service fees evaluation 川上純一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 442-442, 2019. |
|---|
|
|
MS39. ... including the proof report of at-home telemedicine utilizing the ICT and the online medication counseling by cooperation - pharmacist of the pharmacist 高野秀雄1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 443-443, 2019. |
|---|
|
|
Symposium 64. It is the term of ... organizer with the function of the pharmacist whom it is demanded from by the multi-type of job cooperation to support information cooperation - community medical care that hospital pharmacist should work on now 岸本真, 小枝伸行 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 444-444, 2019. |
|---|
|
|
4-12-S64-1. It is ... from the viewpoint of expectation - medical care cooperation practitioner to the pharmacist in the local inclusion care system 木佐貫篤1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 445-445, 2019. |
|---|
|
|
4-12-S64-2. From position of the nurse cooperation mind community medical care cooperation room bought by an area and a leading in-hospital pharmacist 塚本知恵子1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 446-446, 2019. |
|---|
|
|
4-12-S64-3. The medical cooperation that started from the patients information sharing before hospitalization in the Gifu comprehensive medical care center 谷沢克弥1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 447-447, 2019. |
|---|
|
|
4-12-S64-4. We utilize drug control summary to spin a story of the medical therapy of patients to support community medical care and share drug information 賀勢泰子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 448-448, 2019. |
|---|
|
|
Medical seminar 40. Cooperation - MS40 of proper use - antimicrobial proper use support team of infection measures and the antimicrobial which fixed their eyes on control of the drug resistant bacterium 高田徹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 449-449, 2019. |
|---|
|
|
Symposium 65. Term of the organizer thinking about the gender equality in the field of pharmacist, clinical pharmacy and work-style reform 川上純一, 賀勢泰子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 450-450, 2019. |
|---|
|
|
4-14-S65-1. Is flexible - freely towards the pharmacy where I think, "want to work here!", efforts - of the Chikamori society group 筒井由佳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 451-451, 2019. |
|---|
|
|
4-14-S65-2. It is an efforts example of the - Shizuoka hospital pharmacist society and community hospital automation Koga Hospital for the making of society which can play an active part regardless of men and women lively 渡邉学1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 452-452, 2019. |
|---|
|
|
4-14-S65-3. Approach - of - AWA support center toward Tokushima University where men and women can play an active part together 石澤有紀1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 453-453, 2019. |
|---|
|
|
4-14-S65-4. Thing to see from a way of working and the way of thinking of the gender equality in a health insurance pharmacy and the pharmacist society, and the like 宮原富士子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 454-454, 2019. |
|---|
|
|
Symposium 66. With the infusion education to practice the periphery fluid therapy mainly on water, the electrolyte? Term of the organizer 名徳倫明, 佐古守人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 455-455, 2019. |
|---|
|
|
4-15-S66-1. The current situation and problem of the infusion education in university 名徳倫明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 456-456, 2019. |
|---|
|
|
4-15-S66-2. Education and practice of the periphery fluid therapy to think about from dehydration 佐古守人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 457-457, 2019. |
|---|
|
|
4-15-S66-3. We think about periphery fluid therapy education from body fluid adjustment homeostatic mechanism 梶原洋文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 458-458, 2019. |
|---|
|
|
4-15-S66-4. With the intervention to periphery fluid therapy to seek to a pharmacist? It is ... from the situation of ... physician 錦織英史1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 459-459, 2019. |
|---|
|
|
IO01. Availability of Medicine and Universal Health Coverage in Laos Risako Inoue1, Keisuke Seto1, Tomoo Ito2, Hiroyuki Terakado1, Chiaki Miyoshi2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 460-461, 2019. |
|---|
|
|
IO02. Research on the Science Needs on the Internet Related to Gene Editing Baby Event Based on Search Data Xiao-Wen XING1, Yi-Bo WU2, Ze-Yu JIANG1, Cun-Yi KU1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 461-461, 2019. |
|---|
|
|
IO03. Effect of Wechat precision health communication on medication compliance of patients with hypertension Hai-Bin WEI1, Chen-Xin QUAN2, Ya-Qi DENG2, Yuan HU2, Wen-Yang TAN2, Yi-Bo WU3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 462-462, 2019. |
|---|
|
|
IO04. Research on the Structure and Characteristics of Adolescent Health Popularization Needs based on Search Data Shu-Xian JIA1, Jie WANG1, Jin-Yi MENG2, Tao WANG3, Yi-Bo WU4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 462-462, 2019. |
|---|
|
|
IO05. Continuous Medication Consultation for Patients by Private Pharmacists in Community Pharmacies : An Attempt to Introduce a Care Plan Program Keiko Naganuma1, Satoshi Hatazawa1, Kaori Ogawa1, Ryuichi Kinoshita1, Takuro Matsubara1, Mitsuhiro Someya1, Ryouo Taniguchi1, Fumio Nakajima1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 463-463, 2019. |
|---|
|
|
IO06. The Efficacy of Asilol in the Treatment of Severe Hand-foot-mouth Disease in Children : A Systematic Review and Meta-analysis Fang SHI1, Yi-Bo WU2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 464-464, 2019. |
|---|
|
|
2-7-O01-1. One case that led to the use of the Relief System for Sufferers from Adverse Drug Reactions by the intervention of the pharmacist 笠原真理1, 井下田充洋2, 吉倉明枝3, 鶴谷勝実1, 笹川嘉久4, 高丸勇司4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 465-465, 2019. |
|---|
|
|
2-7-O01-2. Proper use and current status of nintedanib at Osaka Habikino Medical Center 和田宜久1, 石樋康浩1, 岩田浩幸1, 上田理絵1, 木村貴1, 嶋津史恵1, 友井理恵子1, 富士芳美1, 松下一樹1, 水口侑子1, 盛谷友梨1, 木澤成美1, 金銅葉子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 466-466, 2019. |
|---|
|
|
2-7-O01-3. One patient who evaluated pilsicainide doses in the pseudo ventricular tachycardia using an electrocardiogram 柴田麻美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 466-466, 2019. |
|---|
|
|
2-7-O01-4. Examination of the factor to have an influence on the self-care using ability for medication judgment study (J-RACT) in the convalescent rehabilitation ward 遠藤秀竜1, 小瀬英司2, 堀浩子1, 細野真吾1, 河村千晶1, 児玉雄大1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 467-467, 2019. |
|---|
|
|
2-7-O02-1. Search of the factor on the reviewer side resulting in a change in the evaluation of the instillation maneuver and the patients side 島田拓弥1, 中川祐紀子1, 菅幸生2, 嶋田努1, 崔吉道1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 468-468, 2019. |
|---|
|
|
2-7-O02-2. The current situation and problem of the HBV reactivation measures for patients receiving immunosuppressive drug 松原菜美1, 冨士原あゆみ1, 馬橋美由季1, 土手賢史1, 小林由佳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 469-469, 2019. |
|---|
|
|
2-7-O02-3. Usefulness of the inhalational evaluation of the on admission inhalant continuation patients by the pharmacist and the re-instruction 菅原拓也1, 鈴木麻友1, 荒井潤1, 延川正雄1, 松田圭一郎1, 荒井浩一1, 岩渕勝好2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 469-469, 2019. |
|---|
|
|
2-7-O02-4. Development and efforts of the "ML ward duties search" to make ward duties standardization, the efficiency section system 柏瀬しのぶ1, 浜田幸宏1, 本郷彰也2, 縣宗彦1, 有賀三希子1, 金田純子1, 河本拓哉1, 倉重梓1, 坂田志保1, 菅原直子1, 只見智恵子1, 橋本直人1, 古越冴香1, 丸山拓実1, 山崎智司1, 吉田まり絵1, 高森祥大1, 木村利美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 470-470, 2019. |
|---|
|
|
2-7-O03-1. Response to participation experience type training in the drugstore business training in revision core Cali 松下隼士1,2, 松村千晶2, 小林大介2, 川尻雄大2, 高木淳一1, 岸田義博1, 小柳香織1, 勢島充1, 吉田理1, 山野徹1, 園田正信1, 吉川学1, 島添隆雄2, 田中泰三1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 471-471, 2019. |
|---|
|
|
2-7-O03-2. Education effect of the antimicrobial proper use by the antibacterial chemotherapy workshop (Osaka ABC) for the young hospital pharmacist 山田智之1, 上田覚2, 安井友佳子3, 行本拓史4, 眞継賢一5, 村井千恵6, 吉野秀紀7, 竹内祐介8, 角谷龍哉9, 石坂敏彦10, 関雅文11 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 472-472, 2019. |
|---|
|
|
2-7-O03-3. Attitude survey of the pharmacy student in the learning of the cancer medical therapy utilizing the smartphone game application 児玉暁人1, 今井兼貴1, 高橋文香1, 岩田智津子1, 水庫彩1, 勝浦正人1, 森信介1, 小竹武2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 472-472, 2019. |
|---|
|
|
2-7-O03-4. Examination and evaluation of the held contents of the workshop-style workshop for the purpose of the local cancer medical therapy elimination by the Saitama cancer medical therapy workshop 龍島靖明1, 芝崎由美子2, 武井大輔3, 大島宗平4, 伊藤剛貴5, 鈴木貴之6, 新津京介7, 新井隆広8, 畠山朋樹9, 中山季昭10, 佐野元彦11 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 473-473, 2019. |
|---|
|
|
2-7-O04-1. It is the multicenter questionary survey about the check system of the stopping medicine during the preoperation by the pharmacist 花田聖典1, 鶴崎泰史1, 井上大奨1, 松尾香奈子1, 坂田光平1, 水町純一1, 中川義浩1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 474-474, 2019. |
|---|
|
|
2-7-O04-2. The effect that the number of the drugs in the on admission bringing medicine and prescription complexity give to effect of treatment of the high blood pressure 若井恵里1, 池村健治1, 加藤千佳1, 岩本卓也1, 奥田真弘2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 475-475, 2019. |
|---|
|
|
2-7-O04-3. One case of the sprue-like enteropathy that valsartan that detailed drug history investigation with the prescription notebook was the opportunity of the diagnosis was thought to be associated with 山下祐果1, 松浦仁志1, 岸渕正典2, 吉岡克宣3, 石倉久美子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 475-475, 2019. |
|---|
|
|
2-7-O04-4. Efforts of the change of the bringing medicine management method 中田一孝1, 冨田有香1, 池田理沙1, 加田昌宏1, 須原良海1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 476-476, 2019. |
|---|
|
|
2-7-O05-1. 1 case that filgrastim Biosimilar preparation administration was effective for the serious neutropenia that occurred by azathioprine 大塚恵理子1, 津下遥香1, 佐藤雄己1, 田中遼大1, 尾崎貴士2, 前島圭佑2, 柴田洋孝2, 伊東弘樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 477-477, 2019. |
|---|
|
|
2-7-O05-2. Therapeutic safe comparison between precedent biomedicine and biofollowing article of rituximab 安達和宏1, 佐藤雄己2, 龍田涼佑2, 中原良介2, 磯田祥3, 本室貴子1, 伊東弘樹2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 478-478, 2019. |
|---|
|
|
2-7-O05-3. The infusion reaction expression situation at the rituximab Biosimilar initial administration 原茉梨絵1, 三角紳博1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 478-478, 2019. |
|---|
|
|
2-7-O05-4. Use experience report to the super elderly people before and after the Biosimilar preparation change of rituximab 今野奈央子1, 多田則道2, 千葉健哉1, 小野垣富美1, 長岡城子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 479-479, 2019. |
|---|
|
|
2-7-O06-1. Comparison of the chemical behavior after starting pharmaceutical products, a saline in the generic medicine docetaxel non-alcohol preparation and the 5% dextrose in water dilution 小川千晶1,2,3,4, 矢田部恵3, 井上元基4, 足立茂4, 伊藤智夫2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 480-480, 2019. |
|---|
|
|
2-7-O06-2. Importance of the cutoff value in the generic medicine introduction and medical economic effect 関屋裕史1, 緒方豊2, 梶原隆広3, 福永洋子3, 森木豊栄3, 池田龍二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 481-481, 2019. |
|---|
|
|
2-7-O06-3. Examination of the case that changed the mesalazine Enteric tablet (hemp call) to the generic medicine 細川宜嗣1, 原田恭江1, 軸原温2, 江藤精二3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 481-481, 2019. |
|---|
|
|
2-7-O06-4. An attempt of the generic name prescription spread by the pharmacist based on the in-hospital protocol and the evaluation 宮崎元康1, 内山将伸1, 松尾宏一1, 鵜木亜矢子1, 島田安希子1, 森由夏子1, 今給黎修1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 482-482, 2019. |
|---|
|
|
2-8-O07-1. Investigation about the background of conveyed patients emergency for lithium poisoning 飛田修康1, 祖川倫太郎1, 木村早希子1, 田崎正信1, 阪本雄一郎3, 成澤寛2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 483-483, 2019. |
|---|
|
|
2-8-O07-2. About safety of the oseltamivir phosphate prophylaxis in the mental disorder 亀井進太郎1, 岩田裕明1, 佐藤雄己1, 伊東弘樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 484-484, 2019. |
|---|
|
|
2-8-O07-3. An adverse event and search of the associated factor to influence tolerability at the Clozapine administration 麻那古信之1, 山本智也1, 渡邊梓1, 門脇裕子1, 奥田真弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 484-484, 2019. |
|---|
|
|
2-8-O07-4. Examination of the effectiveness of the Elobixibat for the chronic constipation in patients with mental disorder 中村奈央1, 幸邦憲1, 大井裕貴1, 中村民生2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 485-485, 2019. |
|---|
|
|
2-8-O08-1. Objective oxidative stress evaluation of children with autistic spectrum disorder using d-ROMs, BAP 北岡泰介1,2, 森本真仁3, 橋本俊顕3, 津田芳見3, 中津忠則3, 京谷庄二郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 486-486, 2019. |
|---|
|
|
2-8-O08-2. Examination of the insomniac frequencies in patients with hospitalized brain tumor and the risk factor 菅野ゆみか1, 関根佳代1, 岩田理恵1, 大谷美子1, 井内俊彦2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 487-487, 2019. |
|---|
|
|
2-8-O08-3. 1 case of patients consulting the several outpatients who bach is difficult, and were admitted to the mental hospital 加藤剛1, 宗像彩香1, 澤口真紀1, 鈴木順子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 487-487, 2019. |
|---|
|
|
2-8-O08-4. Efforts of the benzodiazepine receptor agonist decrease medicine by the stamp pasting to an electronic medical record and the evaluation 進健司1,2, 小林大介1, 川尻雄大1, 猪狩圭介3, 光安博志3, 村上智哉3, 堤一樹3, 金澤康範2, 神村英利4, 島添隆雄1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 488-488, 2019. |
|---|
|
|
2-8-O09-1. Examination of the incompatibility in the coadministration of Fosaprepitant and the magnesium preparation using the high performance liquid chromatography 尾崎正和1, 幸田恭治1, 北原隆志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 489-489, 2019. |
|---|
|
|
2-8-O09-2. It is effectively utilized anticancer agent inspection support system "chemo assistant" 佐竹清1,2, 井上朋子1, 後藤孝之1, 亀井陽子1, 中島孝則2, 町田充1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 490-490, 2019. |
|---|
|
|
2-8-O09-3. Efforts for the elimination of the regimen confirmation matter in the cancer chemotherapy 粂哲雄1, 野村光永1, 佐藤淳也1, 梅坪翔太1, 安田陽子1, 鴨志田武1, 石川寛1, 篠道弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 490-490, 2019. |
|---|
|
|
2-8-O09-4. The actual situation of the HBV infection that became clear by screening before cancer chemotherapy 樋口芙蓉子1, 有野徹1, 清水淳一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 491-491, 2019. |
|---|
|
|
2-8-O10-1. Examination of the medical expenses reduction effect by the use of division of the anticancer medicine 浅野舞美1, 小林一男1, 山端悠介1, 横川貴志1, 鈴木亘1, 平出誠1, 三木真梨杏1, 岩崎愛理1, 濱敏弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 492-492, 2019. |
|---|
|
|
2-8-O10-2. Examination about the sterilitas at eight days storage in the multiple use of the single-use vial 森はづき1, 多賀允俊1, 高橋喜統1, 藤本俊祐1, 政氏藤玄1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 493-493, 2019. |
|---|
|
|
2-8-O10-3. Examination of the exposure measures method that we evaluated from anticancer medicine environmental pollution investigation 高山慎司1, 河野友昭1, 景秀典1, 二階堂恵子1, 池田優子1, 高野めぐみ1, 渡邊由紀子1, 増渕敬久1, 山内照夫2, 後藤一美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 493-493, 2019. |
|---|
|
|
2-8-O10-4. It is ... about the handling and the foreign chemotherapy room of efforts ... anticancer agent of the pharmacy for the JCI certification 與田賢作1, 奥野美和1, 松浦徹1, 内山有理香1, 山下大貴1, 立石裕樹1, 市川美佳1, 大汐欣輝1, 後藤貴央1, 後藤美緒1, 村田智弘1, 重松由加1, 宮津大輔1, 田中博和1, 平川雅章1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 494-494, 2019. |
|---|
|
|
2-8-O11-1. Introduction of the side effect evaluation tool in the foreign chemotherapy center of the middle scale hospital 新美政樹1, 菊池正和2, 尾畑景子3, 谷口結基1, 森智世1, 田中美帆1, 太田達也1, 田中章郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 495-495, 2019. |
|---|
|
|
2-8-O11-2. Outpatient treatment Examination of contribution to treatment by a system (Ringlenbima) including telephone consultation support for patients with hepatocellular carcinoma 坂田幸雄1, 松丸亜紀2, 伊藤由貴子2, 伊藤淳3, 山本義也3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 496-496, 2019. |
|---|
|
|
2-8-O11-3. Attitude survey about the side effect with the appearance change in anticancer agent ambulant treatment patients 鈴木絢子1, 渡邉美知子1,2, 坂本靖宜1, 山下美乃里1, 服部有希1, 小池博文1, 佐橋幸子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 496-496, 2019. |
|---|
|
|
2-8-O11-4. Examination about the transformation of the reporting of the medical person about the effect on fecundity with the cancer medical therapy 馬見新佳那子1, 岩本彩2, 内藤陽一3, 細野亜古3, 南陽介4, 向原徹3, 米村雅人3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 497-497, 2019. |
|---|
|
|
2-8-O12-1. Examination about the effect that the liver, a decreased renal function gives to onset of ifosfamide-related central nerve symptom 志水真也1, 林祐一2, 西田承平1, 藤井宏典1, 小林亮1, 鈴木昭夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 498-498, 2019. |
|---|
|
|
2-8-O12-2. Evaluation ... of the hypersensitivity protective efficacy by onset of hypersensitivity situation investigation - DEX9.9mg by PTX at obstetrics and gynecology department tri-weekly PTX + CBDCA therapy enforcement 杉山弘樹1, 中田淳也1, 原田晴司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 499-499, 2019. |
|---|
|
|
2-8-O12-3. Construction and maintenance doses investigation of the cooperation system for the Palbociclib administration 柿原圭佑1, 三上忠司1, 野田聖奈子1, 武田なつか1, 原田智子1, 篠崎千尋1, 松本美紅1, 藤井裕史1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 499-499, 2019. |
|---|
|
|
2-8-O12-4. About a quality of life improvement effect by the analysis of the adverse event to have an influence on the quality of life of patients in the foreign cancer chemotherapy and the pharmaceutical intervention 藤井宏典1, 廣瀬智恵美1, 飯原大稔1, 石原正志1, 大畑紘一1, 関谷久美子1, 北洞美佳1, 鈴木昭夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 500-500, 2019. |
|---|
|
|
2-9-O13-1. Fluid replacement weight loss in the BEP therapy for the germ cell neoplasm, renal function with the aprepitant day3-7 administration, investigation about the effect on nausea vomiting 渡邊裕之1, 木村錦子1, 村田政軌1, 田村曉識1, 神野正敏2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 501-501, 2019. |
|---|
|
|
2-9-O13-2. Strategy - of the - LEC antiemesis therapy proper use thinking about Steroid Sparing 井上靖隆1, 寺谷俊昭1, 辻本高志1, 加納宏樹1, 上田晃1, 川本由加里1, 村井太一2, 曽根孝之2, 中村路夫2, 後藤仁和1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 502-502, 2019. |
|---|
|
|
2-9-O13-3. Phase II clinical study to examine the effect of 5 mg of olanzapine on prominence-related retching, vomiting at chemotherapy enforcement including the Carboplatin 吉田弘樹1, 前田章光2, 井上裕貴3, 江尻将之4, 山口智江5, 櫛原秀之6, 山本泰大7, 安藤洋介8, 佐藤由美子9, 田代雄祐10, 尾瀬功11, 清水淳市12 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 502-502, 2019. |
|---|
|
|
2-9-O13-4. Study on factor analysis of GEM+nab-PTX therapy in patients with pancreatic cancer-induced retching 左高史織1, 大畑紘一1, 加藤寛子1, 藤井宏典1, 飯原大稔1, 上村真也2, 岩下拓司2, 清水雅仁2, 鈴木昭夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 503-503, 2019. |
|---|
|
|
2-9-O14-1. Examination of the usefulness of 5 mg of olanzapine for the hematopoietic stem cell transplantation pre-treatment treatment containing melphalan 原田知彦1, 大野瑞穂1, 齋藤圭佑1, 新本小百合1, 安藤太基2, 鈴木泰生2, 立花崇孝2, 田中正嗣2, 金森平和2, 林稔展3, 岸本有佳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 504-504, 2019. |
|---|
|
|
2-9-O14-2. Examination of the medical economics about the G-CSF administration at lung cancer treatment by DTX+RAM 鈴木寛人1, 築田晃直1, 山形真一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 505-505, 2019. |
|---|
|
|
2-9-O14-3. Look at onset in the gefitinib monotherapy of hepatic dysfunction and the rear about the association of the BMI; mark investigation 古野龍也1, 木村早希子1, 荒金尚子1,2, 田崎正信1, 成澤寛1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 505-505, 2019. |
|---|
|
|
2-9-O14-4. The use situation investigation of the Fosaprepitant in patients with childhood cancer 甲斐維子1, 加戸奈穂美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 506-506, 2019. |
|---|
|
|
2-9-O15*-1. Effect of the pharmacist intervention based on antimicrobial TDM guidelines on use of aminoglycoside derivative medicine patients 篠田康孝1,2, 大橋健吾1, 松岡知子1, 新井かおり1, 加藤未紗1, 杉山正2, 吉村知哲1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 507-507, 2019. |
|---|
|
|
2-9-O15*-2. Knowledge - that we were able to see it from examination - chronicity kidney disease model of the kidney protection with the PDE5 inhibitor and a nephrotic model 冨田なつみ1, 堀田祐志1, 内木綾2, 吉川麻優1, 片岡智哉3, 高橋智2, 木村和哲3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 508-508, 2019. |
|---|
|
|
2-9-O15*-3. Relative examination of the trace minerals in the acute renal failure and living body after the use of heart-lung machine 松田夏鈴1, 堀田祐志2, 冨田なつみ2, 片岡智哉3, 伊藤秀和4, 山本優子5, 祖父江和哉4, 木村和哲1,2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 508-508, 2019. |
|---|
|
|
2-9-O15*-4. Consideration ... from the adverse event signal detection with research - sleeping drug about the proper use of the medicine of elderly people 泉澤恵1, 菊地智貴1, 上野晃汰1, 金谷潔史2, 羽生春夫2, 亀井美和子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 509-509, 2019. |
|---|
|
|
2-9-O16*-1. Usefulness evaluation of the infliximab blood level measurement in rheumatoid arthritis treatment using real world data 中江一統1,2, 米澤淳1,2, 傳田将也1,2, 増井翔1,2, 橋本求3, 田中真生3, 伊藤宣3, 岩本典子4, 嶋田崇史4, 中川俊作1, 池見泰明1, 早狩誠1, 松原和夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 510-510, 2019. |
|---|
|
|
2-9-O16*-2. A. semi-mechanistic PK/PD analysis ... of construction - time-kill properties of the sulbactam optimal administration method for the baumannii infection 横山雄太1, 猪川和朗2, 松元一明3, 中村智徳1, 森川則文2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 511-511, 2019. |
|---|
|
|
2-9-O16*-3. Effect of CYP3A5 giving it to blood change of the tolvaptan in patients with heart failure and endogenous CYP3A activity marker and the ABCB1 mutation in the gene 星川昂平1, 内藤隆文1, 阿久津駿太1, 早乙女雅夫2, 前川裕一郎2, 川上純一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 511-511, 2019. |
|---|
|
|
2-9-O16*-4. Analysis of the genetic factor influencing an internal change and side effect of the Afatinib in patients with non-small cell lung cancer 福田純久1, 林秀樹1,2,3, 飯原大稔2,3, 廣瀬智恵美3, 上森将吾2, 北洞美佳3, 佐藤幸奈3, 大澤友裕4, 垣内大蔵5, 柳瀬恒明5, 遠渡純輝5, 澤祥幸6, 大野康5, 鈴木昭夫2,3, 杉山正1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 512-512, 2019. |
|---|
|
|
2-9-O17*-1. Economical effect by the intervention of the ICU exclusive duty pharmacist in painkilling, the sedative domain 安部敏生1, 才穂亮介2, 高井信幸3, 鹿島秀明4, 田中太郎5, 丸川征四郎3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 513-513, 2019. |
|---|
|
|
2-9-O17*-2. Renal function attention medicine efforts using bringing medicine differentiation data of a check 延藤勇1, 豊濱隆1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 514-514, 2019. |
|---|
|
|
2-9-O17*-3. Quantitative evaluation about the intrapulmonary drug delivery at problems extraction and inhaler erroneous operation at use of inhalant 末永佳奈1, 石戸恵理1, 平大樹1,2, 小出博義2, 上島智1, 奥田知将3, 山口将史4, 岡本浩一3, 岡野友信1, 中野恭幸4, 寺田智祐2, 角本幹夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 514-514, 2019. |
|---|
|
|
2-9-O17*-4. Of "stopping medicine management Web application during preoperation" development and the effectiveness, safe inspection 木村早希子1,2, 江本晶子2, 嘉村知子2, 祖川倫太郎2, 田崎正信2, 吉村麻里子1, 有水弘太3, 川口淳3, 水田貴久美1,4, 田篭康洋1,4, 夏秋政浩5, 梶原正貴5, 鶴岡ななえ6, 薬師寺祐介7, 檀上敦8, 谷川義則9, 高松千洋1,9, 平川奈緒美10, 蒲原啓司11, 野口満12, 能城浩和13, 坂口嘉郎10, 末岡榮三朗14, 成澤寛15, 木村晋也1,16 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 515-515, 2019. |
|---|
|
|
2-9-O18*-1. Result of the multi-type of job collaboration by the interstitial pneumonia pharmacist outpatient department: Extension of the medication continuance 薩摩由香里1, 楠田かおり1, 池末裕明1, 前田真美1, 室井延之1, 古郷摩利子2, 立川良2, 富井啓介2, 橋田亨1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 516-516, 2019. |
|---|
|
|
2-9-O18*-2. Effect examination of the foreign inhalational instruction using the lung function test value 安達圭織1, 相良克海4, 定村洋士1, 廣澤達哉2, 小田慎4, 松永康二郎3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 517-517, 2019. |
|---|
|
|
2-9-O18*-3. In the insomnia patients whom a benzodiazepine system sleeping drug is given to for a long term, weight loss/change is sleep and effect to give to anxiety 圓東寛基1, 重面雄紀1, 今井哲司1, 中川貴之1, 鶴身孝介2, 杉田尚子2, 磯部昌憲2, 村井俊哉2, 松原和夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 517-517, 2019. |
|---|
|
|
2-9-O18*-4. The association between hypoglycemia and combination drug with the sitagliptin administration in patients with Japanese type 2 diabetes: Than subanalysis results of multicenter cohort study SPIRITS-J 齋藤智之1,2, 大村寛敏1, 野尻宗子3, 代田浩之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 518-518, 2019. |
|---|
|
|
2-10-O19-1. It is compared the adverse event profile in the use of Osimertinib patients after the primary and second treatment 大柿滋1, 牛島智子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 519-519, 2019. |
|---|
|
|
2-10-O19-2. Search of the new preventive preparation for the lithium-induced renal failure using medical big data 坂東寛1, 合田光寛1, 神田将哉1, 武智研志3, 中馬真幸3, 座間味義人1,2, 桐野靖1, 中村敏己1, 寺岡和彦1, 石澤啓介1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 520-520, 2019. |
|---|
|
|
2-10-O19-3. Evaluation of the aspiration pneumonia onset risk using Anticholinergic Risk Scale 小瀬英司1, 平井利幸2, 関利一2, 安野伸浩1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 520-520, 2019. |
|---|
|
|
2-10-O19-4. Investigation about the delirium onset in patients during the steroid pulse enforcement 高橋葵1, 吉川明良1, 波多江崇2, 宮森伸一1, 開浩一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 521-521, 2019. |
|---|
|
|
2-10-O20-1. Effect of the combination of the P-glycoprotein inhibitor giving it to a bleeding risk of the dabigatran and the renal function 横田裕之1, 川上智恵子1, 土岐浩介1,2, 家田真樹2, 青沼和隆2, 本間真人1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 522-522, 2019. |
|---|
|
|
2-10-O20-2. Examination of the onset of carbohydrate metabolism abnormality drug prediction by the genetic analysis using the human hepatocytes chimera mouse 北原隆志1, 榎本初音2, 立木秀尚2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 523-523, 2019. |
|---|
|
|
2-10-O20-3. Analysis of the side effect of rosuvastatin and Bezafibrate combination case 井坂江吏香1, 神鳥周也2, 細野智美1, 土岐浩介1,2, 西山博之2, 本間真人1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 523-523, 2019. |
|---|
|
|
2-10-O20-4. Association of use and the fall event of suvorexant and the ramified microglia 石郷友之1, 近藤蕗1, 高田遼1, 立石莉穂1, 伊部裕太1, 藤居賢1, 北川学1, 木明智子1, 中田浩雅1, 宮本篤1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 524-524, 2019. |
|---|
|
|
2-10-O21*-1. Elucidation of the occurrence of formulations error mechanism based on the eyes trend of the pharmacist using the eye-tracking technique 辻敏和1, 永田健一郎1, 佐々木恵一2, 末次王卓1, 渡邊裕之1, 金谷朗子1, 増田智先1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 525-525, 2019. |
|---|
|
|
2-10-O21*-2. Investigation about the usefulness of the drug control summary in the medicine medicine cooperation 高井靖1, 前田雄太郎1, 木本珠美1, 松岡佳子1, 伊藤涼子1, 梶間勇樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 526-526, 2019. |
|---|
|
|
2-10-O21*-3. Interactive illness medicine cooperation with the health insurance pharmacy through the district pharmacist society 壁谷めぐみ1, 日比聡1, 長岡雅敏1, 岡本千晴1, 湯浅周1, 粥川哲2, 伊奈研次2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 526-526, 2019. |
|---|
|
|
2-10-O21*-4. Effect on test value by the adherence which we saw from Residual medicine adjustment report data obtained by Residual medicine cancellation PBPM 寺門祐介1, 平井利幸1, 関利一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 527-527, 2019. |
|---|
|
|
2-10-O22*-1. Administration adherence of mother of the preschooler and relation - administration environmental examination - of the actual situation and the pharmacist of the administration in the nursery school for appropriate medical treatment 柳奈津代1, 佐藤宏樹1,2, 澤田康文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 528-528, 2019. |
|---|
|
|
2-10-O22*-2. Investigation of the polypharmacy-related factor in Takarazuka city limits 吉岡睦展1, 杉生雅和1, 細見光一2, 門田憲亮3, 佐藤聖子3, 中出勝也3, 若松雄太1, 高子優子1, 横山聡2, 高田充隆2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 529-529, 2019. |
|---|
|
|
2-10-O22*-3. Cost effect analysis of the Durvalumab as the maintenance treatment for the unresectable local progress non-small-cell lung cancer 日高諒1, 古林健吾1, 前田知美1, 森脇健介1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 529-529, 2019. |
|---|
|
|
2-10-O22*-4. Tendency to onset of proteinuria with the VEGF inhibitor using JADER and nephrotic syndrome analysis 森川記道1, 内海敦志1, 横山匠太1, 大山展弘1, 西倉教子1, 原田靖子1, 西原昌幸2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 530-530, 2019. |
|---|
|
|
2-10-O23*-1. Look at the rear about the risk factor of the onset of diarrhea in naldemedine treated patients; mark investigation 岡本明大1, 水谷栄梨1,2, 池村健治1, 岩本卓也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 531-531, 2019. |
|---|
|
|
2-10-O23*-2. Effect on antibody mark rate of ZEVALIN(R) Yttrium (90Y) by the quantity of antibody solution addition 鈴木秀隆1, 加納大輔1, 望月伸夫1, 大橋周平2, 中神佳宏3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 532-532, 2019. |
|---|
|
|
2-10-O23*-3. We look at true doses of the regorafenib and the rear of the effect of treatment and examine a mark 羽鳥正浩1, 川上和宜1, 若槻尊2, 青山剛1, 中野泰寛1, 小林一男1, 鈴木賢一1, 山口研成2, 濱敏弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 532-532, 2019. |
|---|
|
|
2-10-O23*-4. Examination of cisplatin weight loss method and RDI for the decreased renal function patients in the GC therapy 河野光1, 龍島靖明1, 内田康光2, 金井邦光2, 門間哲雄2, 高橋邦雄1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 533-533, 2019. |
|---|
|
|
2-10-O24*-1. A randomized phase III controlled trial to test the usefulness of 5 mg of olanzapine for retching, the vomiting prevention at the cisplatin administration: J-FORCE study 矢内貴子1, 石川寛2, 中尾將彦3, 武井大輔4, 阪田安彦5, 藤田行代志6, 西村知恭7, 國米由希8, 古川美緒9, 見野靖晃10, 坂田幸雄11, 飯原大稔12, 橋本浩伸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 534-534, 2019. |
|---|
|
|
2-10-O24*-2. Examination of the adverse event expression time with the bortezomib administration using the adverse drug reaction database 坂部彩1, 頭金正博1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 535-535, 2019. |
|---|
|
|
2-10-O24*-3. The serious neutropenia in patients received high-dose irinotecan and examination about the serum bilirubin 大畑紘一1, 藤井宏典1, 左高史織1, 山田友奈美1, 加藤寛子1, 上村真也2, 岩下拓司2, 清水雅仁2, 鈴木昭夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 535-535, 2019. |
|---|
|
|
2-10-O24*-4. Examination - of male hormone levels after the medication to give effect - men hypogonadism that treatment with anticancer agent gives to a rat sex glandular function 片岡智哉1, 真川明将2, 鈴木純3, 中島晃3, 堀田祐志3, 前田康博4, 木村和哲1,2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 536-536, 2019. |
|---|
|
|
2-11-O25-1. Examination about the use of the antimicrobial with the antiPseudomonas aeruginosa activity at the COPD exacerbation 太田愛子1, 梅村拓巳1, 武藤義和2, 宮島紀彦1, 中村直人1, 山田哲也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 537-537, 2019. |
|---|
|
|
2-11-O25-2. Report of the AST activity first year in the Nagaoka Red Cross hospital 小林謙一1,3, 丸山智幸1,3, 西堀武明2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 538-538, 2019. |
|---|
|
|
2-11-O25-3. Practice and effect of the antimicrobial proper use support by the working full time pharmacist leadership 本田勝亮1,6, 石塚友一1,6, 柏原道志1,6, 長岡翔1,6, 釋悦子2,6, 石原冬馬2,6, 真壁利枝3,6, 宮木祐一郎4,6, 武地大維5,6, 齊藤一仁5,6, 渡邊卓哉5,6, 矢部勝茂1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 538-538, 2019. |
|---|
|
|
2-11-O25-4. Examination of the optimal blood level of vancomycin in MRCNS bacteremia treatment 竹内祐介1, 宮本朋佳1, 小泉祐一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 539-539, 2019. |
|---|
|
|
2-11-O26-1. Role of the pharmacist in the proper use support team about the antifungal agent 木全柾典1, 中川俊作1, 片田佳希1, 杉本充弘1, 吉田優子1, 糸原光太郎1, 深津祥央1, 佐藤夕紀1, 今井哲司1, 米澤淳1,2, 中川貴之1, 松村康史3, 長尾美紀3, 松原和夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 540-540, 2019. |
|---|
|
|
2-11-O26-2. Compatible examination in a renal failure development factor and the renal failure prediction-type Japanese after the cholistine sulfomethate sodium administration 田沼道也1, 田中昌代1, 中山裕一1, 加藤敏明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 541-541, 2019. |
|---|
|
|
2-11-O26-3. Aggressive intervention ... to introduction - blood culture-positive patients of pharmacist-led Antimicrobial Stewardship Program 佐々木康弘1,8, 天野美里1,8, 山口明子2,8, 金丸亜佑美3,8, 鈴木みき4,8, 知念直史5,8, 高安博史6,8, 矢野雅隆7,8 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 541-541, 2019. |
|---|
|
|
2-11-O26-4. An example of the eyes corneal ulcer that the intervention by the pharmacist was useful 柴田祐一1,2, 萩原真生2, 塩田有史1,2, 斎藤寛子1, 大西正文1, 浅井信博2,3, 小泉祐介2,3, 山岸由佳2,3, 三鴨廣繁2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 542-542, 2019. |
|---|
|
|
2-11-O27-1. Efforts for the quinolone antibacterial prescription reduction to UTIs 野田学1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 543-543, 2019. |
|---|
|
|
2-11-O27-2. Acute renal failure by vancomycin and piperacillin/tazobactam combination in febrile neutropenia treatment of patients with blood tumor 漣航平1,2, 土手賢史1, 堀内望1, 伊藤菜浪1, 村木優一2, 小林由佳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 544-544, 2019. |
|---|
|
|
2-11-O27-3. The use situation investigation of the oral antimicrobial in the foreign prescription for AMR measures 藤居賢1, 藤井怜史1, 清治翔伍1, 國本雄介1, 野々山雅俊1, 北川学1, 木明智子1, 中田浩雅1, 宮本篤1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 544-544, 2019. |
|---|
|
|
2-11-O27-4. An antimicrobial proper use plan and resistant bacteria decrease effect in our hospital 野口周作1,2, 吉田奈央1, 先崎貴洋1, 望月徹2, 笠原英城1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 545-545, 2019. |
|---|
|
|
2-11-O28-1. It is examined the usefulness of the cefazolin alternative agent for the infection prophylaxis after the operation 宇都健太1, 小牧誉典1, 中野公1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 546-546, 2019. |
|---|
|
|
2-11-O28-2. Infection treatment support of blood culture-positive patients 吉田奈央1, 野口周作1,2, 先崎貴洋1, 望月徹2, 笠原英城1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 547-547, 2019. |
|---|
|
|
2-11-O28-3. Does becoming it need non-adoption of the oral third generation cephem-based antimicrobial? Use situation ... after ... reduction failure 長谷川浩司1, 宮崎祐介1, 岩本里味1, 岩城晃一1, 石坂忠博1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 547-547, 2019. |
|---|
|
|
2-11-O28-4. Goal setting and evaluation of the use number of patients of the carbapenem medicine in the antimicrobial proper use support team (AST) activity per day 小野祐志1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 548-548, 2019. |
|---|
|
|
2-11-O29-1. Investigation about the initial therapeutic drug of the MRSA infection in the large Hannan medical center 吉田三矢1, 南翔大1, 田川知津子1, 三浦菜々子1, 鴨田夏実1, 辰巳晃造1, 畝佳子1, 政道修二1, 志馬伸朗2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 549-549, 2019. |
|---|
|
|
2-11-O29-2. Change of the use of antimicrobial trend in inside the hospital accompanied with the supply stop of the cefazolin 池谷修1, 高野八百子1, 長谷川直樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 550-550, 2019. |
|---|
|
|
2-11-O29-3. It is the hand hygiene observance situation investigation of the ward pharmacist by the pharmacy school business trainee using the observation method directly 多賀允俊1, 高橋喜統1, 政氏藤玄1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 550-550, 2019. |
|---|
|
|
2-11-O29-4. Evaluation of making of the blood culture sampling support protocol to patients with S.aureus bacteremia and the operation 片岡優1, 瀬戸崇光1, 小田怜1, 松村友和1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 551-551, 2019. |
|---|
|
|
2-11-O30*-1. The proton pump inhibitor is associated with iron-metabolism abnormality through hepcidin 濱野裕章1, 池田康将2, 堀ノ内裕也2, 合田光寛1, 座間味義人1,3, 桐野靖1, 中村敏己1, 寺岡和彦1, 石澤啓介1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 552-552, 2019. |
|---|
|
|
2-11-O30*-2. Examination about onset of dyslipidemia time and the risk factor in Everolimus remedy renal-transplant recipients 佐藤汐莉1, 赤嶺由美子1, 加賀谷英彰1, 佐藤滋2, 三浦昌朋1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 553-553, 2019. |
|---|
|
|
2-11-O30*-3. Fistulation by the Lenvatinib in thyroid cancer and analysis of the associated factor of the tumor-related bleeding スタッブ由紀子1, 西山明宏2, 菅幸生3, 藤田未来也3, 松下良3, 矢野聖二2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 553-553, 2019. |
|---|
|
|
2-11-O30*-4. The effect that the polypharmacy of children gives to Adverse Drug Event expression 杉岡まゆ子1, 舘知也1,2, 古山愛紗1, 村山あずさ1, 青山智2, 大澤友裕2, 勝野隼人1, 松山卓也1, 野口義紘1, 安田昌宏2, 水井貴詞2, 後藤千寿2, 寺町ひとみ1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 554-554, 2019. |
|---|
|
|
3-7-O31-1. Efforts of the adoption pharmaceutical products adequacy in the small hospital 堀内賢一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 555-555, 2019. |
|---|
|
|
3-7-O31-2. Examination of the optimal consumption adjustment method at antimicrobial supply restrictions 宇夛裕基1, 藺上圭子1, 今井富紀子1, 小路晃平1, 鳥羽英理子1, 中野智尋1, 松永典子1, 吉田芙美1, 竹田和喜1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 556-556, 2019. |
|---|
|
|
3-7-O31-3. Stability evaluation by the cryopreservation of the hospital preparation "poor roasting liquid of the persimmon" 中村仁美1, 加納大輔1, 馬見新佳那子1, 鈴木秀隆1, 望月伸夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 556-556, 2019. |
|---|
|
|
3-7-O31-4. Efforts aiming at hospital preparation duties improvement in the Nagoya University Hospital 宮崎雅之1, 熊倉康郎1, 藤野泰孝1, 矢野亨治1, 山田清文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 557-557, 2019. |
|---|
|
|
3-7-O32-1. Realization of the ideal inventory control by the Cubixx (refrigerator with the RFID function) introduction 阿登大次郎1, 津崎秀斗1, 濱口健一1, 八代哲也1, 東海秀吉1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 558-558, 2019. |
|---|
|
|
3-7-O32-2. About the abolition of the "increase and decrease" rule and the impact of establishing a formulary committee on the adoption of in-hospital drugs 城山めぐみ1, 細田未紀1, 千原里美1, 上田宏1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 559-559, 2019. |
|---|
|
|
3-7-O32-3. Duties improvement effect by the drug management system introduction 大屋和福1, 児玉雄大1, 見尾谷昇1, 遠藤秀竜1, 細野真吾1, 堀浩子1, 山崎崇1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 559-559, 2019. |
|---|
|
|
3-7-O32-4. Participation situation of current situation investigation - AST and guidelines on perioperative prophylactic antimicrobial compliance - in the Gifu medical institution 松岡知子1,6, 上田秀親2,6, 平下智之3,6, 丹羽隆4,6, 青山智5,6, 吉村知哲1,6 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 560-560, 2019. |
|---|
|
|
3-7-O33-1. Economical evaluation of formal doubt inquiry calculated than doubt inquiry investigation 田中秀和1, 若林進2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 561-561, 2019. |
|---|
|
|
3-7-O33-2. Construction of the doubt inquiry system aiming at appropriate prescription depending on renal function 山本高範1, 朝居祐貴1, 鈴山直寛1, 阿部康治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 562-562, 2019. |
|---|
|
|
3-7-O33-3. Analysis of the factor to contribute to the origin of doubt inquiry in the drugstore and a cause 加藤木俊廣1, 佐藤宏樹1,2, 柳奈津代1, 八木下敏彰3, 久住茂3, 月岡良太3, 森澤あずさ3, 大石美也3, 澤田康文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 562-562, 2019. |
|---|
|
|
3-7-O33-4. Efforts to the TPN no bacteria preparation by the pharmacist in the pediatric hospital 石井美野里1, 加藤千枝子1, 清水祐一1, 福原悠太1, 浅井翔子1, 加戸奈穂美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 563-563, 2019. |
|---|
|
|
3-7-O34-1. Video image analysis of success and the failure case of the instillation self-medication 池田博昭1,2, 高本彩音1, 岩崎順也1, 中妻章1, 徳村忠一1, 飯原なおみ1, 二宮昌樹1, 池田純子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 564-564, 2019. |
|---|
|
|
3-7-O34-2. Exploring of the new healthy fair enforcement method based on an attitude survey to self-medication 池田佳代1, 細井徹1, 三浦常代2, 吉井美智子1, 杉山政則3, 野村祐仁4, 豊見雅文2, 小澤光一郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 565-565, 2019. |
|---|
|
|
3-7-O34-4. Through the introduction example to efforts - treatment at home clinic to the remedy drug adjustment support charges as the family pharmacist - 江口真理子1,2, 長崎悦子1, 汐待加織2, 吉田恭子2, 橋野勇一2, 中堀亮一3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 566-566, 2019. |
|---|
|
|
3-7-O35-1. Attitude survey of the physician for the inquiry simplification of the neighborhood 5 Hospital unification 奥薗春奈1, 谷本祐子1, 木下里紗1, 吉良俊彦1, 石倉久美子2, 森田智子3,6, 村田久枝4, 真常美紀5, 津田宜志7,8, 堀越博一7,9, 中島由利恵10, 村西泰法10, 土生康司11, 但馬重俊3,12, 小林政彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 567-567, 2019. |
|---|
|
|
3-7-O35-2. Analysis and evaluation of the inhalational instruction, results contact vote with a hospital cooperating with a health insurance pharmacy 小松正典1, 小松桐子1, 中村道代1, 浅野涼子1, 浅山美智子1, 山口直子1, 前田竜太郎1, 泊口豊1, 福森淳1, 寺脇康文1, 樫田祐一2, 中村伸也2, 山下義仁2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 568-568, 2019. |
|---|
|
|
3-7-O35-3. One case that hospital pharmacist and a health insurance pharmacy pharmacist cooperated with a pharmacist outpatient using a telephone follow-up, and intervened 加藤良隆1, 江島智彦1, 松本有咲1, 溝口貴大2, 村上怜3, 友金幹視1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 568-568, 2019. |
|---|
|
|
3-7-O35-4. It is ... through the medicine medicine cooperation between examination - drugstore, the hospital about the adherence of the oral 5-ASA preparation for patients with inflammatory bowel disease 鈴木景子1, 藤井宏典1, 山内智世1, 加藤寛子1, 石原正志1, 飯原大稔1, 安田浩二1, 伊野陽子2, 玉木啓文2, 山下修司2, 井口和弘2, 野田義紘2, 寺町ひとみ2, 鈴木昭夫2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 569-569, 2019. |
|---|
|
|
3-7-O36-1. Result and the problem that continued Nanto-shi medicine medicine cooperation promotion workshop for four years 鶴居勝也1, 小川紗知1, 讓原千広1, 波多晶子1, 中澤美樹子1, 橋爪和恵1, 窪田真弓1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 570-570, 2019. |
|---|
|
|
3-7-O36-2. About the actual situation of the Residual medicine coordinated based on the prior agreement protocol in the outside Parliament prescription of our hospital 永山浩司1, 松村高志1, 安田亜矢1, 大森清孝1, 三浦誠1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 571-571, 2019. |
|---|
|
|
3-7-O36-3. About the operational construction of the tracing report for the purpose of the information sharing with the health insurance pharmacy 大谷寧次郎1, 畔柳敏弥1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 571-571, 2019. |
|---|
|
|
3-7-O36-4. For the promotion of the inquiry-free protocol in the prior agreement item 前田貴子1, 堀内あす香1, 池田芽衣1, 田中佳奈1, 大坪達弥1, 野口裕介1, 神田英一郎1, 岡橋孝侍1, 藤田敦夫1, 友金幹視1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 572-572, 2019. |
|---|
|
|
3-8-O37-1. Comparison ... with establishment - regular hospital of the quantity of duties rating system for the appropriate staff placement in the ward drug duties of the intensive care domain 只見智恵子1, 浜田幸宏1, 佐藤美絵1, 宮崎雅子1, 木村桂子1, 金田純子1, 藤本裕子1, 木村利美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 573-573, 2019. |
|---|
|
|
3-8-O37-2. Evaluation of the drug information contents which we provided in the multi-type of job by the intensive care unit working full time pharmacist 宮田祐一1, 藤村一軌1, 須賀明輝1, 岩崎睦1, 上野栞1, 大塚秀人1, 桃井歩1, 中村雅敏1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 574-574, 2019. |
|---|
|
|
3-8-O37-3. After the intensive care unit discharge an investigation about the self-discipline of patients, Single institution rearward observational study 吉廣尚大1, 冨田隆志2, 櫻谷正明3, 無漏田香穂1, 小野塚和人1, 向井一樹1, 橋本佳浩1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 574-574, 2019. |
|---|
|
|
3-8-O37-4. Contribution of the pharmacist by the use actual situation and the set operation of the antiarrhythmic drug at the cardiopulmonary resuscitation 篠田健一1, 芝田和輝1, 新家由莉1, 立川一匡1, 濱田竜治1, 庵弘幸2, 大原一将2, 野々村誠2, 亀山智樹2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 575-575, 2019. |
|---|
|
|
3-8-O38-1. Study on intervention effect of the pharmacist to the medical therapy in the pediatric intensive care unit 津田浩和1, 井上暁輝子1, 由留部圭伍1,2, 増井裕亮1,2, 大和由佳1, 安河内尚登1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 576-576, 2019. |
|---|
|
|
3-8-O38-2. Investigation of the drug having an influence on nausea, vomiting (PONV) after the operation 菊地義明1,2, 高橋誠1, 藤田果那1, 庄崎沙耶1, 朝倉幹己1, 田中耕太1, 木下愛1, 山本翔大1, 山田将悟1, 前川英輝1, 藤林遼1, 鈴木直哉1, 青田忠博1, 小林道也2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 577-577, 2019. |
|---|
|
|
3-8-O38-3. About the current situation of a doubt inquiry by the ICU ward permanent residence of the pharmacist and the consultation meeting a demand 伊藤博美1, 野々内裕紀1, 河野恵1, 真継賢一1, 濱口良彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 577-577, 2019. |
|---|
|
|
3-8-O38-4. About the head trauma instruction situation by the acute phase response of the patients with head trauma during antithrombotic drug remedy and the pharmacist 中西裕明1, 瀬下貴大1, 西崎恵利1, 荻野仁未1, 岡橋孝侍1, 藤田敦夫1, 友金幹視1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 578-578, 2019. |
|---|
|
|
3-8-O39-1. Drug history investigation of the follow with the telephone after the formulations which the antiinfluenza medicine remedy patients received 笹原侑祐1, 高橋渉2, 池貴幸3, 板垣幸太郎2, 長沼未加2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 579-579, 2019. |
|---|
|
|
3-8-O39-2. Effective evaluation of the inhalational device choice protocol by the pharmacist for patients with climax COPD 塩飽英二1, 土手賢史1, 金子忍1, 岩田敏之2, 西村尚志2, 野崎歩1, 小林由佳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 580-580, 2019. |
|---|
|
|
3-8-O39-3. Approach to JMIP (the foreign patients acceptance medical institution certification system) in our hospital drug department 安田陽子1, 益子里美1, 浅利貴奈1, 福山博務1, 真柴友紀1, 三村雅一2, 塩地園代1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 580-580, 2019. |
|---|
|
|
3-8-O39-4. The effect that polypharmacy gives to Functional Independence Measure (FIM) 村山あずさ1, 舘知也1,2, 大坪愛実1, 勝野隼人1, 上野杏莉1, 野口義紘1, 樋島学3, 青山智2, 安田昌宏2, 水井貴詞2, 後藤千寿2, 寺町ひとみ1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 581-581, 2019. |
|---|
|
|
3-8-O40-1. Introduction of PBPM by hospitalization support room duties and duties development of a wide variety of pharmacists 妹尾啓司1, 吉川明良1, 水上皓喜1, 伊藤実里1, 岡崎夏実1, 阪田安彦1, 開浩一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 582-582, 2019. |
|---|
|
|
3-8-O40-2. Examination of the at-home self-injection instruction of the pharmacist outpatient department pharmacist by the in-house prescription 上野良夫1, 玉木真紀子2, 伊原木沙智代1, 三枝貢1, 眞鍋伸次1,2, 石川真也3, 村尾敏4, 高木雄一郎5, 前田剛6, 森由弘6, 厚井文一6 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 583-583, 2019. |
|---|
|
|
3-8-O40-3. Efforts for the hospitalization support manual preparation in the drugstore 鈴木由佳1, 佐野麻璃奈1, 田中富美1, 瀬戸洋行1, 阿部元昭1, 出口佳奈美1, 山田佳代1, 出口華子1, 高田恭子1, 渡邊裕子1, 安田美代子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 583-583, 2019. |
|---|
|
|
3-8-O40-4. About the duties of the pharmacist in the hospitalization and release support center 岡村礼江1, 藤田祐規子1, 河田麻美1, 前田昌徳1, 笠原庸子1, 林聖二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 584-584, 2019. |
|---|
|
|
3-8-O41-1. Investigation about the medication situation of the prescription pharmaceutical products in the cancer perioperative patients and the intake situation of the supplement 渡部大介1, 水頭望1, 齊藤由記1, 日比野英幸1, 近江一太1, 橋本浩伸1, 関口昌利1, 近野健一1, 牧野好倫1, 山口正和1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 585-585, 2019. |
|---|
|
|
3-8-O41-3. Evaluation of the working full time system in the foreign chemotherapy room in the pharmacist 小川智孝1, 小椋千絵1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 586-586, 2019. |
|---|
|
|
3-8-O41-4. The need and construction of the pharmacist outpatient department in the hospital pharmacist 大西順子1, 坪井仁美1, 澤之珠1, 岩野大輔2, 石松義人2, 湯本英一郎2, 渡辺佑介2, 冨岡憲明2, 渡辺伸一郎2, 渡辺哲夫2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 587-587, 2019. |
|---|
|
|
3-8-O42-1. Role of the pharmacist in the perioperative pharmaceutical management in the medicine confirmation outpatient department 吉川里香1, 川島佳恵1, 石本学司1, 奥野昌宏1, 田中詳二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 588-588, 2019. |
|---|
|
|
3-8-O42-2. An index and the threshold to evaluate the appropriate tablet, shape of the capsule for patients 佐藤宏樹1,2, 壁矢健司3, 堀里子4, 三浦康正5, 澤田康文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 589-589, 2019. |
|---|
|
|
3-8-O42-3. Examination of efforts and the problem to the polypharmacy measures that started from the hospitalization and release support center in our hospital 大森清孝1, 藤田葵1, 長谷川広樹1, 尾浜直子1, 櫻井登代子1, 大津山裕美子1, 三浦誠1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 589-589, 2019. |
|---|
|
|
3-8-O42-4. The perioperative pharmaceutical management intervention improves quality metrics and affects the decrease in complication rate in the aftercare 平田一耕1, 原田佳弘2, 大友謙太朗2, 早坂磨優1, 寺口徹1, 船木麻美1, 岩本真拡1, 石塚寛和1, 小林収4, 舟越亮寛1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 590-590, 2019. |
|---|
|
|
3-9-O43-1. Association with adverse effect expression and the blood level in daptomycin treated patients 山下祐二1, 山田孝明1, 西田留梨子2, 三宅典子2, 下野信行2, 戸石七海3, 下田遥香3, 曽田翠3, 北市清幸3, 石田茂1, 渡邊裕之1, 江頭伸昭1, 増田智先1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 591-591, 2019. |
|---|
|
|
3-9-O43-2. Evaluation of antimicrobial consultation meeting a demand, the suggestion contents of the antimicrobial proper use support team in the southern part of Saiseikai Yokohama-shi Hospital 畠山英司1, 松本勝城1, 村田明子1, 山崎彩華1, 深沢貴志1, 川嶋郁2, 藤田浩之3, 加藤一郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 592-592, 2019. |
|---|
|
|
3-9-O43-3. Intervention and antimicrobial proper use support to the otolaryngology perioperative clinical path in the pediatric special hospital 福原悠太1, 中村悠佳1,2, 川端未祈1, 渡邉真菜実1, 甲斐維子1, 加戸奈穂美1, 井上真規3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 592-592, 2019. |
|---|
|
|
3-9-O43-4. Examination about the dose of the ST medical mixture in the pneumocystis pneumonia prophylaxis of HIV non-infection patients on dialysis 山下花南恵1, 池末裕明1, 室井延之1, 吉本明弘2, 橋田亨1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 593-593, 2019. |
|---|
|
|
3-9-O44-1. Efforts to pass inspection intervention for the proper use of the perioperative antimicrobial included in the clinical path 馬場安里1, 中川博雄1, 岸川礼子1, 今村政信1,2, 赤松隼人1, 福重友理1, 藤田あゆみ2, 田代将人2, 田中健之2, 兒玉幸修1, 中村忠博1, 泉川公一2, 佐々木均1, 室高広1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 594-594, 2019. |
|---|
|
|
3-9-O44-2. The need evaluation of the prophylactic antimicrobial in front of the art in the cataract surgery 後藤裕美子1, 柴田祐一1, 大西正文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 595-595, 2019. |
|---|
|
|
3-9-O44-3. A review of the prophylactic antimicrobial oral after the surgery and the evaluation 田中広紀1, 粟屋真理子1, 戸村和希1, 鈴木絢子2, 島本一志1, 柳原麻里2, 横江琢也3, 池田裕一4, 渡邊徹1, 佐々木忠徳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 595-595, 2019. |
|---|
|
|
3-9-O44-4. Effect on treatment of the Candida blood symptom accompanied with the enforcement of Antifungal stewardship 藤田将輝1,2, 澤田真嗣1,2, 大山翔1, 村木優一3, 友金幹視1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 596-596, 2019. |
|---|
|
|
3-9-O45-1. It is examined shortening in the administration days in the oseltamivir prophylaxis for the roommate 杉山昌宏1,2, 照沼保徳1,2, 西畑利恵子2, 宮澤正紹2, 佐々島朋美2, 田井真弓2, 皆川陽子2, 佐藤弘子2, 梶原徹1, 宇都直哉1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 597-597, 2019. |
|---|
|
|
3-9-O45-2. Investigation of the use of oral antimicrobial trend after the adoption item reduction of the third generation oral cephalosporin medicine 小林正拓1, 鵜野竜馬1, 上野太佑1, 長原しのぶ1, 寺谷俊昭1, 大下直宏1, 上田晃1, 川本由加里1, 後藤仁和1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 598-598, 2019. |
|---|
|
|
3-9-O45-3. Activity evaluation (comparison with pharmacist-led AS) of antimicrobial proper use support team (AST) 遠山泰崇1, 堀光愛子1, 福島祐子1, 新宮裕美1, 柴田麻美1, 小野友香理1, 福田智哉1, 武石優哉1, 野村一馬1, 村上里穂1, 後藤友里絵1, 井上真1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 598-598, 2019. |
|---|
|
|
3-9-O45-4. Efforts ... mainly on the hospital crossing-like AST-related activity - blood culture examination suggestion in the middle scale medical treatment type hospital 行本拓史1, 田中千恵2, 佐近滝実子2, 赤川聡美2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 599-599, 2019. |
|---|
|
|
3-9-O46-1. Examination about the dose of fosphenytoin in children 岡本剛1, 橋本磨里奈1, 古谷絵茉里1, 安川久美2, 小林恵美子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 600-600, 2019. |
|---|
|
|
3-9-O46-2. Correlative analysis of trough level/doses of sirolimus and tacrolimus in the lung transplantation patients 菊地正史1,2, 重田健介1, 田中雅樹2, 高崎新也2, 秋場美紀3, 大石久4, 佐渡哲4, 松田安史4, 野田雅史4, 山口浩明4, 岡田克典3,4, 眞野成康1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 601-601, 2019. |
|---|
|
|
3-9-O46-3. The construction of blood drug concentration predictive model of zonisamide: Examination by the population pharmacokinetics analysis in consideration of enzyme induction 金子哲也1, 鬼木健太郎1, 古郡規雄2, 石津棟暎3,4, 猿渡淳二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 601-601, 2019. |
|---|
|
|
3-9-O46-4. Association of blood level and a side effect, the clinical response of the hepatocytes cancer therapeutic drug Lenvatinib 野田哲史1, 若杉吉宣1, 藪田直希1, 須藤正朝1, 平大樹1,2, 飯田洋也3, 大崎理英4, 藤本剛英4, 谷眞至3, 安藤朗4, 森田真也1, 寺田智祐1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 602-602, 2019. |
|---|
|
|
3-9-O47-1. Evaluation of the blood level change by the changes from voriconazole parenteral injection to an oral formulation 原田紗希1, 丹羽隆1, 星野佑介1, 伊藤朱里1, 藤林彩里1, 鈴木昭夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 603-603, 2019. |
|---|
|
|
3-9-O47-2. The effect that onset of diarrhea during voriconazole remedy gives to blood level, an absorption factor drop 中山裕一1, 折井孝男1, 臼杵憲祐2, 加藤敏明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 604-604, 2019. |
|---|
|
|
3-9-O47-3. Examination about the initial administration plan of vancomycin between young people and elderly people 高田容希1, 小川智孝1, 小椋千絵1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 604-604, 2019. |
|---|
|
|
3-9-O47-4. It is comparison ... of ... analysis software and guidelines recommendation doses about administration plan in the vancomycin initial administration 永光華菜1, 森田真樹子1, 迫田英樹1, 橋本未雷2, 谷口潤1, 尾之江剛樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 605-605, 2019. |
|---|
|
|
3-9-O48-1. Examination of the effect factor to give to a trough level of the rivaroxaban in patients with atrial fibrillation 飯塚芽依2, 金城貴彦2, 中川潤一1, 上野桂代1, 富田泰史2, 新岡丈典1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 606-606, 2019. |
|---|
|
|
3-9-O48-2. Effect of the pharmacokinetics-related genetic polymorphism giving it to blood level of the Perampanel 大久保翔1, 赤嶺由美子1, 菊池結花2, 三島和夫2, 三浦昌朋1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 607-607, 2019. |
|---|
|
|
3-9-O48-3. The development of the LC-MS/MS method for human serum nivolumab densitometry using the immunoglobulin G refinement to immobilize and the trypsin digestion and the clinical application 阿部一樹1, 柴田海斗1, 内藤隆文1, 柄山正人2, 前川真人3, 須田隆文4, 山田康秀2, 川上純一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 607-607, 2019. |
|---|
|
|
3-9-O48-4. Basic examination for the construction of the simultaneous assay of the psychotropic drug by LC-MS/MS using Insource CID 小林大典1, 前川正充1, 鈴鹿雅人1, 岩渕理子1, 高崎新也1, 菊地正史1,2, 塚本多矩3, 早川禎宏3, 小倉次郎1, 佐藤祐司1, 眞野成康1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 608-608, 2019. |
|---|
|
|
3-10-O49-1. Elucidation of the digestive organ toxicity expression of metformin mechanism due to a serotonin change change 奈良部友花1, 白坂善之1, 内山弘貴1, 鷹野遥1, 岸本久直1, 井上勝央1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 609-609, 2019. |
|---|
|
|
3-10-O49-2. The effect of the drink giving it to the gastrointestinal absorption change of oral pharmaceutical products and the quantitative mechanism analysis 鮒井悠汰1, 白坂善之1, 竹村美由記1, 田中裕己1, 川喜多佑香1, 澤村定1, 岸本久直1, 井上勝央1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 610-610, 2019. |
|---|
|
|
3-10-O49-3. Itraconazole and effect of the metabolite concentrations to give to the serum creatinine level 井元優美1, 内藤隆文1, 小野孝明2, 川上純一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 610-610, 2019. |
|---|
|
|
3-10-O49-4. Pharmacokinetic analysis - vancomycin infusion ... using the artificial intelligence (Support Vector Regression) 山口泰弘1,4, 中村敦士1, 浦本邦弘1, 高城沙也香2, 小柳悟3, 大戸茂弘4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 611-611, 2019. |
|---|
|
|
3-10-O50-1. Establishment of the high sensitive assay of free form pazopanib concentrations using UPLC-MS/MS 松本麻美1,2, 白岩健1, 鈴木陽介2, 田中遼大1, 佐藤雄己1, 伊東弘樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 612-612, 2019. |
|---|
|
|
3-10-O50-2. - that effect - sebum that skin surface environment gives to the transdermal absorbency of the commercial fentanyl patch disturbs absorption of the fentanyl 林友典1, 高科結衣2, 川口陽奈子2, 永福紡2, 松岡寛1, 川畑篤史2, 長井紀章2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 613-613, 2019. |
|---|
|
|
3-10-O50-3. The effect that oral anticancer medicine and intestinal tract immune function give to pro-discharge transporter expression 保田元気1, 小林正紀2, 窪田篤人1, 更科壮太1, 鳴海克哉2, 古堅彩子2, 鈴木裕治3, 鈴木夏子3, 井関健2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 613-613, 2019. |
|---|
|
|
3-10-O50-4. Relations with a change of the CYP3A activity in the asthmatic patients and inflammatory related molecules 鈴木裕也1, 平井啓太1, 下敷領貴之1, 木村朋起1, 白井敏博2, 伊藤邦彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 614-614, 2019. |
|---|
|
|
3-10-O51-1. Medical economic effect by test value mention to a prescription 國津侑貴1, 森河内彩1, 平大樹1,2, 十亀裕子3, 上西幸治1, 星野伸夫1, 寺田智祐1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 615-615, 2019. |
|---|
|
|
3-10-O51-2. Costs comparison depending on a treatment strategy choice in the terminal phase of patients with cancer at admission 橋本悠生1,4, 三ツ木英子1, 川名賢一郎1, 後藤一美1, 林章敏2, 利根川崇3, 五十嵐中4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 616-616, 2019. |
|---|
|
|
3-10-O51-4. Comparison of the tendency to detection of the signal detection algorithm of the pharmaceutical products interaction 野口義紘1, 舘知也1, 寺町ひとみ1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 617-617, 2019. |
|---|
|
|
3-10-O52-1. Examination of the medical economics about the way of the outside Parliament prescription in the night emergency visit 寺井大輝1,2,3, 大石学2, 村田雄介1, 江川孝3, 遠城寺宗近3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 618-618, 2019. |
|---|
|
|
3-10-O52-3. Cost effectiveness analysis of the Lenvatinib as the primary treatment for unresectable stem cell cancer 古林健吾1, 日高諒1, 前田知美1, 森脇健介1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 619-619, 2019. |
|---|
|
|
3-10-O52-4. Attempt of the cost effectiveness evaluation of the nivolumab + ipilimumab combination therapy as the primary treatment for progressive nephrocyte cancer 前田知美1, 日高諒1, 古林健吾1, 森脇健介1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 620-620, 2019. |
|---|
|
|
3-10-O53-1. Analysis of the factor having an influence on the extra effect and liver function test value improvement of the SGLT2 inhibitor 竹澤崇1, 鳥居慶子1, 三村享1, 本木絵梨奈1, 山折大1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 621-621, 2019. |
|---|
|
|
3-10-O53-2. Efforts and results of rounds team and the pharmacist for the medical therapy of patients with old diabetes ソディ保子1, 森あさひ1, 弓場優佳1, 大西暁枝1, 山本里香1, 松山温子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 622-622, 2019. |
|---|
|
|
3-10-O53-3. Safety [longitudinal study] of the sustained GLP-1 receptor agonist for the dialysis case 前川志穂1, 谷口靖樹1, 田中勝正1, 前川純一1, 中島和喜1, 羽田麻希1, 松浦史佳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 622-622, 2019. |
|---|
|
|
3-10-O53-4. Relation of a change and the pharmacist of blood glucose level, the insulin dose of the pregnant woman who experienced gestational diabetes, the diabetes merger pregnancy 三上有希1, 澤井麻記1, 山野言2, 前田万里紗3, 野崎歩1, 長嶋一昭2, 藤井剛3, 小林由佳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 623-623, 2019. |
|---|
|
|
3-10-O54-1. Diabetes medical therapy of each patients to choose among pharmacokinetics 富岡節子1, 山崎勝弘2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 624-624, 2019. |
|---|
|
|
3-10-O54-2. Examination about the usefulness of the DPP-4 inhibitor in the pancreatic cancer postoperative blood sugar treatment 上代大地1, 大東敏和1, 林華代1, 平田かおり1, 佐伯康之1, 垰越崇範1, 中川直哉2, 上村健一郎2, 村上義昭2, 松尾裕彰1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 625-625, 2019. |
|---|
|
|
3-10-O54-3. Examination of the antidiabetic drug used in our hospital for a blood sugar rise at use of steroid 安部真一1, 中村江理1, 高橋友佳1, 鈴木英則1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 625-625, 2019. |
|---|
|
|
3-10-O54-4. The comparison between participant and HbA1c level of the nonparticipant to the meeting (we instruct it continuously) to review and change of the number of the drugs 滝澤康志1, 曽山恭子1, 鈴木隆子1, 久保田令枝1, 山谷秀喜2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 626-626, 2019. |
|---|
|
|
3-11-O55-1. Evaluation of the in-hospital correspondence of the eye disorders by the anticancer medicine tears shift and the lacrymal duct ophthalmology practice cooperation flow construction 関根佳代1,2, 大谷美子1, 辻村秀樹2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 627-627, 2019. |
|---|
|
|
3-11-O55-2. The case that was taking Abiraterone ester acetate tablets, and showed protraction of the hypokalemia 大野凜太郎1, 森清人2, 菊地隆之3, 沢仁美1, 斎藤和悦1, 稲見正幸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 628-628, 2019. |
|---|
|
|
3-11-O55-3. Obesity, the overweight is an aggravation risk factor of the hypertriglyceridemia by the bexarotene 真川明将1,2, 早川智章1, 須藤遥1,2, 森悠香梨2, 堀田祐志2, 近藤勝弘1, 木村和哲1,2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 628-628, 2019. |
|---|
|
|
3-11-O55-4. Fundamental researches about the inhibitory effect of the alogliptin for anticancer medicine-induced peripheral neuropathy 重松奈央1, 川尻雄大1, 清水栞1, 峯圭佑1, 小林大介1, 島添隆雄1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 629-629, 2019. |
|---|
|
|
3-11-O56-1. Example that rheumatoid arthritis aggravated after the Lenvatinib for the hepatocellular carcinoma, the sorafenib administration 野坂陽子1, 樋口純一1, 上野真行2, 西村健二1, 森谷康志1, 亀井健人1, 高柳和伸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 630-630, 2019. |
|---|
|
|
3-11-O56-2. The onset of thromboembolism situation in the patients who received Pembrolizumab therapy 磯田祥1,2,3, 佐藤雄己2, 龍田涼佑2, 中原良介2, 安達和宏3, 縄田好一1, 伊東弘樹2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 631-631, 2019. |
|---|
|
|
3-11-O56-3. Relations with expression situation and RDI of peripheral neuropathy in the rhabdomyosarcoma vincristine + actinomycin D+ cyclophosphamide therapy 前勇太郎1, 三木真梨杏1, 横川貴志1, 渡邉大至1, 友松純一2, 高橋俊二2, 濱敏弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 631-631, 2019. |
|---|
|
|
3-11-O56-4. One case that developed a drug-related aortitis syndrome by peg filgrastim subcutaneous injection 石井聡一郎1, 櫻下弘志1, 真志田絵美子1, 佐伯康之1, 松尾裕彰1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 632-632, 2019. |
|---|
|
|
3-11-O57-1. The effect that a decreased renal function gives in the effectiveness of oxaliplatin and safety 渡辺大地1, 藤井宏典1, 山田友奈美1, 松橋延壽2, 高橋孝夫2, 吉田和弘2, 鈴木昭夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 633-633, 2019. |
|---|
|
|
3-11-O57-2. The examination of the risk factor of the hyponatremia by the cisplatin: Case control study 畠山史朗1,2, 志田敏宏1, 山口浩明1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 634-634, 2019. |
|---|
|
|
3-11-O57-3. Examination of the early risk of death factor in patients with non-small cell lung cancer which Pembrolizumab monotherapy was given in 七尾谷充1, 森彩夏1, 宮坂優人1, 稲野寛1, 菅原充広1, 厚田幸一郎1,2, 西成田詔子3, 楠原政一郎3, 石原未希子3, 日吉康弘3, 笠島真志3, 福井朋也3, 井川聡3, 横場正典4, 三藤久5, 久保田勝3, 片桐真人4, 猶木克彦3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 634-634, 2019. |
|---|
|
|
3-11-O57-4. Inspection of the symptom improvement effect with the current situation and the medical therapy of eye disorders due to docetaxel 野口裕介1,2, 川島悠吾2, 丸山恵未2, 瓦比呂子2, 徳山洋子2, 友金幹視1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 635-635, 2019. |
|---|
|
|
3-11-O58-1. About the possibility that proteinuria to develop early in administration in the bevacizumab administration for patients with breast cancer becomes the effect of treatment predictor 田中裕章1, 高橋功一1, 山口佳津騎1, 安宅希美子1, 本田由紀1, 元木貴大1, 加地雅人1, 小坂信二1, 芳地一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 636-636, 2019. |
|---|
|
|
3-11-O58-2. Effect of various 5-HT3 receptor blockers on cisplatin-induced renal failure 神田将哉1,2, 合田光寛1,2, 村井陽一2, 吉田愛美2, 新村貴博2, 石澤有紀3, 座間味義人1,2, 中馬真幸4, 濱野裕章1, 岡田直人1, 武智研志4, 堀ノ内裕也5, 池田康将5, 桐野靖1, 中村敏己1, 寺岡和彦1, 石澤啓介1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 637-637, 2019. |
|---|
|
|
3-11-O58-3. Examination about the effect that a decreased liver function gives to side effect of TS-1 expression 柴田有紀1, 安藤洋介2, 西部星来2, 石原拓磨3, 平嶋一貴2, 田中千裕1, 池田義明1, 林高弘1,2, 河田健司4, 山田成樹2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 637-637, 2019. |
|---|
|
|
3-11-O58-4. An example of the onset of hand-and-foot syndrome in standard quantity cytarabine 森智世1, 伊藤公人2, 尾畑景子3, 新美政樹1, 谷口結基1, 田中美帆1, 太田達也1, 田中章郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 638-638, 2019. |
|---|
|
|
3-11-O59-1. Use investigation of the peg filgrastim in the docetaxel cisplatin, 5-FU therapy for head and neck cancer 橘川奈生1, 祖川倫太郎1, 山内盛泰2, 古野龍也1, 木村早希子1, 田崎正信1, 倉富勇一郎2, 成澤寛1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 639-639, 2019. |
|---|
|
|
3-11-O59-2. Association between immune-mediated adverse event expression of Pembrolizumab and effect of treatment in the urothelial carcinoma 小林一男1,3, 鈴木賢一2, 青山剛1, 横川貴志1, 式部さあ里1, 平出誠1, 橋本幸輝1, 飯倉佑介1, 湯浅健3, 佐藤均4, 杉山恵理花4, 田島正教4, 米瀬淳二3, 濱敏弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 640-640, 2019. |
|---|
|
|
3-11-O59-3. An immune-mediated adverse event of the renal carcinoma nivolumab and association with the overall survival 飯倉佑介1, 小林一男1,4, 青山剛1, 横川貴志1, 式部さあ里1, 平出誠1, 橋本幸輝1, 鈴木賢一2, 湯浅健3, 佐藤均4, 杉山恵理花4, 田島正教4, 米瀬淳二3, 濱敏弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 640-640, 2019. |
|---|
|
|
3-11-O59-4. Effect on anticoagulant ability of the warfarin by the capecitabine combination and examination about the time 齋藤豪1, 赤嶺由美子2, 三浦昌朋2, 平泉達哉1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 641-641, 2019. |
|---|
|
|
3-11-O60-1. One consideration - about the requirements that enabled a judgment and the policy conversion of - palliative care team when patients explained to that we could not leave the hospital hoped for home discharge 隅田美紀1, 曽我みゆき2, 田邊裕3, 松本卓也4,5, 関谷正徳3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 642-642, 2019. |
|---|
|
|
3-11-O60-2. Examination of naldemedine administration start time and the efficacy to opioid-induced constipation 奥田泰考1,2, 三瓶裕貴1, 品田誠1, 高倉祐希1, 菅留理1, 齋藤賢宏1, 毛塚ちひろ1, 星ちはる1, 小林直人1, 藤井博文2, 須藤俊明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 643-643, 2019. |
|---|
|
|
3-11-O60-3. Efforts about the proper use promotion of the Abstral sublingual tablet using e- learning 尾崎誠一1, 荒神一博2, 片山恵美子1, 三好浩一郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 643-643, 2019. |
|---|
|
|
3-11-O60-4. Efforts of our hospital for the terminal heart failure 橋本百世1, 江頭佐都美2, 橋野陽子2, 金井菜穂子3, 西山菜々子4, 古野史子4, 菅由美2, 山下由紀子5, 大前隆仁3, 松田良信3, 田中育子1, 端山明子1, 仁木一順6, 岡本禎晃1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 644-644, 2019. |
|---|
|
|
3-11-O61-1. Example that a pharmacist was involved in for the delirium in the use of opioid patients 荒川真萌1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 645-645, 2019. |
|---|
|
|
3-13-O61-2. One patient who is addicted to amantadine who was discovered by the pharmaceutical intervention of the pharmacist 山本麻里子1, 井出直仁1, 松島暁2, 三上智3, 伊藤政治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 646-646, 2019. |
|---|
|
|
3-13-O61-3. Relation to a side effect report and the Relief System for Sufferers from Adverse Drug Reactions of the ward exclusive duty pharmacist 中川義浩1, 鶴崎泰史1, 花田聖典1, 井上大奨1, 横田千明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 646-646, 2019. |
|---|
|
|
3-13-O61-4. The case that PT-INR fluctuated with a change, the cancellation of the tube feeding agent under the warfarin administration remarkably 松本徳人1, 山本達郎1, 島田美樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 647-647, 2019. |
|---|
|
|
3-13-O62-1. Questionary survey about recognition, the knowledge of the drug for the rehabilitation staff 小松めぐみ1, 乾朱里1, 西内祥子1, 木村美保子1, 田島千愛1, 西村奈保1, 田所美和1, 吉岡りえ1, 市吉真貴子1, 八木亜紀子1, 田中照夫1, 藤本弘昭2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 648-648, 2019. |
|---|
|
|
3-13-O62-2. The effect that a positional information game for smartphones gives to the clinical test value and medical treatment of the user 名倉慎吾1, 佐藤宏樹2,3, 柳奈津代2, 堀里子4, 澤田康文2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 649-649, 2019. |
|---|
|
|
3-13-O62-3. Enforcement of the case conference for the purpose of the RMP utilization to the clinical settings and the effect 岩崎克也1, 森谷康志1, 上田夏瑞1, 渡邊翔太1, 井元裕夏1, 野坂陽子1, 亀井健人1, 赤木晋介1, 高柳和信1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 649-649, 2019. |
|---|
|
|
3-13-O62-4. Questionary survey about the current situation of the instillation maneuver of the satisfaction to an instillation container and patients 小野優子1, 衛藤大樹1, 佐藤雄己1, 伊東弘樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 650-650, 2019. |
|---|
|
|
3-13-O63-1. Remedy medicine for osteoporotic fracture investigation about primary prophylaxis 久保みさき1, 渡邊瑞加2, 戸邊隆夫1,2, 江藤祥子1, 戸田貴洋1, 林高弘1,2, 山田成樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 651-651, 2019. |
|---|
|
|
3-13-O63-2. Examination about the effectiveness and the safety of the chronic administration of hydroxychloroquine 小武和正1, 板野理沙子1, 田平明哲1, 山足佳奈1, 川上恭弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 652-652, 2019. |
|---|
|
|
3-13-O63-3. The in-hospital adoption reduction of the benzodiazepine system sleeping drug for the sleeping drug proper use and the effect 下田賢一郎1, 星野輝彦1, 塩津和則1, 杉山留美子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 652-652, 2019. |
|---|
|
|
3-13-O63-4. Change of the potassium level in the ARB user 大石愛海1, 荒井希文2, 佐々木祐樹2, 福島栄2, 福岡憲泰1, 大場延浩1, 菊池憲和2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 653-653, 2019. |
|---|
|
|
3-13-O64-1. The effect that adherence of the 5-ASA preparation in the ulcerative colitis gives in an endoscopic image for remission 宮武賢司1, 上出紗栄加1, 長橋かよ子1, 福知工1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 654-654, 2019. |
|---|
|
|
3-13-O64-2. It is examination ... from a fact of the administration in ... our hospital for anticoagulation adequacy after the cesarean section 上森恵里1, 松岡順子1, 宮田広樹1, 海老井佳織1, 今村真沙美1, 川田桂子1, 野口周作1, 笠原英城1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 655-655, 2019. |
|---|
|
|
3-13-O64-3. Intervention to a psychotropic drug, antipsychotics, the antidepressant of patients with terminal cancer 今井一輝1, 二村昭彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 655-655, 2019. |
|---|
|
|
3-13-O65-1. Usefulness of the tetraapproach to a renal excretion type drug 山中理1,2,3, 山村篤史1, 中山英夫1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 657-657, 2019. |
|---|
|
|
3-13-O65-2. The construction of the prescription order system supporting generic name prescription and the evaluation 河崎尚史1, 松山真範1, 北島正大1, 名村隆2, 金桂洙3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 658-658, 2019. |
|---|
|
|
3-13-O65-3. Efforts for a problem, needs grasp and the improvement by the "voice of the customer" analysis 大町成樹1, 有和泰子1, 中井徹1, 竹村卓哉1, 酒井保浩1, 太田和人1, 京井由加利1, 高野修一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 658-658, 2019. |
|---|
|
|
3-13-O65-4. The use situation of the system for exclusive use of construction and insulin of the instructions input screen of the hospitalization insulin hypodermic injection 金内幸子1, 青柳京子1, 小谷野圭子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 659-659, 2019. |
|---|
|
|
3-13-O66-2. An association between use and cataractogenesis of statin: Analysis using receipt data 高科桃子1, 田口みなみ1, 大場延浩1, 福岡憲泰1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 661-661, 2019. |
|---|
|
|
3-13-O66-3. The effect on uric acid level by the use of antihypertensive medications: Analysis using the medical information data of the hospital 麻生洋哉1,2, 大場延浩1, 依馬理咲子1, 荒井希文2, 佐々木祐樹2, 福島栄2, 福岡憲泰1, 菊池憲和2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 661-661, 2019. |
|---|
|
|
3-13-O66-4. Search of the signal of the drug affecting the cognitive function in the patients with chronic kidney disease utilizing the association analysis 長澤宏之1,2, 野口義紘1, 舘知也1, 寺町ひとみ1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 662-662, 2019. |
|---|
|
|
4-3-O67-1. The study on factor to give it to malpractice: Inspection duties 宮地佑佳1, 小粥夏日1, 堀場崇志1, 仲山千佳1, 磯貝正人2, 田村摩紀2, 杉浦奈美3, 中澤直美3, 加藤美樹4, 舟橋智美4, 長芝計代4, 大西正文4, 松浦惠子2, 斎藤寛子4, 大嶋耐之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 663-663, 2019. |
|---|
|
|
4-3-O67-2. Efforts to the analysis of the incident accident report associated with the drug for the medical care and recurrent prevention 田中怜1,2, 飯島久子3, 青山隆夫2, 石川寛1, 佐藤淳也1, 川岸佐和子1, 梅坪翔太1, 佐藤哲1, 篠道弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 664-664, 2019. |
|---|
|
|
4-3-O67-3. System construction and use experience ... of usefulness examination (the first report) - formulations inspection duties about the improvement in quality of the medical security using the camera solution with the voice recording 久保田綾乃1, 牧野和也1, 海野亜実1, 鈴木高弘2,3, 平澤典保2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 664-664, 2019. |
|---|
|
|
4-3-O68-1. Analysis of the potentially serious medical errors example about the internal use self-care medicine 舘合慶一1, 川上和宜1, 森本重輝1, 二木翔平2, 保田知生2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 666-666, 2019. |
|---|
|
|
4-3-O68-2. Attitude survey about a design element and the misunderstanding to contribute to the appearance resemblance of the PTP sheet 北村美帆1, 佐藤宏樹2,3, 柳奈津代2, 澤田康文2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 667-667, 2019. |
|---|
|
|
4-3-O68-3. Intelligence and evaluation ... by the multi-type of job collaboration utilizing construction - interview sheet of a side effect, the uniform management system of the allergic information which was outpatient subject 荒木良介1,2, 加藤加奈恵1, 浜本知之2, 田中恒明3, 山田英紀1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 667-667, 2019. |
|---|
|
|
4-3-O68-4. Increase of the major bleeding event by the edoxaban off-label use 福井里佳1, 平大樹1,2, 國津侑貴1, 磯野哲一郎1, 田淵陽平1, 生野芳博1,3, 上島智2, 伊藤英樹3,4, 寺田智祐1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 668-668, 2019. |
|---|
|
|
4-3-O69-1. Characteristic every institution of the incident associated with the medication in the assisted-living pay nursing home 木崎速人1, 堤桃花1, 山本大輔2, 馬来秀行2, 益子幸太郎2, 小西ゆかり2, 浅井康平2, 佐藤宏樹3,4, 澤田康文3, 堀里子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 669-669, 2019. |
|---|
|
|
4-3-O69-3. Effect on fall with the sleep inducing drug 大谷徹1, 永田裕章1, 野口祥紀1, 荒木康羽1, 世古口拓也1, 井田諭2, 金児竜太郎2, 谷村学1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 670-670, 2019. |
|---|
|
|
4-3-O69-4. The effectiveness of the pharmacist intervention in the community pharmacy 玉城武範1,2, 吉山友二2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 671-671, 2019. |
|---|
|
|
4-3-O70-1. Effect on drug costs of doubt inquiry associated with the renal function 中島誠1,2, 桐野玲子1, 瀧下恭子1, 高橋武士1, 中木原由佳1, 新上香奈子1, 福元裕介1, 川添希1, 林秀樹2, 杉山正2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 672-672, 2019. |
|---|
|
|
4-3-O70-2. Effective and safe examination accompanied with changes from cinacalcet to Evocalcet 辻卓矢1, 渡邊泰子1, 佐藤みのり2, 有元克彦3, 佐々木緑1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 673-673, 2019. |
|---|
|
|
4-3-O70-3. Attitude survey about the renal function evaluation for the nurse 竹内陽亮1, 森本健幹1, 高橋雄也1, 宮脇洋平1, 長島裕樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 673-673, 2019. |
|---|
|
|
4-3-O70-4. Examination of the effect on glomerulonephritis expression factor in the adrenal cortical steroid monotherapy 森田真樹子1, 永光華菜1, 鳥山陽子1, 谷口潤1, 尾之江剛樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 674-674, 2019. |
|---|
|
|
4-4-O71-1. Investigation about the prescription change of the antiepileptic drug in the pregnant woman based on administrative data 塩澤誠1, 菊池大輔1,2, 千葉紗耶花1, 城坂理紗1, 三浦良祐1, 小原拓2,3, 渡辺善照1,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 675-675, 2019. |
|---|
|
|
4-4-O71-2. The actual situation of the antimicrobial prescription for the pregnant woman: Examination based on the receipt database 高木秀侑1, 石川智史2, 大柳元1,3,4, 野田あおい1,3,4, 小原拓1,3,4, 眞野成康1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 676-676, 2019. |
|---|
|
|
4-4-O71-3. Theoretical consideration about the safety at mother's milk shift and nursing of cefpodoxime proxetil 大久保正1,2, 田中真理子2, 大久保七枝3, 大久保節子4, 大久保美穂5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 676-676, 2019. |
|---|
|
|
4-4-O71-4. A mother's milk shift and placental passage of the lamotrigine 宮原芽久美1, 成瀬勝彦2, 前田雅之1, 八幡郁子1, 谷川恵子1, 小川恵美子1, 池田和之1, 吉川一吾1, 辻力夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 677-677, 2019. |
|---|
|
|
4-4-O72-1. Questionnaire research about the medication of the nursing mother having infants during children's ward hospitalization 松岡順子1, 上森恵理1, 森角裕貴1, 川田桂子1, 宮田広樹1, 島義雄2, 笠原英城1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 678-678, 2019. |
|---|
|
|
4-4-O72-2. About contrast media administration and the reporting to a nursing mother, the efforts 桐林美緒1, 佐藤千比呂1, 金田美咲緒1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 679-679, 2019. |
|---|
|
|
4-4-O72-3. Attitude survey of a pregnant woman and the spouse for the medical therapy of the gestation period 吉井圭佑1, 芦田直子1, 原 (野上) 愛2, 見尾光庸2, 杉山哲大1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 679-679, 2019. |
|---|
|
|
4-4-O72-4. One patient who responded to olanzapine in serious hyperemesis gravidarum 土井由布子1, 中田和宏1, 矢口絢子1, 木村美由喜1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 680-680, 2019. |
|---|
|
|
4-4-O73-1. The actual situation of the medical therapy to patients with dementia that entered a nursing facility 浜田将太1, 小島太郎2, 石井伸弥2, 大河内二郎3, 秋下雅弘2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 681-681, 2019. |
|---|
|
|
4-4-O73-2. The number of the on admission remedy drugs has an influence on the ADL of the rehabilitation at discharge 山元孝俊1, 小瀬英司1, 榎本弘美1, 渡部多真紀1,3, 河村剛至1,3, 安井洋一2, 河野博隆2, 渡邊真知子3, 安野伸浩1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 682-682, 2019. |
|---|
|
|
4-4-O73-3. Relation - example report - of the pharmacist to the prescription contents of patients with dementia 谷博子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 682-682, 2019. |
|---|
|
|
4-4-O73-4. Evaluation about the need of the pharmacist in the dementia support team 山本早絵1,4, 林田颯志1, 佐道紳一1, 吉野走1,4, 川原隆2,4, 六倉和生3,4, 樋口則英1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 683-683, 2019. |
|---|
|
|
4-4-O74-1. Dr. in the neurosurgical acute phase hospital Follow-up of the elderly people polypharmacy using SUPERMAN 曽和鮎美1,2, 山崎みどり1, 伊藤愛1, 大石雅子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 684-684, 2019. |
|---|
|
|
4-4-O74-2. Of the drug proper use promotion in the multi-type of job polypharmacy measures team, actually 田中成枝1, 越智大輔1, 木下玄子1, 大西順子1, 白石剛一1, 村上雅基2, 田中陽子3, 加地七彩4, 合田貴史1, 山崎宙5, 近藤祥代1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 685-685, 2019. |
|---|
|
|
4-4-O74-3. Effect accompanied with the acceptance duties start of the prescription information 津曲恭一1, 大窪典子1, 杉尾由希子1, 雪竹英志1, 植村ちひろ1, 平峯侑恵1, 上丸祥恵1, 安富佑思1, 杉町代1, 宮下裕央1, 松石裕也1, 西村尚芳2, 長岡麻沙美3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 685-685, 2019. |
|---|
|
|
4-4-O74-4. Efforts to the held method and attendance up of the medical safe workshop 平田備子1,6, 磯弓子1,6, 小椋千絵2,6, 森島毅3,6, 長野英樹4,6, 大西尚5,6, 戸部智5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 686-686, 2019. |
|---|
|
|
4-7-O75-1. A supplement effect of zinc acetate and effect of the inhibitor on zinc deficiency disorders 細野真吾1,2, 森光輝2, 廣瀬達也2, 中島彩子1, 細野亜由美1, 宇佐美英績2, 吉村知哲2, 山崎崇1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 687-687, 2019. |
|---|
|
|
4-7-O75-2. Examination of the drug influencing an outcome of the rehabilitation that we provided after the crisis of cerebral apoplexy 松崎貴志1, 安島秀友1, 新嶋茂正1, 勝田雄太1, 最上谷拓磨2, 笠原酉介2, 森みさ子3, 川畑亜加里3, 豊崎祥子4, 清水朋子4, 小野寺英孝5, 植草秀介6, 松尾和廣6, 田中恒明1, 吉尾隆6 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 688-688, 2019. |
|---|
|
|
4-7-O75-3. 1 case that a change made possible improvement of the asthmatic control and the secession from oral steroid from Mepolizumab to Benralizumab administration 渡辺昌子1, 設楽芙月2, 狭間翔平2, 櫻井淳二3, 佐藤伸輔3, 高橋知子2, 石澤文章3, 渡辺善照1, 高橋識至4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 688-688, 2019. |
|---|
|
|
4-7-O75-4. Pain, association between postoperative complications and frailty after the gastrectomy 西健太郎1, 守田和憲1, 田上治美1, 高森啓史2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 689-689, 2019. |
|---|
|
|
4-7-O76-1. Analysis about the drug which the Residual medicine in the knob medicine bag motion is easy to produce and the area difference 木原太郎1, 小林大介2, 小柳香織1, 窪田敏夫3, 川尻雄大2, 金子絵里奈1, 都築加奈2, 高山浩太郎2, 脇山えりか2, 加崎哲夫4, 國武雅弘4, 竹下文明5, 安東恵津子6, 馬場智弘7, 浅尾一夫8, 濱野明子8, 高木淳一1, 田中泰三1, 島添隆雄2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 690-690, 2019. |
|---|
|
|
4-7-O76-2. Results of use and application promotion - video training of the medication reporting book and future problem ... 荒井玲美1, 伊藤昌裕1, 渡邉泰崇1, 田井中絹代1, 福岡勝志1, 弓削吏司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 691-691, 2019. |
|---|
|
|
4-7-O76-3. Fact-finding of the use of test value that we described in outside Parliament prescription 荒井久暢1, 長谷川晃司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 691-691, 2019. |
|---|
|
|
4-7-O76-4. The development of the multiple drug adjustment system and inspection of the usefulness 杉生雅和1, 吉岡睦展1, 石津智司1, 根上朋子1, 若松雄太1, 長尾彰太1, 河岡真由美1, 小川佳美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 692-692, 2019. |
|---|
|
|
4-7-O77-1. Examination of the factor associated with the quality of life drop of patients with chronic hepatitis C given LDV/SOF therapy 四十物由香1,2, 神山紀子1, 山元俊憲3, 鴨志田敏郎4, 齋藤祥子2, 青山芳文2, 向後麻里1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 693-693, 2019. |
|---|
|
|
4-7-O77-2. Comparison between Baloxavir and neuraminidase inhibitor three drugs at the health insurance pharmacy of the symptom lightness ratio in the influenza season 高橋渉1, 笹原侑祐2, 池貴幸3, 板垣幸太郎1, 長沼未加1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 694-694, 2019. |
|---|
|
|
4-7-O77-4. Comparison of the method of DVO at preparation of the injection drug anticancer agent 吉野裕梨佳1, 齋藤智之2, 近藤泰礼2, 小嶋伸二2, 佐藤邦義2, 荒川隆太郎2, 久保田理恵1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 695-695, 2019. |
|---|
|
|
4-7-O78-1. Attempt of the medication management capability evaluation by the multi-type of job cooperation 横山敏紀1, 佐藤未季1, 澤岡理咲1, 大野育美1, 伊藤明美2, 永田宏樹3, 永田学4, 櫻井秀彦5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 696-696, 2019. |
|---|
|
|
4-7-O78-2. Significance of the adverse event report investigation for care jobs and the pharmacist intervention in care settings 浅見友一1, 藤田茂起1, 飯塚敏美1, 柳下早苗2, 原広子2, 堀口雅巳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 697-697, 2019. |
|---|
|
|
4-7-O78-3. Analysis of the incident accompanied with the medication assistance in the house for elderly people with the service 池田百合香1, 佐藤宏樹2, 柳奈津代2, 益子幸太郎3, 木崎速人4, 山本大輔3, 馬来秀行3, 小西ゆかり3, 浅井康平3, 堀里子4, 澤田康文2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 697-697, 2019. |
|---|
|
|
4-7-O78-4. Development for method "OMOTENASHI" which aimed at the foreign patients wanting to be prescribed, and using a pickpocket appropriately application 鈴木渉太1,2, 山川紘希3, 宮本敬子4, 原田祐希4, 岡田浩2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 698-698, 2019. |
|---|
|
|
4-8-O79-1. Is acetaminophen a really safe pain-killer? - Examination - of the risk factor of the liver enzyme rise 廣瀬正幸1,2, 田島康介3, 瀬川悠史3, 小川広晃3, 坂崎多佳夫3, 新垣大智3, 廣末美幸3, 平川昭彦4, 山田成樹1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 699-699, 2019. |
|---|
|
|
4-8-O79-2. Safe comparison between an innovator drug, the generic drug of tazobactam/piperacillin combination drug 中蔵伊知郎1, 森幸代1, 田中裕貴子1, 森田貴子1, 北澤文章1, 辻川正彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 700-700, 2019. |
|---|
|
|
4-8-O79-3. Search of the factor associated with the onset of impaired renal function by Liposomal amphotericin B 高橋悠1, 片田佳希1, 中川俊作1, 杉本充弘1, 吉田優子1, 木全柾典1, 糸原光太郎1, 北田徳昭1, 深津祥央1, 米澤淳1, 中川貴之1, 松村康史2, 長尾美紀2, 松原和夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 700-700, 2019. |
|---|
|
|
4-8-O79-4. One case of the elderly people whom aciclovir nephropathy and encephalopathy usually developed in in the dose of valacyclovir 野々内裕紀1, 眞継賢一1, 津崎光司2, 猪川和朗3, 森川則文3, 濱口良彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 701-701, 2019. |
|---|
|
|
4-8-O80-1. Inflection to an investigation and drugstore duties of the adverse event (AE) report that we collected at a health insurance pharmacy 飯塚敏美1, 浅見友一1, 藤田茂起1, 堀口雅巳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 702-702, 2019. |
|---|
|
|
4-8-O80-2. Association between study (1) - DRPs and source of information and outcome ... about Drug Related Problems (DRPs) of drugstore doubt inquiry 高木博子1, 金子絵里奈2, 石橋久2, 園田正信2, 山野徹2, 家入一郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 703-703, 2019. |
|---|
|
|
4-8-O80-3. Comparison ... of an expression example and the evasion example of the side effect based on study on Drug Related Problems (DRPs) (2) - MedDRA classification of drugstore doubt inquiry 金子絵里奈1, 高木博子2, 石橋久1, 園田正信1, 家入一郎2, 山野徹3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 703-703, 2019. |
|---|
|
|
4-8-O80-4. Efforts to the construction of the in-hospital side effect report system for the purpose of the uniform management of information on adverse drug reactions, the allergic drug registration 西迫多重1, 伊藤加津枝2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 704-704, 2019. |
|---|
|
|
4-8-O81-1. The drug interactions management of protocol and DOAC utilizing the drug section system 平山陽奈1, 木村丈司1, 高橋知子1, 冨田猛1, 野崎晃1, 山本和宏1, 大本暢子1, 大村友博1, 矢野育子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 705-705, 2019. |
|---|
|
|
4-8-O81-2. We elucidate a case with suspected interaction of Lenvatinib and the warfarin and the mechanism in the patients with hepatocytes cancer 柳下博信1, 加藤正太郎1, 赤嶺由美子1, 南慎一郎2, 高橋健一2, 千葉充2, 飯島克則2, 三浦昌朋1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 706-706, 2019. |
|---|
|
|
4-8-O81-4. The effect that the combination of a proton pump inhibitor or the H2 receptor blocker gives to an effect and a side effect of the dasatinib on chronic myelogenous leukemia 永石浩貴1, 高武嘉道2,3, 谷口潤4, 安森奈緒子2, 衛藤智章5, 徳井志野6, 深澤真実7 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 707-707, 2019. |
|---|
|
|
4-8-O82-1. One case of seriously ill febrile thrombocytopenia syndrome (SFTS) due to the ixodid bite 上ノ段友里1, 池田元彦2, 辛島正信3, 富田珠美1, 縄田好一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 708-708, 2019. |
|---|
|
|
4-8-O82-2. The treatment outcome of patients with rheumatoid arthritis receiving treatment with biological drug and relations of the BMI 平井利典1, 舩木文子1, 村上公美1, 花田和彦2, 伊東俊雅1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 709-709, 2019. |
|---|
|
|
4-8-O82-3. Examination of the factor affecting antiXa activity in the edoxaban administration 太田洋貴1, 西村寿貴2, 小野亮平3, 生島五郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 709-709, 2019. |
|---|
|
|
4-8-O82-4. Effect on side effect and effect of treatment of MTX accompanied with the change of the folate remedy method in patients with rheumatoid arthritis (we look at the rear mark investigation) 佐々木恵一1, 辻敏和2, 柳原有希1, 益口賢1, 近森綾子2, 渡邊裕之2, 橋本昌文1, 木本泰孝3, 堀内孝彦3, 増田智先2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 710-710, 2019. |
|---|
|
|
4-9-O83-1. Evaluation of the opioid gradual decrease program by the pharmacist after the head and neck cancer chemoradiotherapy successful execution 堀之内藍1,2,3, 鈴木真也2, 鎌田隼2, 金子明日美2, 藤澤孝夫3, 上田百合3, 榎田智弘3, 伊東和恵3, 岡野晋3, 真壁秀樹1, 川崎敏克2, 田原信3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 711-711, 2019. |
|---|
|
|
4-9-O83-2. Search of the factor to give the event of the rise in serum creatinine level in patients with non-small cell lung cancer given maintenance therapy by the pemetrexed 梅原健吾1, 小池希望2, 後藤桂輔1, 岡山有希1, 野表しおり1, 岡崎泰香1, 若本あずさ1, 初山多恵1, 佐藤秀紀1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 712-712, 2019. |
|---|
|
|
4-9-O83-3. Effect of the polypharmacy to give it to onset of febrile neutropenia by the docetaxel 槙原克也1, 松村友和1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 712-712, 2019. |
|---|
|
|
4-9-O83-4. Examination about an adverse event and the treatment continuity according to the hippopotamus diTaki cell (CBZ) initial dosage 森本江美1, 清水克次2, 金銅葉子2, 藤田敬子2, 坂上嘉浩3, 伊丹祥隆4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 713-713, 2019. |
|---|
|
|
4-9-O84-1. Investigation about the Infusion Reacution expression situation with the Daratumumab administration 井上勝光1, 藤田強記1, 鶴崎泰史1, 花田聖典1, 中川義浩1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 714-714, 2019. |
|---|
|
|
4-9-O84-2. Examination of an onset of proteinuria risk factor and the administration pronephros function with the Bevacizumab administration 村地康1,2, 坂井大介2, 山本智也1, 西田尚弘2, 佐藤太郎2, 奥田真弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 715-715, 2019. |
|---|
|
|
4-9-O84-3. Comparison about the pre-medication at the Obinutuzumab initial administration in our hospital 佐々侑寿香1, 淺野肇1, 竹上学1, 芦田隆司2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 715-715, 2019. |
|---|
|
|
4-9-O84-4. Analysis of the infusion reaction expression risk factor by the trastuzumab 松本咲耶1, 高橋正也1, 高橋克之1, 高島勉2, 柏木伸一郎2, 野田諭2, 小野田尚佳2, 大平雅一2, 永山勝也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 716-716, 2019. |
|---|
|
|
4-9-O85-1. We evaluate usefulness of the G-CSF prophylaxis in the adjuvant chemotherapy (EC therapy) after the operation in preoperation of the breast cancer 櫻田巧1, 柴田高洋1, 井上貴久1, 山川祐介1, 合田光寛1, 座間味義人2, 桐野靖1, 中村敏己1, 寺岡和彦1, 石澤啓介1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 717-717, 2019. |
|---|
|
|
4-9-O85-2. Fact-finding of the administration cancellation by the immune-mediated adverse event in the immune checkpoint inhibitor 早坂州生1, 岩本浩史1, 出町拓也1, 田中宏尚1, 芦崎雅之1, 平田力1, 北山秀則1, 竹内公美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 718-718, 2019. |
|---|
|
|
4-9-O85-3. Examination about the effectiveness and the economic effect of the low-dose Atovaquone in the pneumocystis pneumonia prevention for patients with blood-forming organ tumor 杉富行1, 串亮太1, 才郷博久1, 花井誉1, 萩原政夫2, 高畠啓輔1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 718-718, 2019. |
|---|
|
|
4-9-O85-4. Examination for the pseudo renal failure with rim parser tablets 今村牧夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 719-719, 2019. |
|---|
|
|
4-9-O86-1. The effectiveness and safety of the laterality in colon cancer treatment 濱武清範1, 小西史子1, 酒井ちひろ1, 野間敏也1, 後藤仁美1, 宮西將之1, 松本弘誠1, 中西輝1, 仲忠士1, 美和孝之1, 小島一晃1, 神田直樹2, 恒松一郎3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 720-720, 2019. |
|---|
|
|
4-9-O86-2. Reactivity of the antiEGFR antibody by the colon cancer part distinction in Real World Data 鳥居良太1, 内藤雅人1, 下雅意彩1, 竹村敏也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 721-721, 2019. |
|---|
|
|
4-9-O86-3. Participation of the nutritional status in neutropenias Grade3 developing just after a ramucirumab paclitaxel combination therapy start for the gastric cancer or more 佐々木紀彰1, 古元俊徳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 721-721, 2019. |
|---|
|
|
4-9-O86-4. Rearward observational study about the clinical response by the presence or absence of Bevacizumab combination in the TAS-102 therapy for patients with metastatic colon cancer 北洞美佳1, 藤井宏典1, 廣瀬智恵美1, 山田友奈美1, 渡辺大地1, 飯原大稔1, 松橋延壽2, 高橋孝夫2, 吉田和弘2, 鈴木昭夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 722-722, 2019. |
|---|
|
|
4-13-O87-1. Search of the estrangement factor of propofol blood level target value and the actual value in patients with obesity 中山紗里1, 平大樹1, 米田茉由1, 栗原二葉2, 小田真也2, 上島智1, 岡野友信1, 川前金幸2, 角本幹夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 723-723, 2019. |
|---|
|
|
4-13-O87-2. Population pharmacokinetics analysis of the rivaroxaban in patients with atrial fibrillation 上島智1, 平大樹1,2, 桑田健司1, 平田華鈴1, 田淵陽平2, 伊藤英樹3,4, 小澤友哉3, 中川義久3, 堀江稔3,5, 寺田智祐2, 桂敏也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 724-724, 2019. |
|---|
|
|
4-13-O87-3. Effect of STAT3 genetic polymorphism and the quantity of internal exposure in the effect of treatment of the gefitinib 横田隼人1, 佐藤一洋2, 坂本祥2, 奥田佑道2, 中山勝敏2, 三浦昌朋1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 724-724, 2019. |
|---|
|
|
4-13-O87-4. Blood level and side effect of the Lenvatinib, study on change-related genetic polymorphism 尾関智子1, 長濱充二2, 鈴木章文2, 杉野公則2, 伊藤公一2, 藤田一馬1, 三浦昌朋1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 725-725, 2019. |
|---|
|
|
4-13-O88-1. Analysis of the effect of NSAIDs giving it to cisplatin origin-related renal failure based on reverse translational research 岡本敬介1,2, 齋藤佳敬3, 小林正紀4, 古堅彩子4, 鳴海克哉4, 井関健4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 726-726, 2019. |
|---|
|
|
4-13-O88-2. The onset of adverse event in the foreign pancreatic cancer chemotherapy and examination about the quality of life drop 國府田真綾1, 藤井宏典2, 廣瀬智恵美2, 大畑紘一2, 林秀樹1, 杉山正1, 鈴木昭夫2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 727-727, 2019. |
|---|
|
|
4-13-O88-3. Progress, the effect that a proton pump inhibitor gives to a low Mg blood symptom of the panitumumab in recurrent colon cancer and the effectiveness 桂英之1, 菅幸生2, 久保杏奈3, 杉村勇人4, 熊谷要5, 春木一伸6, 米澤美和3, 成田綾香3, 石嶋麗4, 小川依1, 坂野ひとみ1, 石田外樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 727-727, 2019. |
|---|
|
|
4-13-O88-4. 1 case that HBV screening test became false-positive by immunoglobulin preparations 間瀬悟1, 平岩いずみ1, 加藤潤1, 古田美里1, 榊原崇芳1, 近藤有1, 佐々木英雄1, 三宅芳男1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 728-728, 2019. |
|---|
|
|
4-13-O89-1. Clinical significance of the CYP2D6 genetic polymorphism measurement in the analgesic effect of tramadol 神谷貴樹1, 中島亮2, 平大樹3, 元持杏津子1, 森河内彩1, 篠田和葉3, 米田真悟4, 今井晋二4, 寺田智祐1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 729-729, 2019. |
|---|
|
|
4-13-O89-2. Examination about the correlation of diarrhea and the genetic polymorphism by the Afatinib 祖川倫太郎1, 中島千穂2, 中村朝美2, 竹内耕治1, 木村早希子1, 小宮一利2, 成澤寛1,3, 木村晋也2, 荒金尚子1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 730-730, 2019. |
|---|
|
|
4-13-O89-3. The effect that GST genetic polymorphism in the hematopoietic stem cell transplantation children patient gives to pharmacokinetics of busulfan 茂見茜里1, 西川拓朗2, 猪川和朗3, 山口博樹4, 中山一隆4, 東英里香1, 宮原恵弥子2, あべ松貴成2, 中川俊輔2, 児玉祐一2, 田邊貴幸2, 新小田雄一2, 岡本康裕2, 河野嘉文2, 武田泰生1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 730-730, 2019. |
|---|
|
|
4-13-O89-4. Examination of the genetic factor associated with the survival period in patients with AC therapy enforcement breast cancer 佐原由莉1, 辻大樹1, 金容壱3, 中道秀徳2, 山本圭祐2, 塩川満2, 伊藤邦彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 731-731, 2019. |
|---|
|
|
4-13-O90-1. The usability test of elderly people in the foreign chemotherapy and fact-finding of the treatment 大神正宏1, 小島寛2, 山下真以1, 市塚亜由美1, 五耒佳央里1, 坪山勝平1, 小島友恵1, 鈴木美加1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 732-732, 2019. |
|---|
|
|
4-13-O90-2. The development of the oral anticancer agent checking prescription tool and examination of the usefulness 石川星1, 松林和幸1, 佐伯潤1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 733-733, 2019. |
|---|
|
|
4-13-O90-4. Trend after a quantity of volatilization and the volatilization of cyclophosphamide 小竹武1, 山本理恵1, 大森優花里1, 光野真理子1, 遠藤晋吾1, 益子高1, 井上知美1, 石渡俊二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 734-734, 2019. |
|---|
|
|
P0001-2-AM. The effect that the introduction of the formulations inspection system gives for an incident 元持杏津子1, 神谷貴樹1, 中屋友紀子1, 小澤慶祐1, 森河内彩1, 上田智弘1, 福井里佳1, 上西幸治1, 寺田智祐1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 735-735, 2019. |
|---|
|
|
P0003-2-AM. Comparison between pharmacist and variation index between the persons except the pharmacist in the half lock division act 太田栄亮1, 榎原健1, 外山智章1, 田城泰則1, 井上陽晶1, 本田雅巳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 736-736, 2019. |
|---|
|
|
P0005-2-AM. About the preservation stability of the divided powder Belsomra (R) tablets which we did 中島孝則1, 菊池蘭1, 伊藤創馬1, 太田美鈴2,3, 日高慎二3, 瀧沢裕輔1, 栗田拓朗1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 736-736, 2019. |
|---|
|
|
P0007-2-AM. An investigation of the proper use situation depending on renal function of the edoxaban in our hospital and future problem 甲元大樹1, 小原香那1, 森英樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 737-737, 2019. |
|---|
|
|
P0009-2-AM. Role of the pharmacist concerned with TPN prescription checking of the NICU 松澤麻紀子1, 鈴木英二1, 西條純1, 堀勝幸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 737-737, 2019. |
|---|
|
|
P0002-2-PM. The effect that the information sharing of doubt inquiry contents gave to a young pharmacist 中屋友紀子1, 柏木優花1, 神谷貴樹1, 寺田智祐1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 738-738, 2019. |
|---|
|
|
P0004-2-PM. Mixed comparison - between between the examination (2) - equivalence basis of the factor influencing the mixed nature of the semisolid preparation and the different basis 湯谷玲子1, 山地佑太1, 今坂優希1, 河野真希1, 安福泉1, 田中晶子1, 古林呂之1, 坂根稔康1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 739-739, 2019. |
|---|
|
|
P0006-2-PM. Quantity of duties analysis for the staff standardization in compounding of medicines duties of the private medical college Hospital 深谷寛1, 大野祥2, 浜田幸宏1, 木村利美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 739-739, 2019. |
|---|
|
|
P0008-2-PM. Analysis of the injection drug anticancer agent doubt inquiry example after the anticancer agent regimen registration system introduction 橋本充広1, 筑田和豊1, 木場真樹1, 臼井勇治1, 小野恭平1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 740-740, 2019. |
|---|
|
|
P0011-2-AM. Analysis of the reuse, disposal of return of goods medicine situation and future efforts (the second report) 岩田真子1, 貝瀬眞由美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 741-741, 2019. |
|---|
|
|
P0013-2-AM. About duties burden reduction and economic effect when we introduced Cubixx(R) into inventory control of the expensive cool place medicine 田端香1, 市毛智子1, 飯田敬一1, 石和田遼1, 浅子恵利1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 742-742, 2019. |
|---|
|
|
P0015-2-AM. The current situation report after the inventory control system introduction using RFID in the poison anticancer agent injection of the cool place preservation 齋藤圭佑1, 戸津舞衣子1, 岸本有佳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 742-742, 2019. |
|---|
|
|
P0017-2-AM. Formula reconstruction of the erythropoietin preparation 澤田雄太1, 佐藤光2, 金井紀仁3, 安藤正純4, 宮崎美子5,6, 齋藤俊夫6 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 743-743, 2019. |
|---|
|
|
P0019-2-AM. Examination about the administrative work of the hospital preparation which we applied GS1 code to 高柳聡子1, 新谷智則1, 田端志帆1, 大岡由朋1, 五十嵐敏明1, 笠松眞吾2, 矢野良一1, 塚本仁1, 後藤伸之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 744-744, 2019. |
|---|
|
|
P0021-2-AM. Preservation effect test in eye drops of the hospital preparation 奥田亜希子1, 山田陽一2, 佐藤可奈1, 木村真菜2, 塩田澄子2, 高柳和伸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 745-745, 2019. |
|---|
|
|
P0023-2-AM. Relations with air-fuel ratio and the stability in the mixture of betamethasone butyric acid ester propionate ester ointment and the heparinoid from animal organ oil-related cream 尾堤文音1, 小出達夫2, 深水啓朗3, 山本佳久1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 746-746, 2019. |
|---|
|
|
P0025-2-AM. Evaluation of the usefulness of the stock pharmaceutical products management in the ward exclusive duty pharmacist 伊藤真美1, 松元美香1, 小林寛典1, 信澤弘美1, 大谷道輝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 747-747, 2019. |
|---|
|
|
P0027-2-AM. Efforts of NICU in our hospital and PICU resident duties 岩本悠花1, 寺岡知香1, 浅原章裕1, 飯野香菜子1, 辻有梨1, 伊地知政美1, 外山真理奈1, 大垣智子1, 岸田美和1, 望月千枝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 748-748, 2019. |
|---|
|
|
P0029-2-AM. Report about the duties contents of the pharmacist demanded from medical staff in an emergency ward 坂井孝行1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 748-748, 2019. |
|---|
|
|
P0031-2-AM. Usefulness ... of the screening by practice - ward exclusive duty pharmacist of the discharge support of the hospitalization early stage when we aimed at the seamless medical therapy 稲葉静香1, 満田正樹1, 岡田雅弥1, 石川裕大1, 本郷志帆1, 藤井美紀1, 中谷亮介1, 奥下梨賀1, 野際俊希1, 尾崎加織1, 松本篤1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 749-749, 2019. |
|---|
|
|
P0033-2-AM. Information sharing ... utilizing the writing a postscript operation of efforts - drug control summary of the changing hospital information sharing that aimed at the seamless medical therapy 藤井美紀1, 満田正樹1, 岡田雅弥1, 石川裕大1, 本郷志帆1, 稲葉静香1, 中谷亮介1, 奥下梨賀1, 野際俊希1, 尾崎加織1, 松本篤1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 749-749, 2019. |
|---|
|
|
P0035-2-AM. Effect ... to give the blood sugar control of patients with practice - diabetes of the continuation instruction after the discharge in the pharmacist outpatient who aimed at the seamless medical therapy 満田正樹1, 尾崎加織1, 野際俊希1, 岡田雅弥1, 石川裕大1, 本郷志帆1, 藤井美紀1, 稲葉静香1, 中谷亮介1, 奥下梨賀1, 松本篤1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 750-750, 2019. |
|---|
|
|
P0037-2-AM. An effect and inspection in the aggressive participation in before discharge conference in ward drug duties to be enabled at a small and medium size scale hospital 土屋貴1, 倉田賢生1, 荒木弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 750-750, 2019. |
|---|
|
|
P0039-2-AM. It is setup ... of ... drug adequacy conference team looking for the role of the further pharmacist in the convalescent ward 副島將司1, 織田雄一郎1, 小川大輔1, 三苫薫梨1, 中野聡1, 嶋彩夏1, 山本大策1, 海瀬有沙1, 深田充知1, 上野遙香1, 齋藤千秋1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 751-751, 2019. |
|---|
|
|
P0041-2-AM. The introduction of the drug control instruction duties in the medical treatment type hospital and the result 鈴木直志1, 藤井美由紀1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 751-751, 2019. |
|---|
|
|
P0043-2-AM. Making - clinical path utilization case ... of the list of management for the standardization of the pharmaceutical management, medication counseling 辻本高志1, 中村健一1, 上野太佑1, 住川麻美1, 檜山亜由美1, 加納宏樹1, 上田晃1, 川本由加里1, 後藤仁和1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 752-752, 2019. |
|---|
|
|
P0045-2-AM. For patients with cardioembolic associated with the non-valvular atrial fibrillation is examination about prescription situation and off-label under dose of the oral anticoagulant drug directly 川崎夏海1, 清水敦子1, 青木洸英1, 土肥大典1, 鍵山智樹1, 丸山元1, 加藤裕司2, 出口一郎2, 高尾昌樹2, 真壁秀樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 752-752, 2019. |
|---|
|
|
P0047-2-AM. Efforts of our hospital for the benzodiazepine receptor agonist weight loss 若林厚史1, 辻依利1, 高橋彩1, 田畑寛明1, 猿谷淳1, 向一美1, 地野幹子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 753-753, 2019. |
|---|
|
|
P0049-2-AM. Role of the atopic classroom in atopic dermatitis treatment 吉田遥香1, 鈴木理子1, 江藤隆史2, 大谷道輝3, 本多秀俊1, 並木路広1, 杉浦宗敏4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 753-753, 2019. |
|---|
|
|
P0051-2-AM. The current situation investigation about the treatment continuance rate of the teriparatide day after day preparation in our hospital 薄田百合子1, 垣本光未1, 大谷寧次郎1, 畔柳敏弥1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 754-754, 2019. |
|---|
|
|
P0053-2-AM. Examination of an investigation and the risk prevention of the risk drug-related at a discharge at the pharmacist absence 若原美沙紀1, 高木竜一1, 宇佐美伶奈1, 井野裕美1, 森巧一1, 伊藤匡伸1, 濱石華乃子1, 久保田敏行1, 杉浦洋二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 754-754, 2019. |
|---|
|
|
P0055-2-AM. Ward duties to be carried out by a team 玉置むつみ1, 木村成一1, 松井綾香1, 平井梨紗子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 755-755, 2019. |
|---|
|
|
P0057-2-AM. Contribution to appropriate oral medicine self-care of the inpatient using the internal use self-care assessment sheet 常松柚希1, 高谷甲波1, 西村恵里子1, 稲村澄子1, 本多秀俊1, 林由紀子1, 並木路広1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 755-755, 2019. |
|---|
|
|
P0059-2-AM. Efforts of the ward drug duties in the convalescent rehabilitation hospital 雨森祐貴1, 中野克哉1, 筒井由佳2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 756-756, 2019. |
|---|
|
|
P0061-2-AM. Study on behavior of the injection drug when we stood in a row and used a syringe pump 篠崎浩司1, 土屋香代子1, 山本正子1, 内山真一郎2, 千葉義彦3, 稲野祥宗1, 仲佐啓詳1,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 757-757, 2019. |
|---|
|
|
P0063-2-AM. It is ... for improvement of ward drug duties - pharmaceutical intervention in the NICU 木村純子1, 小穴真貴1, 高木祥子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 758-758, 2019. |
|---|
|
|
P0065-2-AM. Evaluation of the usefulness of the protocol introduction for painkilling, the abatement of ICU admission in intubated patients 小牧誉典1, 帖佐俊行2, 井上尊文3, 花田歩4, 徳永綾乃4, 迫田耕輔1, 中野公1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 758-758, 2019. |
|---|
|
|
P0067-2-AM. Look at the rear of the intervention contents by the ward pharmacist in EICU; mark investigation 尾田未来1, 宇野洋司1, 坂本修1, 椙山聡一郎1, 小濱弥眞斗1, 小杉三弥子1,2, 竹内一郎2, 橋本真也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 759-759, 2019. |
|---|
|
|
P0069-2-AM. Investigation for the sorting of the catheter lock drug in the ICU 上田昌宏1, 日笠真一1, 堀直人2, 木村健1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 759-759, 2019. |
|---|
|
|
P0071-2-AM. Efforts of the foreign pharmacist in the IMiDs checking prescription 寺本真弓1, 水野貴仁1, 堀田磨理1, 小崎耕自1, 梶口智弘2, 山田哲也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 760-760, 2019. |
|---|
|
|
P0073-2-AM. Aggressive intervention (2) to the pharmaceutical management of the perioperative patients in our hospital 山田奈緒1, 左右田和恵1, 滝川亜弥1, 太田久美子1, 田村睦弘2, 清水歩3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 761-761, 2019. |
|---|
|
|
P0075-2-AM. It is tested the effectiveness of the stopping medicine management Web application during the preoperation in the medical support center 嘉村知子1,2, 祖川倫太郎1,2, 江本晶子1, 木村早希子1, 田崎正信1, 成澤寛1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 761-761, 2019. |
|---|
|
|
P0077-2-AM. Evaluation of the contribution degree to efforts and the ward drug duties to a hospitalization support task in the pharmacist outpatient department 大登剛1, 土屋裕伴1, 塩野このみ1, 塚田昌樹1, 沖田彩1, 諸橋賢人1, 齋藤由貴1, 新井亘1, 増田裕一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 762-762, 2019. |
|---|
|
|
P0079-2-AM. Construction of the new bringing medicine management system accompanied with the PFM introduction 原田彩加1, 藤田將嗣1, 枝崎香織1, 清水久美子1, 渡辺優希1, 福澤正隆1, 川嵜英二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 762-762, 2019. |
|---|
|
|
P0081-2-AM. The efforts to the hospitalization and release support center in the on call system and the evaluation 伊藤真也1, 濱田陽子1, 細川佐智子1, 河出摩由璃1, 丹羽伊紀詠1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 763-763, 2019. |
|---|
|
|
P0083-2-AM. It is a physician instructions observance investigation in the stopping medicine confirmation during the prehospital preoperation by the pharmacist 辻亜紀1, 池田久雄1, 古久保有希子1, 足立充司1, 野村浩英1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 763-763, 2019. |
|---|
|
|
P0085-2-AM. Role of the pharmacist in the hospitalization support ambulatory service 起塚美沙1, 西岡敬貴1, 大上寛子1, 黄前尚樹2, 中村美樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 764-764, 2019. |
|---|
|
|
P0087-2-AM. The activity result of the pharmacist in the urination care team and new efforts 林剛史1, 古川大樹1, 長谷川雅哉1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 765-765, 2019. |
|---|
|
|
P0089-2-AM. The inflection of the balun strike scorecard in our hospital and effect on member 林哲哉1, 男全昭紀1, 阿部多一1, 井口恵美子1, 猪股克彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 766-766, 2019. |
|---|
|
|
P0091-2-AM. Approach "construction by an anti-VAIO gram automatic making system" aiming at the automation of duties 山田将悟1, 鈴木直哉1, 朝倉幹己1, 藤田果那1, 田中耕太1, 庄崎沙耶1, 木下愛1, 山本翔太1, 前川英輝1, 菊地義明1, 藤林遼1, 高橋誠1, 青田忠博1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 767-767, 2019. |
|---|
|
|
P0093-2-AM. The construction of the system for the generic name prescription introduction and the evaluation 鈴山直寛1, 春田桃歩1, 山本高範1, 阿部康治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 768-768, 2019. |
|---|
|
|
P0095-2-AM. Change of DI duties by the pharmaceutical products data update using the Internet line 冨岡謙二1, 淀川進也1, 堀江信彦2, 三宅健郎3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 769-769, 2019. |
|---|
|
|
P0097-2-AM. Consideration (for ... 2020 Tokyo cage Para ...) of fact-finding and the number of the making increase of the bookmark of the English version medicine 黒川寛之1, 栗原理1, 工藤香代子1, 平林文子1, 橋口佳恵1, 池田薫1, 野村香織2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 770-770, 2019. |
|---|
|
|
P0099-2-AM. Side effect analysis of "the hyperkalemia" using PMDA side effect database (JADER) 門口直仁1, 森田有香1, 濱本真歩1, 段松雅弘1, 田中聡1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 770-770, 2019. |
|---|
|
|
P0101-2-AM. Associated - with the number of the prescription drugs which we looked at according to analysis - side effects about the polypharmacy utilizing real world data 馬渕賢幸1,2, 細見光一1, 丸野なつみ1, 森田真央1, 横山聡1, 村田卓2, 高田充隆1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 771-771, 2019. |
|---|
|
|
P0103-2-AM. Examination of the effect that an oral antidiabetic drug gives in the onset of unexpected side effect risk of amiodarone using the adverse event spontaneous report database 木下佐昌子1, 細見光一2, 横山聡2, 高田充隆2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 771-771, 2019. |
|---|
|
|
P0105-2-AM. The prescription situation of the fomentation for the inpatient 鈴木健1, 水野翼1, 野田絢子1, 岩澤瞳1, 藤井晶子1, 舟橋智美1, 大西正文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 772-772, 2019. |
|---|
|
|
P0107-2-AM. Efforts to duties improvement in the shift system introduction in the Fukuoka University Nishijin Hospital 舌間清晃1, 永江寛子1, 谷田繁夫1, 山本瞳1, 安部亜紀子1, 萩原大樹1, 田村明子1, 岐部七子2, 長岡麻由2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 773-773, 2019. |
|---|
|
|
P0109-2-AM. It is investigated the delirium prevention after the ramified microglia, the operation by the suvorexant 土元研史1, 安田礼子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 773-773, 2019. |
|---|
|
|
P0111-2-AM. Use fact-finding of the measurement situation and statin of the LDL-C level in patients with ST rising type myocardial infarction of our hospital 長戸優也1, 多留木崇志1, 村田龍宣1, 村岡淳二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 774-774, 2019. |
|---|
|
|
P0113-2-AM. Introduction of the representation answer protocol for doubt inquiry from the outside Parliament health insurance pharmacy in the wide area medical institution and the evaluation 山田真由美1, 石井真理子1, 柳下祥子1, 佐々木真理1, 高橋勇人1, 山谷明正1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 774-774, 2019. |
|---|
|
|
P0115-2-AM. Age-specific analysis according to the type of job of the person concerned with investigation - medical care of the inflection situation about the package insert of the ethical drug 青木良子1, 鈴木奈穂1, 鈴木美佳1, 今任拓也1, 佐井君江1, 斎藤嘉朗1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 775-775, 2019. |
|---|
|
|
P0119-2-AM. Efforts to the proper use of the hypozincaemia therapeutic agent 日野裕子1, 延藤勇1, 豊濱隆1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 776-776, 2019. |
|---|
|
|
P0121-2-AM. The use situation investigation of the saccharated iron oxide injection in the Oita Oka Hospital 武石優哉1, 井上真1, 遠山泰崇1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 776-776, 2019. |
|---|
|
|
P0123-2-AM. Use fact-finding of the Lenvatinib for hepatocytes cancer 浅見祥崇1, 大下瑚姫1, 船田茜1, 尾形朱史鈴1, 須藤大雄1, 村中一大1, 須藤美穂子1, 鈴木千波1, 小原秀治1, 小原郁司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 777-777, 2019. |
|---|
|
|
P0125-2-AM. Change of the practice process outcome index for antimicrobial proper use promotion 河原陽介1, 木内貴章1, 森川貴弘2, 入澤奈津江2, 加藤良治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 777-777, 2019. |
|---|
|
|
P0127-2-AM. Examination of the factor to affect the determination of pharmaceutical products stock 坂井優希1, 安酸建二2, 松野純男1, 北小路学1, 大鳥徹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 778-778, 2019. |
|---|
|
|
P0129-2-AM. It is efforts of the reduction of attendant drug costs for a change of the extracellular fluid sending it from a ward pharmacist 影本渉1, 磯谷聡1, 伊藤和幸1, 浦崎圭太1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 779-779, 2019. |
|---|
|
|
P0131-2-AM. Characteristic - of the checking prescription for the purpose of analysis - Residual medicine adjustment of the checking prescription in the ethical pharmacy 上田祐稀乃1, 鈴木学1,2, 海野茜1, 味澤香苗1, 林由依1, 林秀樹1,2,3,4, 小林篤史3, 生木庸寛4, 甲斐絢子3, 小原道子4, 棚瀬友啓2, 杉山正1,2,3,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 780-780, 2019. |
|---|
|
|
P0133-2-AM. Examination ... based on the data utilization that cooperated with operational construction - bringing medicine outpatient department of the bringing medicine for digestive organ surgery hospitalization planned patients instructions input before hospitalization 藤田菜緒1, 後藤敏也1, 正木銀三1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 781-781, 2019. |
|---|
|
|
P0135-2-AM. The change of the pharmacist intervention method in the hospitalization and release management room and the evaluation 高橋希美1, 鈴木さとみ1, 本田和則1, 田村淳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 781-781, 2019. |
|---|
|
|
P0137-2-AM. Interaction - with fact-finding - pharmaceutical products about the use of the supplement 吉岡三郎1, 犬伏彩夏1, 柴田愛2, 宮崎恭治2, 三好博子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 782-782, 2019. |
|---|
|
|
P0139-2-AM. Comparison of the clinical benefit in the starting pharmaceutical products and generic medicine of the loxoprofen sodium for patients with chronic pain 植松卓也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 783-783, 2019. |
|---|
|
|
P0143-2-AM. Further search of the factor having an influence on thrombocytopenia of the linezolid 宮原宣博1, 永野浩之1, 小岩まの1, 野田幸一1, 貝嶋亮1, 谷水達也1, 鈴木善樹1, 林良行1, 岸野亨1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 785-785, 2019. |
|---|
|
|
P0145-2-AM. Evaluation of serum cystatin C and the serum magnesium level in the magnesium oxide preparation internal use patients 馬場美咲1, 高武嘉道1, 川俣洋生1, 福石和久1, 高島伸也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 785-785, 2019. |
|---|
|
|
P0147-2-AM. About the issuance of drug allergy (side effect) card in our hospital 山田倭花1, 中島のぞみ1, 内山乃映1, 上田奈緒美1, 大窪真理絵1, 丸岡浩太1, 伊代田萌子1, 梅澤仁美1, 原幸子1, 河村紳介1, 小林誠一1, 富沢裕之1, 土佐直子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 786-786, 2019. |
|---|
|
|
P0149-2-AM. The effect that combination of TAZ/PIPC and VCM in the critical care center gives for renal function 岡崎弘志1, 橋田真佐1, 濱田一成1, 田中広大1, 公文登代1, 段松雅弘1, 田中聡1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 786-786, 2019. |
|---|
|
|
P0151-2-AM. Clinical application of the antithrombotic drug information on adverse drug reactions using the artificial intelligence 川上準子1, 林玄健2, 林誠一郎3, 星憲司1, 青木空眞1, 佐藤憲一1, 渡部輝明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 787-787, 2019. |
|---|
|
|
P0153-2-AM. Using cyclopedic analysis - adverse event spontaneous report database of the adverse event with the antithrombotic drug - 小松唯可1, 細見光一1, 横山聡1, 高田充隆1, 近畿大学 薬学部1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 787-787, 2019. |
|---|
|
|
P0155-2-AM. The use of anticoagulant situation investigation of patients with cerebral hemorrhage in our hospital 白坂友基1, 小林薫1, 伊藤宏彰1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 788-788, 2019. |
|---|
|
|
P0157-2-AM. The use actual situation of the Osimertinib in the non-small cell lung cancer and safe examination 藤本亜弓1, 山崎直樹1, 大嶋美咲1, 木村仁美1, 中尾將彦2, 吉田徹也1, 駄賀晴子3, 村田みどり1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 788-788, 2019. |
|---|
|
|
P0159-2-AM. Change of the bleeding rate by off-period shortening before antithrombotic drug technique in endoscopic mucosal resection (EMR) 山田健太郎1, 島谷桜子1, 工藤真弓1, 松本浩1, 伊藤由香1, 坂下裕子1, 末谷敬吾2, 奥瀬千晃2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 789-789, 2019. |
|---|
|
|
P0161-2-AM. Examination of the development situation and the risk factor of the hypermagnesemia 岡村和彦1, 藤本孝則1, 谷村隼人2, 秦良輝2, 木村孝司2, 佐和章弘2, 佐々木雄啓1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 789-789, 2019. |
|---|
|
|
P0163-2-AM. 1 case that linezolid caused neurologic symptoms 穂積廣1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 790-790, 2019. |
|---|
|
|
P0165-2-AM. The onset of hypersensitivity situation of the injection antitumor agents and validity of measures 合澤啓二1, 岩田一史1, 西上依里1, 陣上祥子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 790-790, 2019. |
|---|
|
|
P0167-2-AM. One case that conducted readministration for nivolumab patients with head and neck cancer which caused thrombocytopenia after administration 藤川史子1, 木崎秀和1, 本間信次1, 大植謙一1, 岡崎和一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 791-791, 2019. |
|---|
|
|
P0169-2-AM. Diabetes marker 1 in the rat, internal kinetic analysis of 5-anhydroglucitol 竹林裕美子1, 志熊真理1, 西岡千晶1, 木村遥華1, 井辻真由1, 本橋秀之1, 宮崎誠2, 永井純也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 792-792, 2019. |
|---|
|
|
P0171-2-AM. Clinical analysis of PK/PD parameter about the effectiveness, the safety of vancomycin by the new construction model 千代谷大志1, 佐古兼一1, 伊賀正典2, 高野温志2, 榊拓人1, 町田充2, 藤掛佳男1, 松田佳和1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 793-793, 2019. |
|---|
|
|
P0173-2-AM. Examination of the adsorption of the antimicrobial for the AN69ST membrane 稲野祥宗1, 熊野諒太1, 篠崎浩司1, 三浦剛2, 仲佐啓詳1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 794-794, 2019. |
|---|
|
|
P0177-2-AM. One patient whom a rise of PT-INR was found in by combination of Rifaximin and warfarin 鶴永大貴1, 堀ノ内志織1, 中松穂菜美1, 堀内智裕1, 中村有莉恵1, 赤星真広1, 上原友美1, 池増鮎美1, 佐多照正1, 最勝寺晶子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 795-795, 2019. |
|---|
|
|
P0179-2-AM. 1 case that we combined metronidazole with the warfarin remedy patients, and PT-INR extended to 河村美弥子1, 田代将貴1, 佐藤潤2, 妹川史朗2, 正木銀三1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 796-796, 2019. |
|---|
|
|
P0181-2-AM. Effect of the cyclodextrin handling of grapefruit deuce to give to CYP3A activity inhibition 山崎啓之1, 小山陽子1, 西崎成美1, 河津誠太郎1, 庵原大輔1,2, 田口和明1,3, 門脇大介1,2, 小田切優樹1,2, 瀬尾量1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 796-796, 2019. |
|---|
|
|
P0183-2-AM. Initial blood level of vancomycin by the ward pharmacist in our hospital and safe evaluation 大森淳史1, 今村陽子1, 柏田匡広1, 大石貴裕1, 池田浩和1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 797-797, 2019. |
|---|
|
|
P0185-2-AM. Examination about a blood level monitoring clinical response and the side effect of the Perampanel 山本吉章1,2, 臼井直敬1, 西田拓司1, 今井克美1, 賀川義之2, 高橋幸利1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 798-798, 2019. |
|---|
|
|
P0189-2-AM. An investigation of VCM doses for the children patient, the dosage interval and anticipatory examination of the blood level 宿谷光則1, 小林俊博1, 大森春采1, 藤重瑶子1, 島谷桜子1, 赤津真衣子1, 松本浩1, 伊藤由香1, 宮地悠輔2, 品川文乃2, 森内巧2, 宮本雄策2, 坂下裕子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 799-799, 2019. |
|---|
|
|
P0191-2-AM. Analysis of the blood vancomycin levels in children and the pharmacokinetic parameter and the change factor 岡崎美香1, 立岡美穂1, 三浦佳江1, 石原慎之1, 玉木宏樹1, 矢野貴久1, 西村信弘2, 直良浩司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 799-799, 2019. |
|---|
|
|
P0193-2-AM. Examination of the vancomycin hydrochloride blood level change factor in patients with congenital heart disease 金井梓1, 青木洸英1, 鍵山智樹1, 森弘樹1, 唐牛春香1, 土肥大典1, 連翔太2, 小林俊樹2, 真壁秀樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 800-800, 2019. |
|---|
|
|
P0195-2-AM. Are blood level and the effectiveness, the side effect of the tyrosine kinase inhibitor associated with ABCG2 genetic polymorphism? 齋藤健一1,2, 小野塚真理1,2, 佐野元彦1, 井上嘉余子1, 近藤正巳1, 金子怜奈2, 吉田瑛里奈2, 佐野和美2, 花田和彦2, 岸野亨3, 木村勇太4, 得平道英4, 木崎昌弘4, 池上洋二2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 801-801, 2019. |
|---|
|
|
P0197-2-AM. Examination about the adsorption of the bevacizumab for the infusion filter in the paclitaxel + bevacizumab therapy 小林優奈1, 牛尾聡一郎2, 蔵田靖子2, 江角悟2, 北村佳久1,2, 千堂年昭2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 802-802, 2019. |
|---|
|
|
P0199-2-AM. Medical expenses reduction effect of the use of anticancer medicine division at use of preparation robot 澤田広樹1, 志田敏宏1, 山口浩明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 803-803, 2019. |
|---|
|
|
P0201-2-AM. Construction of the follow-up system between hospital - health insurance pharmacies in the Lenvatinib 中井昌紀1, 越智理香1, 佐々木優1, 越智友美1, 濟川聡美1, 飛鷹範明1, 田中守1, 田中亮裕1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 804-804, 2019. |
|---|
|
|
P0203-2-AM. Fact-finding of the side effect management in patients who received Pembrolizumab 和田依子1, 樋口美奈子1, 佐々木好美1, 山口竜司1, 児玉沙奈恵1, 檜山智子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 805-805, 2019. |
|---|
|
|
P0205-2-AM. Duties ... of the pharmacist in the other types of job collaboration - outpatient department chemotherapy room for security and effective chemotherapy practice 樋口美奈子1,2, 和田依子1, 山口竜司1, 佐々木好美1, 児玉沙奈恵1, 檜山智子1, 花田清彦2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 805-805, 2019. |
|---|
|
|
P0207-2-AM. Inspection of the optimal vial standard for the cost cut of the wasted drug in the trastuzumab 中村暢彦1, 一島知樹2, 武田智子2, 長谷川晃司2, 矢野義孝1, 楠本正明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 806-806, 2019. |
|---|
|
|
P0209-2-AM. The effect that the use of the closed system anesthesia drug transportation system gives at anticancer medicine preparation time 江崎翔平1, 横山雄一1, 篠原義剛1, 植木哲也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 807-807, 2019. |
|---|
|
|
P0211-2-AM. Cost cut effect by the injectable anticancer agent division preparation in our hospital 夘月博和1, 若月秀明1, 佐達勇之1, 平野享1, 大木孝夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 807-807, 2019. |
|---|
|
|
P0213-2-AM. Exposure measures effect by the closed system anesthesia drug transportation system full-scale introduction in the foreign chemotherapy 小笹英祐1, 計良貴之1, 秋山七海1, 竹端琴美1, 圓山絵理1, 湊川紘子1, 田中恒明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 808-808, 2019. |
|---|
|
|
P0215-2-AM. Examination of the effect by duties efficiency and the RMP introduction with the cancer consultation in chemotherapy support tool 小林智徳1, 佐藤祐司1, 菊地正史1, 小原拓1, 眞野成康1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 809-809, 2019. |
|---|
|
|
P0217-2-AM. 1 case of the lung adenocarcinoma which a pharmacist intervened in for immune-mediated adverse event suspicion after the Pembrolizumab administration 宇都宮奈々1, 沖田健太郎1, 長谷川将1, 安河内寿成1, 山村真貴子1, 羽山千尋1, 安藤暢彦1, 三村英恵1, 白石貴寿1, 中村泰士1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 810-810, 2019. |
|---|
|
|
P0219-2-AM. An example of platinum-resistant recurrent ovarian cancer which complicated idiopathic thrombocytopenic purpura 平山拓史1, 木本真司1, 河原史明1, 安齊泰裕1, 香内綾1, 原田伸彦1, 塩川秀樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 810-810, 2019. |
|---|
|
|
P0221-2-AM. Formulations support tool making and the prescription situation aiming at Abemaciclib proper use 西崎成美1, 須古杏子1, 大佐古智文2, 奥村恭博2, 中野正啓2, 藤末真実子2, 西村令喜2, 森岡淳子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 811-811, 2019. |
|---|
|
|
P0223-2-AM. The expression situation investigation of sickness/nausea, vomiting by having switched from palonosetron to 3 mg of granisetron 矢吹剛1, 山田宜和1, 貝瀬眞由美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 812-812, 2019. |
|---|
|
|
P0225-2-AM. Evaluation of the supportive care in the breast cancer adjuvant chemotherapy 祖父江彰1, 山本桂子1, 渡辺早也佳1, 堀内保孝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 813-813, 2019. |
|---|
|
|
P0227-2-AM. Investigation of irinotecan doses by the UGT1A1 genetic polymorphism analysis and the neutropenic expression situation 坂柳悦章1, 荒木寛也1, 西川隆一1, 澤柳直樹1, 藤井友和1, 辻博幸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 814-814, 2019. |
|---|
|
|
P0229-2-AM. The use situation and irAE measures of the immune checkpoint inhibitor in our hospital 村上幸恵1, 竹野裕晶1, 桑原玄樹1, 樋口利晴1, 樋口理恵1, 本間健道1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 815-815, 2019. |
|---|
|
|
P0231-2-AM. Examination of the early onset of high blood pressure and effect factor of the Lenvatinib therapy for unresectable hepatocytes cancer 高田遼1, 相神智宏1, 石郷友之1, 山崎将英1, 國本雄介1, 北川学1, 木明智子1, 中田浩雅1, 宮本篤1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 815-815, 2019. |
|---|
|
|
P0233-2-AM. Risk factor search of the diachronic renal function aggravation by the cisplatin 興梠靖幸1, 甲斐晃弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 816-816, 2019. |
|---|
|
|
P0235-2-AM. Fact-finding of the venous thromboembolism with the bevacizumab administration in patients with gynecologic cancer 宇佐美友佳子1, 近藤篤1, 三宅麻文1, 尾上雅英1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 816-816, 2019. |
|---|
|
|
P0237-2-AM. Cockcroft-Gault type estimate Ccr revision in the Carboplatin doses calculation for the initial TC therapy for gynecologic cancer patients and investigation about the side effect 北本真一1, 古谷智裕1, 白木政博1, 野村実由1, 金田公平1, 松本俊治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 817-817, 2019. |
|---|
|
|
P0239-2-AM. Examination of the volume of infusion weight loss of the cisplatin for the intraarterial injection before administration 川島悠吾1, 徳山洋子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 817-817, 2019. |
|---|
|
|
P0241-2-AM. Examination of the clinical characteristic in efforts and the side effect for the proper use of the immune checkpoint inhibitor in our hospital 向山龍司1,2,3,4, 里村藍子1, 永村陽一郎1, 坂榮里絵2, 八木太門3, 山口雄4, 中根実4, 日野斉一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 818-818, 2019. |
|---|
|
|
P0243-2-AM. The proper use of the immune checkpoint inhibitor in the small and medium size hospital and examination of immune-mediated adverse event measures 渡邉絵美1, 増田尚子2, 唐澤匠太1, 荒川基記4, 日高慎二4, 山田博文3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 818-818, 2019. |
|---|
|
|
P0245-2-AM. Activity by the multi-type of job team for the side effect of the immune checkpoint inhibitor 宮本康敬1, 小笠原隆2, 神谷智子3, 平野公美1, 遠藤拓未1, 川口千香1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 819-819, 2019. |
|---|
|
|
P0247-2-AM. Inventory survey about the usefulness of the cutaneous symptom care handbook in the Miyagi Prefectural cancer center 嶺岸なつみ1, 土屋雅美1, 江刺晶央1, 猪岡京子1, 高村千津子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 819-819, 2019. |
|---|
|
|
P0249-2-AM. It is a new choice to improvement in quality of life for oral mucositis at cancer treatment 丸林万希子1, 武井大輔1, 柵木信男2, 中村益美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 820-820, 2019. |
|---|
|
|
P0251-2-AM. Usefulness of the irAE supporting program in the Takeda synthesis hospital 原田伸彦1, 木本真司1, 河原史明1, 香内綾1, 安齊泰裕1, 平山拓史1, 成田浩気1, 星美奈子1, 山田麻帆1, 遠宮賢二1, 塩川秀樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 820-820, 2019. |
|---|
|
|
P0253-2-AM. Examination of the usefulness of the test for glucose in urine paper for the purpose of the early detection of type I diabetes mellitus through immune checkpoint inhibitor 鎌田宏和1,2, 清水克次1, 高橋幸三1, 角川幸男1, 中野寛之1, 高木麻里1, 藤田敬子1, 井上貴子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 821-821, 2019. |
|---|
|
|
P0255-2-AM. The low Mg blood symptom management by Panitumumab using PBPM 鈴木直哉1, 菊地義明1, 藤林遼1, 前川英輝1, 山田将悟1, 朝倉幹己1, 藤田果那1, 山本翔太1, 庄崎沙耶1, 田中耕太1, 木下愛1, 高橋誠1, 青田忠博1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 821-821, 2019. |
|---|
|
|
P0259-2-AM. 1 case that the drug continuation subcutaneous injection after the hospital transfer was able to continue by inflection of the drug control summary smoothly 千葉芙美1, 福島真実1, 熊谷範之1, 小笠原信敬1, 鵜浦利江2, 熊谷敏宏1, 村上雅彦3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 823-823, 2019. |
|---|
|
|
P0261-2-AM. Use of Elobixibat hydrate tablets fact-finding for the constipation during use of drug for the medical care 細田奈七恵1, 松本晃一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 824-824, 2019. |
|---|
|
|
P0263-2-AM. The use situation investigation of the fentanyl oral mucosa absorbent in the Saiseikai Hospital of the whole country 尾形美絵1,2, 中村槙一郎1, 財津孝希1, 瀧内瑛輔1, 長澤欣弘1, 羽生智宏1, 田村亜矢子1, 田村和彦1, 新関みどり1, 近藤和宏1, 曽我部直美2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 824-824, 2019. |
|---|
|
|
P0265-2-AM. We examine the effect of methadone on analgesic effect insufficiency case in strong opioid 石川敬祐1, 伊藤慎二1, 磯貝潤一1, 小林沙矢香1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 825-825, 2019. |
|---|
|
|
P0267-2-AM. One case that opioid switching was effective for the delirium after the oxycodone preparation start 熱海幸恵1, 李娜1, 添田真司1, 渡邊昌之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 825-825, 2019. |
|---|
|
|
P0269-2-AM. Constipation improvement effect of the naldemedine in patients with opioid-induced constipation 世古口拓也1, 野口祥紀1, 永田裕章1, 三宅知宏1, 谷村学1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 826-826, 2019. |
|---|
|
|
P0271-2-AM. Example that was given Osimertinib by the simple suspension method in the patients with lung cancer of the ileus concurrence due to the cancerous peritonitis 三屋良太1, 鈴木雅人1, 牧原明秀1, 高原悠子1, 吉田弘樹1, 土方寿聡2, 木全司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 827-827, 2019. |
|---|
|
|
P0273-2-AM. Examination of the usefulness of the pharmaceutical management for the long-term continuation in the foreign chemotherapy room 菅井瞳1, 有田仁紀1, 今川未紀1, 川上達也1, 越川一誠1, 渡辺和美1, 坂本真紀1, 西澤健司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 828-828, 2019. |
|---|
|
|
P0275-2-AM. Use experience of the Olaparib for patients with platinum in our hospital-sensitive recurrent ovarian cancer 立花京香1, 後藤健志1, 竹尾恵理子1, 酒井欣嗣2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 828-828, 2019. |
|---|
|
|
P0277-2-AM. The allergic expression of oxaliplatin preparation situation investigation accompanied with the generic medicine maker change 横田千明1, 花田聖典1, 鶴崎泰史1, 中川義浩1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 829-829, 2019. |
|---|
|
|
P0279-2-AM. The expression situation of the adverse event in study on adverse event frequency - our hospital of the immune checkpoint inhibitor and the continuation situation of the treatment 丸山昌広1, 梅村雅之2, 定盛理純1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 829-829, 2019. |
|---|
|
|
P0281-2-AM. Examination of the onset of adverse event situation of the treatment with temozolomide preparation and bevacizumab preparation in the malignant glioma of the first 堀江美香子1,2, 熊澤里美1,2, 西山悠也3, 大場茂生3, 廣瀬雄一3, 山田成樹1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 830-830, 2019. |
|---|
|
|
P0283-2-AM. 1 case that neutropenia developed after nivolumab ipilimumab combination therapy 加藤潤1, 橋本良博2, 佐々木英雄1, 三宅芳男1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 830-830, 2019. |
|---|
|
|
P0285-2-AM. Investigation about the antiPD-L1 antibody administration and influenza immunization in patients with non-small cell lung cancer 八瀬恵理子1, 高橋政成1, 山本理恵2, 田路章博1, 南山啓吾1, 砂金秀美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 831-831, 2019. |
|---|
|
|
P0287-2-AM. One case of the serious dermatopathy that Osimertinib causes 渡邉紘章1, 伊與田友和1, 安藤真弘2, 高橋紗英子1, 高田あゆみ1, 田崎政則1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 831-831, 2019. |
|---|
|
|
P0289-2-AM. Effect of the antimicrobial giving it to the clinical response of the antiPD-1 antibody 南島拓矢1, 肥田裕丈1, 今俊介1, 千崎康司1, 永井拓1, 山田清文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 832-832, 2019. |
|---|
|
|
P0291-2-AM. One case of renal cell carcinoma which developed serious hepatic dysfunction, and maintained high pazopanib blood level 柏倉正太1, 鈴木裕之2, 大内竜介1, 薄井健介1,3, 岡田浩司1,3, 佐藤信4, 海法康裕4, 伊藤淳4, 阿南剛4, 岩村大径4, 村井ユリ子4, 中村仁4, 渡辺善照1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 832-832, 2019. |
|---|
|
|
P0295-2-AM. Efforts in the enforcement situation and our hospital of the colon cancer chemotherapy in elderly people 中市里実1, 善積司行1, 前田智佳子1, 楠本臣彌1, 岩佐沙希子1, 山本紗世1, 藤本明由美1, 岡本悠紀1, 溝端友希1, 三浦絢1, 台野佳代1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 833-833, 2019. |
|---|
|
|
P0297-2-AM. The HBV reactivation measures situation and problems of patients who received chemotherapy 阿部多一1, 住谷達也1, 林哲哉1, 井口恵美子1, 猪股克彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 834-834, 2019. |
|---|
|
|
P0299-2-AM. Efforts to HBV reactivation measures with immunodepression, the chemotherapy 山下千草1, 川原裕1, 佐野雅昭1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 834-834, 2019. |
|---|
|
|
P0301-2-AM. It is examination about the difference in evaluation of Performance Status between a pharmacist, a physician, nurses at the beginning of the medical treatment of the unresectable progress, recurrent lung cancer 長田志織1, 米田太郎2, 木場隼人2, 田中伸佳3, 城座圭子4, 桂英之1, 柴田結希乃1, 小川依1, 石田外樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 835-835, 2019. |
|---|
|
|
P0303-2-AM. Example that performed Carboplatin desensitization for patients with recurrent ovarian cancer of Carboplatin hypersensitivity, and was able to continue treatment 樋口裕哉1,2, 大島宗平1, 八島秀明1,2, 平川隆史3, 岩瀬明3, 阿部正樹1, 荒木拓也1,2, 山本康次郎1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 835-835, 2019. |
|---|
|
|
P0305-2-AM. Fact-finding about the pharmacist duties of the foreign cancer treatment section in the cancer practice cooperation base Hospital, and the like 花香淳一1, 堤大輔2, 脇本麻美3, 村田勇人4, 丹原由希5, 中田千博6, 河野友昭7, 林啓文8, 川澄賢司6, 櫻井洋臣9, 濃沼政美10, 近藤直樹3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 836-836, 2019. |
|---|
|
|
P0307-2-AM. Clinical difference of the mutation in the gene in the EGFR mutation in the gene-positive non-small cell lung cancer 滝澤苑美1, 有山智博1, 田中博之1, 木下雅子1, 藤枝正輝1, 磯部和順2, 石井敏浩1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 836-836, 2019. |
|---|
|
|
P0309-2-AM. The antimicrobial proper use promotion for the AMR measures action plan and future measures 外山智章1,2, 平原康寿1,2, 岩尾千紘2, 中山雄貴2, 荒武舞2, 山田明輝2, 高城一郎2, 岡山昭彦2, 池田龍二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 837-837, 2019. |
|---|
|
|
P0311-2-AM. After the operation in the backbone laminectomy about the use situation of the cefazolin as the infection prophylaxis antimicrobial 吉田悦朗1, 白石貴寿1, 臼井和明1, 山村真貴子1, 大石丸美1, 上前里香1, 近藤真由1, 宇都宮奈々1, 森田佳博1, 中村泰士1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 838-838, 2019. |
|---|
|
|
P0313-2-AM. Consideration about the current situation of the antimicrobial prescription for acute upper respiratory infection of children and the background factor 臼井和明1, 吉田悦朗1, 宇都宮奈々1, 安藤暢彦1, 安河内寿成1, 岩武幹乃1, 栗原江未1, 沖田健太郎1, 白石貴寿1, 中村泰士1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 838-838, 2019. |
|---|
|
|
P0315-2-AM. The current situation of the antimicrobial administration for the treatment of the peritoneal dialysis-related peritonitis in our hospital 永松翔1, 東里美1, 岩下龍史2, 寺口記代2, 上山逹典2, 寺師守彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 839-839, 2019. |
|---|
|
|
P0317-2-AM. Analysis of the factor having an influence on the thrombocytopenia of the linezolid 小久保綾乃1, 中村麗紗1, 喜多洋嗣1, 仲村亮太1, 駒井勇太1, 人見百合子1, 石井奈津季1, 峯浩太郎1, 吉村美菜1, 鈴木里香1, 野下綾子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 839-839, 2019. |
|---|
|
|
P0319-2-AM. Examination about the integration of the amikacin population pharmacokinetics model in neonates and the optimal administration 岡田章1, 鈴木匠1, 竹内祐斗1, 永井尚美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 840-840, 2019. |
|---|
|
|
P0321-2-AM. Effect on aim concentrations arrival rate and effect of treatment by a pharmacist being concerned with initial administration plan of the Teicoplanin 片岡達夫1, 冨田隆志1, 檜山洋子1, 宮本佳奈1, 久保有子1,2, 佐伯康之1, 垰越崇範1, 松尾裕彰1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 840-840, 2019. |
|---|
|
|
P0323-2-AM. Approach ... to realize speedy staphylococcemia treatment by antimicrobial proper use support team ... multi-type of job cooperation in our hospital 古川大樹1, 伊藤嘉英1, 大橋武司1, 林房枝2, 寺島恭子2, 菱田志乃3, 長谷川雅哉1, 中尾彰宏4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 841-841, 2019. |
|---|
|
|
P0325-2-AM. Effective evaluation of the cefaclor for UTIs in our hospital 立石忠昭1, 濱田洋平2, 山下義巳1, 岩根紳治1, 藤岡康彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 841-841, 2019. |
|---|
|
|
P0327-2-AM. The change situation from intravenous antimicrobial in our hospital to internal use antimicrobial and the effect 佐々英也1, 冨田敦和1, 内山耕作1, 鈴川誠1, 平尾祐樹1, 三浦毅1, 今西忠宏1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 842-842, 2019. |
|---|
|
|
P0329-2-AM. It is efforts to adequacy of the infection prophylaxis antimicrobial after the operation in the clinical path 佃晶子1,2, 三橋未帆1,2, 杉尾和昭1,2, 増田雅行2, 寺井幸子1, 内野卯津樹1, 長島誠1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 842-842, 2019. |
|---|
|
|
P0331-2-AM. Examination about the renal failure by the combination of vancomycin hydrochloride and tazobactam/piperacillin 染谷雅弘1, 篠崎陽一1, 明石岩雄1, 長澤仁志1, 加藤潤一郎1, 赤石和久1, 川久保孝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 843-843, 2019. |
|---|
|
|
P0335-2-AM. Intervention by the antimicrobial proper use support team to a case using Tazobactam/Piperacillin more than six days 佐藤陽介1, 伊藤貴亮1, 菅野和1, 佐藤圭吾1,2, 茄子川智子2, 永沼結花3, 川村直美3, 尾池泰典2,3, 松本亜紀2, 井上顕治2,4, 篠崎滋5, 小林誠一6, 矢内勝2,6, 佐賀利英1,7 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 844-844, 2019. |
|---|
|
|
P0337-2-AM. It is impact statement to the infection prevention after the operation by the antimicrobial review of the cataract surgery clinical path 福原佐知1, 吉田宣政1, 江嶋祐樹1, 檜山智子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 844-844, 2019. |
|---|
|
|
P0339-2-AM. Cooperation in the AS activity of AST charge pharmacist and the ward charge pharmacist 大林巧志1, 舩越真理1, 津田正博1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 845-845, 2019. |
|---|
|
|
P0341-2-AM. As a result of internal use observance situation questionary survey in the oseltamivir prophylactic internal use to the staff 莊司智和1,2, 松村大樹1,2, 入倉悠2, 窪川佳世2, 荻原真二2, 内田幹2, 井上修2, 波呂浩孝2, 河田圭司1, 鈴木正彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 846-846, 2019. |
|---|
|
|
P0343-2-AM. Normal tooth extraction and investigation examination of the prophylactic use of antimicrobial actual situation and SSI development situation to an outpatient for the extraction of impacted wisdom teeth 吉田謙介1, 鈴木直人1, 磯辺浩和1,2, 金子奨太1, 齋藤千愛1, 山田瑛子3, 児玉泰光3, 高木律男3, 外山聡1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 846-846, 2019. |
|---|
|
|
P0345-2-AM. About antibody titers of our hospital staff for four kinds of epidemicity virus disease and the vaccination situation 小迫晶寛1, 黒田紘生1, 加茂章弘1, 上村豪1, 古市由香2, 植村隆1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 847-847, 2019. |
|---|
|
|
P0347-2-AM. Evaluation of the AST activity judging from a viewpoint of the medical economy 阿部純也1, 小島安紀子1, 松本朋美2, 堀内保孝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 847-847, 2019. |
|---|
|
|
P0349-2-AM. The effectiveness of the cefazolin sodium intravenous administration in the cataract surgery perioperative period and safe examination 新海永梨奈1, 鶴崎大1, 深滝利也1, 中静裕之2, 菊池憲和1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 848-848, 2019. |
|---|
|
|
P0351-2-AM. Experimental inspection of the effect factor to give to the calcium salt formation based on the findings of the gallstones-related disorder expression tendency by the ceftriaxone 田口和明1, 伊藤瑠衣1, 吉田亜沙美1, 榎木裕紀1, 松元一明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 848-848, 2019. |
|---|
|
|
P0353-2-AM. Examination of the effect that an antimicrobial proper use support activity gives to the use situation of the antimicrobial 立石翼1, 滝波昇悟1, 安尾哲郎1, 松田真哉2, 田口剛士2, 矢島尚子3, 濱野政弘3, 大村正恵3, 友田恒一4, 羽井佐実5, 監物英男1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 849-849, 2019. |
|---|
|
|
P0355-2-AM. The effect that an activity of AST gives for use of in-hospital antimicrobial 山村翔1, 荒木良介1, 山田英紀1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 849-849, 2019. |
|---|
|
|
P0357-2-AM. Effect to the process index by the activity of the antimicrobial proper use support team 山崎晃憲1,2, 駒澤宏紀1,2, 猫宮由美子2, 松坂俊2, 芹沢良幹2, 安保義恭2, 本郷文教1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 850-850, 2019. |
|---|
|
|
P0359-2-AM. The current situation evaluation and problem of the antimicrobial proper use round by Antimicrobial stewardship team 高野温志1,2, 伊賀正典1,2, 神山治郎1, 大川直美1, 阿保一茂1, 町田充2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 850-850, 2019. |
|---|
|
|
P0361-2-AM. How did the acquisition of the preventive measures against infection addition and the authorized number of the pharmacists, the intervention situation change in 2010 and 2,016 years? : Comparison using the JACS 田中真幸1, 村木優一1, 日馬由貴2,3,4, 石金正裕2,3, 大曲典夫2,3,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 851-851, 2019. |
|---|
|
|
P0363-2-AM. About a preparation of the suspension of the antiHIV medicine that crush is necessary for the simple suspension method application 寺岡麗子1, 橋本佳那子1, 高橋稔1, 河野奨2, 白木孝2, 矢倉裕輝3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 852-852, 2019. |
|---|
|
|
P0365-2-AM. Prescription situation and tendency ... of the antiHIV medicine in efforts (1) - our hospital for the outside Parliament shift of the prescription containing the antiHIV medicine in our hospital 保戸塚里美1, 井手頌美1, 南谷奈々1, 朽木絵美1, 黒木あかね1, 前波麻里子1, 井戸澤弘美1, 山形亜紀子1, 林みどり1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 853-853, 2019. |
|---|
|
|
P0367-2-AM. Change of the D dimer with the lipid microsphere administration 大塚淳一1, 石倉あゆみ1, 山口祐希1, 伊藤圭介1, 湯浅瑠美2, 笹木織絵2, 松村暁3, 島崎博士1, 長谷川英雄1, 坪井一人5, 尾高真5, 内山幹4, 藤岡秀一5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 854-854, 2019. |
|---|
|
|
P0369-2-AM. Efforts to the use current situation and the proper use of the dose of medicine to the long-term inpatient in the psychopathic ward 新保一1, 苗田洋生1, 浅見友美子1, 関川敬1, 伊東秀幸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 855-855, 2019. |
|---|
|
|
P0371-2-AM. Role - of the pharmacist in efforts - multi-type of job interview for the discharge to patients with schizophrenia during long-term hospitalization 小林泰子1, 大塚桂子1, 馬場元2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 856-856, 2019. |
|---|
|
|
P0373-2-AM. Attempt for the pharmaceutical products proper use in dementia, the elderly people ward 福山雄卯介1, 福山順子2, 宮崎敦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 856-856, 2019. |
|---|
|
|
P0375-2-AM. How does attitude survey - psychiatry pharmacist about the medication counseling to patients with schizophrenia arrest him? 五味和彦1,2, 竹平理恵子2, 有田悦子2, 和田美由紀1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 857-857, 2019. |
|---|
|
|
P0377-2-AM. Inspection of the delirium protective efficacy by the ramified microglia suvorexant internal use 石塚雅人1, 奥村知香2, 岡本和之1, 山内拓1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 857-857, 2019. |
|---|
|
|
P0379-2-AM. Comparison of ritodrine and the progesterone vaginal tablet which a canalis cervicis uteri shortening pregnant woman can put 日野光記枝1, 大橋健吾1, 吉田真也1, 宇佐美英積1, 吉村知哲1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 858-858, 2019. |
|---|
|
|
P0381-2-AM. About the need that a pharmacist is associated with after initial diagnosis for the pregnant woman with suspected teratogenic increased risk 古久保有希子1, 辻亜紀1, 岡藤博2, 橋本奈美子2, 田中篤志3, 野村浩英1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 859-859, 2019. |
|---|
|
|
P0383-2-AM. Efforts to the mother's milk childcare support of the woman in childbed in the medical treatment in our hospital 村田文1, 新木美枝1, 安部和子2, 河野美幸3, 伊藤理廣2, 鈴木達宙1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 859-859, 2019. |
|---|
|
|
P0385-2-AM. Making of the administration drug table to a pregnant woman 七田和佳子1, 内藤哲哉1, 酒井義朗1, 樋口恭子1, 福江弘子1, 橋本温美1, 三輪涼子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 860-860, 2019. |
|---|
|
|
P0387-2-AM. Example that by having introduced the SAP therapy with the PLGS function into patients with 3 years old type I diabetes mellitus said to that it was hard to accept it from a nursery school, made possible going to kindergarten 石原祥子1, 水野彩1, 大谷寧次郎1, 畔柳敏弥1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 861-861, 2019. |
|---|
|
|
P0389-2-AM. Examination of the use situation of the SGLT-2 inhibitor of diabetes internal medicine, the circulatory organ internal medicine in our hospital 石橋真実1, 大森麻江1, 向井めぐみ1, 宮下雄博2, 森英樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 862-862, 2019. |
|---|
|
|
P0391-2-AM. Examination about the concomitant drug of the GLP-1 receptor agonist choice patients 井上稚枝子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 862-862, 2019. |
|---|
|
|
P0393-2-AM. About a change of HbA1c after the sustained blood sugar determination introduction in our hospital 近藤理美1, 田中祐子1, 岸本実優1, 喜多洋嗣1, 森智子1, 府川祥子1, 白木萌1, 市原麻友子1, 井上千尋1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 863-863, 2019. |
|---|
|
|
P0395-2-AM. Report about the use situation of the ipragliflozin in our hospital 中山潤美1, 加藤まゆ1, 大谷寧次郎1, 畔柳敏弥1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 863-863, 2019. |
|---|
|
|
P0397-2-AM. About the course after having conducted sitagliptin weight loss about patients with moderate or severe impaired renal function 塚本名奈子1, 安居佐織1, 小西敦子1, 田路章博1, 南山啓吾1, 砂金秀美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 864-864, 2019. |
|---|
|
|
P0399-2-AM. Examination of the factor to have an influence on the dissection of eGFRcre and eGFRcys 山崎翔太1, 菅原浩介1, 鈴木英則1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 865-865, 2019. |
|---|
|
|
P0401-2-AM. The effect that the number of daily administration of ampicillin/sulbactam in patients with old pneumonia gives to the effectiveness 鈴木朋克1,2, 高橋京香2, 田島正教2, 杉山恵理花2, 吉井雅美1, 鈴木秀則1, 佐藤均2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 866-866, 2019. |
|---|
|
|
P0403-2-AM. Practice of fact-finding of the prescription inappropriate potentially using STOPP-J and the reporting to a physician 山田航輔1, 大久保駿一1, 笹木拓郎1, 岡本麻里子1, 横川祐美1, 船木映二1, 橋本義宏1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 867-867, 2019. |
|---|
|
|
P0405-2-AM. About the effect that polypharmacy measures in the normal business routine in the convalescent ward give in ADL 前田悠里1, 阪本久未子1, 樺木美香1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 867-867, 2019. |
|---|
|
|
P0407-2-AM. Efforts of the multiple drug prescription adequacy for the special elderly nursing home entering patients 上田由貴1, 稲垣芙美佳1, 山代栄士1, 川元崇志1, 宮村友梨子1, 平賀愛実1, 森一生1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 868-868, 2019. |
|---|
|
|
P0409-2-AM. Examination about prescription fact-finding and the proper use of the laxative in our aging garden to go ahead through 阪元孝志1, 下地厚子1, 松原洋孝2, 知念一3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 868-868, 2019. |
|---|
|
|
P0411-2-AM. Comparison of the anesthesia management propofol buprenorphine fentanyl during atrial fibrillation ablation technique 木下照常1, 柴田大地1, 足立守1, 原田光徳2, 杢野晋司2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 869-869, 2019. |
|---|
|
|
P0413-2-AM. Effect to be vital, and to give after switching from transdermal type bisoprolol to the titer oral form 馬橋美由季1, 奥川寛1, 堀内望1, 野崎歩1, 小林由佳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 870-870, 2019. |
|---|
|
|
P0415-2-AM. The prevention of recurrence prescription support that was carried out for atherothrombotic cerebral infarction and a cardioembolic concurrence case 原田百華1, 薬師寺寿世1, 河村聡志1, 森一生1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 870-870, 2019. |
|---|
|
|
P0417-2-AM. The effectiveness of antiIL-5 monoclonal antibody medicine for the COPD with many blood eosinophil counts and antiIL-5 receptor α monoclonal antibody medicine and safe evaluation 山崎優1, 嶋田修治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 871-871, 2019. |
|---|
|
|
P0419-2-AM. Effect of treatment of the SGLT2 inhibitor for patients with heart failure that left ventricle shrinkage ability was maintained 堀部聖1, 猪野達也1, 瀬尾達朗1, 鈴木貴之1, 池上幸子1, 福本由美子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 871-871, 2019. |
|---|
|
|
P0421-2-AM. Examination about the medication counseling of the Tokishakuyakusan for the anosmia 岩瀬裕治1, 小野恵美子1, 丹羽直人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 872-872, 2019. |
|---|
|
|
P0423-2-AM. Effect on pain that the acetaminophen administration from all over the operation in patients who underwent hip joint replacement gives 松井美月1, 須永登美子1, 神崎浩二2, 桑迫勇登3, 渡邊徹1, 佐々木忠徳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 872-872, 2019. |
|---|
|
|
P0425-2-AM. Lipid management for patients with acute coronary syndrome based on arteriosclerotic disease prevention guidelines 2017 岩堀真弓1, 中田絵梨1, 八木遥1, 東修司1, 田畑裕和1, 稲垣育宏1, 小寺隆二1, 柴波明男1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 873-873, 2019. |
|---|
|
|
P0427-2-AM. Practice of the polypharmacy measures by the multi-type of job collaboration team 越智大輔1, 木下玄子1, 大西順子1, 田中成枝1, 白石剛一1, 須々木健太郎1, 南薗淳1, 白髪恵美1, 村上雅基2, 田中陽子3, 中村和美4, 山崎宙5, 近藤祥代1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 873-873, 2019. |
|---|
|
|
P0429-2-AM. Blinding-related maintenance method at the formulations in the placebo-controlled double-blind randomized third phase controlled trial to test usefulness of olanzapine for CINV 秋山加菜1, 増島広幸1, 櫻井美満1, 石川寛1, 篠道弘1, 安部正和2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 874-874, 2019. |
|---|
|
|
P0431-2-AM. Visualization of the ethic examination necessity or not about the outside announcement of our hospital pharmacy 小川博史1, 川本晃男1, 川島弓枝1, 大隅規充1, 山本博美1, 友金幹視1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 875-875, 2019. |
|---|
|
|
P0433-2-AM. Characteristic and economic effect - of the checking prescription which assumed analysis - drug cancellation of the checking prescription in the ethical pharmacy results 海野茜1,2,3,4, 鈴木学1,2, 上田祐稀乃1, 林由依1, 味澤香苗1, 林秀樹1,2,3,4, 生木庸寛3, 小林篤史4, 小原道子3, 甲斐絢子4, 棚瀬友啓2, 杉山正1,2,3,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 876-876, 2019. |
|---|
|
|
P0435-2-AM. Questionary survey about the multi-type of job cooperation patients support system utilizing the ICT for the setting type ventricular assist device wearing patients 河野紀子1, 菊田紋華1, 山田恵里1, 倉地茜1, 宮川泰宏1, 矢野亨治1, 佐伯純2, 池本千春2, 水野久美子2, 日比恵美子2, 相木一輝3, 後藤和大3, 竹内晴美4, 藤本和朗5, 六鹿雅登5, 碓氷章彦5, 近藤徹6, 奥村貴裕6, 室原豊明6, 笹山哲7, 野本愼一8, 山田清文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 877-877, 2019. |
|---|
|
|
P0437-2-AM. Qualitative analysis ... by SCAT of current situation and problem - focus group about the cooperation with the pharmacist judging from Care manager 市之川彩花1, 竹平理恵子1, 小倉未来1, 有田悦子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 877-877, 2019. |
|---|
|
|
P0439-2-AM. Led by a relation - seamless for relaxation case to be hospitalized, and to be at home to the community medical care of the pharmacist in the Saiseikai young grass hospital and at-home visit practice - 宮永幸実1, 西野美沙1, 高梨明恵1, 仲田涼1, 小杉満孝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 878-878, 2019. |
|---|
|
|
P0441-2-AM. Efforts to improvement in adherence of patients by the medicine medicine cooperation 工藤誠一朗1, 小笠未遥1, 森野太一1, 駒澤愛1, 多田知弘1, 久保悠1, 小財弘己1, 今田深雪1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 879-879, 2019. |
|---|
|
|
P0443-2-AM. About the problem on the prescription order system obtained from the doubt inquiry information of the outside Parliament prescription 廣井順子1, 早船真弘1, 肥沼理映子1, 藤波薫1, 羽瀬悟聖2, 平井健3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 880-880, 2019. |
|---|
|
|
P0445-2-AM. Usefulness of the in front of hospitalization confirmation of the drug taking medicine which fixed its eyes on after construction - discharge of the medical cooperation to think about from a support task before hospitalization 久岡清子1, 増田博也1, 合田さやか1, 佐々木健志1, 澤口友紀1, 亀岡喬1, 大荒政志1, 間千晴1, 鹿沼奈央1, 川村大輔1, 坂本真衣1, 吉川真央1, 松浦亜里沙1, 井上萌1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 880-880, 2019. |
|---|
|
|
P0447-2-AM. For construction - medicine for drug control instruction duties medicine cooperation promotion utilizing eXChart - 深澤真実1, 兵藤沙耶1, 潟永安亘1, 草葉一友1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 881-881, 2019. |
|---|
|
|
P0449-2-AM. Efforts of the patients follow-up for the Lenvatinib remedy patients 津村紗代1, 井上光鋭1, 福江弘子1, 樋口恭子1, 三輪涼子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 881-881, 2019. |
|---|
|
|
P0451-2-AM. About making, the operation of "the doubt inquiry protocol in the outside Parliament prescription" 出口幾文1, 末永拓也1, 岩尾恭寛1, 工藤真裕1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 882-882, 2019. |
|---|
|
|
P0453-2-AM. Operational report of the outside Parliament prescription doubt inquiry simplification protocol 水野康平1, 喜多洋嗣1, 長濱藍1, 石井英之1, 久田潤平1, 三浦捺樹1, 宮川千珠1, 山中愛美1, 宇根良祐1, 喜友名侑舞1, 田仲祐子1, 棚田雅貴2, 濱口武司3, 松田絵理菜4, 南保智宏5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 882-882, 2019. |
|---|
|
|
P0455-2-AM. About operation of the doubt inquiry simplification protocol in the outside Parliament prescription 田中誠1, 甲斐達夫1, 中禮希咲1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 883-883, 2019. |
|---|
|
|
P0457-2-AM. Questionary survey to the drugstore pharmacist about test value mention to outside Parliament prescription 喜多朝菜1, 石嶋麗1, 間瀬広樹1, 綿谷敏彦2, 村田世里子2, 齋藤讓一1, 秋山哲平1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 883-883, 2019. |
|---|
|
|
P0459-2-AM. Investigation of the inflection situation in the destination of the pharmacy management summary 宮川幸典1, 宮崎俊明1, 川村知子1, 筒井由佳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 884-884, 2019. |
|---|
|
|
P0461-2-AM. Efforts to the anti-stress reinforcement of the pharmacist at disaster occurrence 角田健1, 小室治孝1, 喜古康博1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 885-885, 2019. |
|---|
|
|
P0463-2-AM. Efforts in our hospital to make we accumulate a potentially serious medical errors report, and an incident report have degression 和田祐一郎1, 新居亜里沙1, 成田慧未1, 坂井裕美1, 穂積廣1, 加藤香奈1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 886-886, 2019. |
|---|
|
|
P0465-2-AM. Making of the management sheet of injection antimicrobial six drugs in the Chiba west general hospital 加藤紗耶香1, 香取哲哉1, 小林亜貴子1, 小川直紀1, 谷古宇修平1, 出雲貴文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 887-887, 2019. |
|---|
|
|
P0467-2-AM. Construction - of the monitoring system of corresponding - hospital preparation to high relative difficulty medical care support, pharmaceutical products off-label use 片岡晃一1, 白石佳世1, 平田歩1, 石田七生1, 石田智滉1, 伊東睦弘1, 上田真由美1,3, 北岡裕章2,3, 常風興平1, 門田亜紀1, 森田靖代1, 宮村充彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 887-887, 2019. |
|---|
|
|
P0471-2-AM. Efforts of the allergic cover suspicion drug control by the cooperation with the nursing department 橋本晴香1, 佐藤史織1, 菅田佳子1, 佐脇久美1, 陸丸幹男1, 原尻学志1, 森一生1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 888-888, 2019. |
|---|
|
|
P0473-2-AM. Current situation investigation (2) of the medical therapy to have an influence on the aspiration pneumonia of elderly people 渡邊梓1, 西川満則1, 山本智也1, 大石雅子1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 889-889, 2019. |
|---|
|
|
P0475-2-AM. Fact-finding for the appropriate simple suspension method enforcement and future problem 大野峻1, 武田元樹1, 菊池健1, 角谷直志1, 尾又玲伊1, 相馬貴史1, 佐々木啓1, 鶴山辰1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 889-889, 2019. |
|---|
|
|
P0477-2-AM. The safety management report analysis of the pharmacy business trainee and medical safety education 佐瀬裕子1,2, 加藤能子1, 永田将司1, 鳥羽三佳代2,3, 尾林聡2, 高橋弘充1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 890-890, 2019. |
|---|
|
|
P0479-2-AM. Factor analysis to give to an understanding degree, a global assessment of contents of the hospital business training based on student questionary survey and the significance 小島穂菜美1, 吉田都1, 内田享弘1, 桑原晶子1, 豊原朋子1, 濱宏仁1, 辻本勉1, 片岡和三郎1, 綿本有希子1, 田崎眞生1, 波多江崇2, 森山賢治1, 三木知博1, 篠塚和正1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 891-891, 2019. |
|---|
|
|
P0481-2-AM. Attitude survey of the business training student about the perinatal medical care 曽我部直美1, 北畑智英1, 植松和子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 891-891, 2019. |
|---|
|
|
P0483-2-AM. Analysis - of the training contents which a student using upbringing 19th report - text mining of the pharmacist who carried the next generation learned 川端崇義1, 猪田宏美1, 久保和子1, 北村佳久1, 千堂年昭1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 892-892, 2019. |
|---|
|
|
P0485-2-AM. How does upbringing 20th report - student of the pharmacist carrying the next generation learn about "cancer" during business training? - 久保和子1, 川端崇義1, 猪田宏美1, 北村佳久1, 千堂年昭1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 892-892, 2019. |
|---|
|
|
P0487-2-AM. About a source of information using it for questionary survey - paper chase about study other than Buddhism Osamu at the time of the pharmacy student - 幡生あすか1, 上田幹子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 893-893, 2019. |
|---|
|
|
P0489-2-AM. Education contents of "an evaluation and the prescription suggestion of the medical treatment based on the case" evaluate prior learning for the hospital business training (the second report) 飛田夕紀1, 平山武司1,2, 厚田幸一郎2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 894-894, 2019. |
|---|
|
|
P0491-2-AM. Approach (cancer medical care domain) to train a specialty, an authorized pharmacist of the Kanagawa hospital pharmacist society 宮田広樹1,10, 菅原充広2,10, 縄田修一3,10, 原田知彦4,10, 湊川紘子5,10, 相澤康子6, 門谷靖裕7, 橋口宏司8, 厚田幸一郎2,10, 橋本真也9,10, 佐藤透10 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 895-895, 2019. |
|---|
|
|
P0493-2-AM. It is ... about efforts - high alert medicine of the pharmacy for the JCI certification 立石裕樹1, 宮津大輔1, 村田智弘1, 柏木亜子1, 横田沙紀1, 田中博和1, 井上幸子1, 平川雅章1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 896-896, 2019. |
|---|
|
|
P0495-2-AM. Findings report about a shape and the materials of the infusion solution bag 岡田圭史1, 隅田徹1, 石川元章1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 897-897, 2019. |
|---|
|
|
P0497-2-AM. Change of the prescription suggestion by the DST intervention after the dementia support team (DST) organization and activity start 宮城景1, 高本早希1, 北村悠里子1, 木村真策1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 897-897, 2019. |
|---|
|
|
P0499-3-AM. Intervention of the drugstore pharmacist for the dose adequacy of the renal excretion type DPP-4 inhibitor 入澤佑紀1, 恩田幸憲2, 石黒貴子2, 前田守3, 長谷川佳孝3, 月岡良太3, 森澤あずさ3, 大石美也3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 898-898, 2019. |
|---|
|
|
P0501-3-AM. It is (1) about the appropriate medication methods such as problems and OD tablets, and the like of the medication with the thickness agent of the eating deglutition person with a disability 倉本敦夫1, 島崎学2, 大越すみ江1, 五十嵐玲子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 899-899, 2019. |
|---|
|
|
P0503-3-AM. The effectiveness of the Residual medicine adjustment using the doubt inquiry simplification protocol 西岡茉奈1, 宮崎俊明1, 筒井由佳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 899-899, 2019. |
|---|
|
|
P0505-3-AM. Epicritic evaluation - of the prescription product needing discontinuation before epicritic evaluation - surgery, examination of the tablet, capsule body 岩佐昌広1, 矢野忠1, 市川訓1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 900-900, 2019. |
|---|
|
|
P0507-3-AM. Application to the analysis of the doubt inquiry record and effective and safe medical therapy enforcement 大石美奈子1, 上田紘子1, 戸田史恵1, 山中佑合子1, 足立亜希子1, 幡生あすか2, 上田幹子2, 浦川龍太1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 900-900, 2019. |
|---|
|
|
P0509-3-AM. The factorial experiments of the in-hospital return of goods drug and future problem 野田絢子1, 加藤美樹1, 後藤裕美子1, 舟橋智美1, 手塚剛彦1, 大西正文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 901-901, 2019. |
|---|
|
|
P0511-3-AM. The effect that was obtained by adequacy of the emergency cart drug for household delivery of the radiation department 普賢淳子1, 神谷貴樹1, 星野伸夫1, 寺田智祐1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 902-902, 2019. |
|---|
|
|
P0513-3-AM. Formula reconstruction of the fibrate drugs for convalescent rehabilitation wards 橋本貴史1, 金井紀仁1, 鈴木義人1, 宮崎美子2,3, 齋藤俊夫3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 902-902, 2019. |
|---|
|
|
P0515-3-AM. Correspondence of our hospital in the preparation supply stop for the cefazolin Na injection 弓長藤佳1, 廣田侑真1, 小沼大祐1, 神長雅浩1, 大塚知信1, 金田暁2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 903-903, 2019. |
|---|
|
|
P0517-3-AM. Examination about the incompatibility of the cocktail injection to use for pain relief after the total hip replacement (THA) 山内理恵1, 大野修司1, 中島りり子1, 井上信宏1, 久保元1, 竹場和代2, 川崎智子2, 北岡晃2, 浅井和範1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 904-904, 2019. |
|---|
|
|
P0519-3-AM. Introduction of the 1.6% peppermint suspension preparation in the endoscopy 米田奈美1, 白川敦規2, 末松直幸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 905-905, 2019. |
|---|
|
|
P0521-3-AM. Investigation of the regulations temperature retention time of the para-cool injection drug under the room temperature environment 百瀬麻子1, 丹勝弘1, 安藤井達1, 木村元範2, 青森達2, 村松博2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 906-906, 2019. |
|---|
|
|
P0523-3-AM. An evaluation between the preparation of herbal medicinal products, the Kakkonto extract for the medical care: The difference in quantity of insoluble particulate matter in the water and ultrafine presence 稲葉一訓1,2, 福岡侑也1, 大竹裕子1, 井上知美1, 石渡俊二1, 小竹武1, 長井紀章1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 907-907, 2019. |
|---|
|
|
P0527-3-AM. Relation of the pharmacist in the Lenvatinib cecal fistula administration for hepatocytes cancer 久保靖憲1, 山本譲1, 大滝康一1,2, 三嶋一登1, 小野尚志1, 山下恭範1, 福土将秀1, 田崎嘉一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 909-909, 2019. |
|---|
|
|
P0529-3-AM. The making of the template of the drug management instruction record and examination about the usefulness 神原諒1, 山中理1, 杉山由紀子1, 中山英夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 909-909, 2019. |
|---|
|
|
P0531-3-AM. Evaluation - of the medical treatment protocol in importance - cataract surgery clinical path of the pharmacist participation for the clinical path operation 船戸裕樹1, 清水倫子1, 依岡千恵子1, 柳澤成佳1, 垣内綾乃1, 岡崎萌水1, 野村政孝1, 八木祐助1, 常風興平1, 門田亜紀1, 森田靖代1, 宮村充彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 910-910, 2019. |
|---|
|
|
P0533-3-AM. The case that was given blood sugar control of the type I diabetes mellitus children patient using three kinds of insulin preparation 福田葉月1, 井上和子1, 門脇美智子1, 加藤隆之1, 植木智美1, 島田美樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 910-910, 2019. |
|---|
|
|
P0535-3-AM. Examination - creatinine and cystatin C - of the operation pronephros usability test method of the cardiovascular surgery 伊藤悠里子1, 菅野貴寛1, 池上久貴1, 高野純希1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 911-911, 2019. |
|---|
|
|
P0537-3-AM. Examination about polypharmacy and a fall, the delirium in our center 竹林佳菜1, 中込哲1, 野呂竜太郎1, 田村亜優夏1, 坂上達也2, 江守沙奈恵3, 中村香織3, 熊木良太4, 池田敦1, 南郷栄秀5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 911-911, 2019. |
|---|
|
|
P0539-3-AM. Polypharmacy-related factor investigation 遠藤晋吾1,2, 山本圭城1, 安井友佳子1, 石坂敏彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 912-912, 2019. |
|---|
|
|
P0541-3-AM. We challenge medical therapy adequacy in a convalescent rehabilitation ward 伊藤真紀子1, 細木慈子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 912-912, 2019. |
|---|
|
|
P0543-3-AM. The first step of the efforts to make an adverse event evaded in protocol 宇佐美初雄1, 加藤洋介1, 櫻井英俊1, 前田直希1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 913-913, 2019. |
|---|
|
|
P0545-3-AM. Evaluation of the activity contents of the pharmacist in the heart failure team and the pharmaceutical management 三浦佳江1, 立岡美穂1, 岡崎美香1, 牧野華子1, 石原慎之1, 玉木宏樹1, 矢野貴久1, 大内武2, 佐藤寛大2, 遠藤昭博2, 田邊一明2, 直良浩司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 913-913, 2019. |
|---|
|
|
P0547-3-AM. About the intervention of the aspirin-containing drug rate of use and ward pharmacist to patients with acute myocardial infarction 成田桃子1, 村谷美帆1, 廣井順子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 914-914, 2019. |
|---|
|
|
P0549-3-AM. To realize ward drug duties to snuggle up to 1 ... patients about the importance of the ward round; ... 澤口友紀1, 井上萌1, 大荒政志1, 久岡清子1, 西村善也2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 914-914, 2019. |
|---|
|
|
P0551-3-AM. Efforts of our hospital for the polypharmacy correction 西川桃子1, 田中こずえ1, 上條美咲1, 福井圭亮1, 山下恵梨香1, 北野恵莉子1, 澤井陽1, 河邉瑶子1, 陶山美穂1, 松本友希1, 本田友生1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 915-915, 2019. |
|---|
|
|
P0553-3-AM. The use situation of the morphine hydrochloride for the palliation of a feeling of dyspnea of patients with heart failure 前田朱香1, 曽我弘道1, 上村澪1, 波多江沙織1, 木原慶子1, 富田敏章1, 入江利行1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 915-915, 2019. |
|---|
|
|
P0555-3-AM. Role of the ward pharmacist in the local inclusion care ward 宇賀尚子1, 川尻尚子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 916-916, 2019. |
|---|
|
|
P0557-3-AM. Through the pharmacist intervention at discharge in the orthopedics ward 高木春乃1, 石黒貴洋1, 彦坂紗世1, 生田知子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 916-916, 2019. |
|---|
|
|
P0559-3-AM. About the participation of the pharmacist in discharge prescription in the University of Occupational and Environmental Health Hospital mixture ward 川道直子1, 稲村由香1, 竹中美紗1, 篠原義剛1, 植木哲也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 917-917, 2019. |
|---|
|
|
P0561-3-AM. The development of the medication confirmation check seat for safe enforcement of surgery, the examination in the stroke care unit and the usefulness 福田裕子1, 伊東里紗1, 森あやか1, 今井裕美3, 井岡瑞樹子1, 道下佳子1, 稲場純子1, 池野智子2, 冨家幸子2, 長谷川由美子2, 田中雅美2, 酒井和江2, 中藏伊知郎1, 北澤文章1, 辻川正彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 917-917, 2019. |
|---|
|
|
P0563-3-AM. Relation of the pharmacist in the intensive care unit 湯村健一1, 佐野邦明1, 上野正夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 918-918, 2019. |
|---|
|
|
P0565-3-AM. For measures establishment of nausea post-operative vomiting in our hospital 濱浦弘光1, 高橋弘泰1, 大谷寧次郎1, 畔柳敏哉1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 919-919, 2019. |
|---|
|
|
P0567-3-AM. Content analysis of the ward drug duties for the bacteremia case during intensive care unit (ICU) admission 大山翔1, 澤田真嗣1,2, 中西裕明1, 藤田将輝1,2, 村木優一3, 岡橋孝侍1, 藤田敦夫1, 友金幹視1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 919-919, 2019. |
|---|
|
|
P0569-3-AM. Construction ... of the cooperation system of efforts first report - perinatal ward and NICU to drug control instruction in the NICU 湖城由佳1, 丹沢彩乃1, 三浦寄子1, 柳下祥子1, 川崎裕世1, 三大寺紀子1, 高山寿里1, 石井真理子1, 山谷明正1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 920-920, 2019. |
|---|
|
|
P0571-3-AM. Blood pressure fluctuation and the postoperative acute nephropathic evaluation that angiotensin converting enzyme inhibitors, an angiotensin receptor blocker in the perioperative period gives 大柿佳織1, 豊島慶太1, 枦秀樹1, 山本涼子1, 太田哲徳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 920-920, 2019. |
|---|
|
|
P0573-3-AM. About efforts and the problem of the pharmacist in the hospitalization and release support center 植松夏子1, 桜井美咲子1, 加藤潤1, 近藤有1, 戸田州俊1, 間瀬悟1, 井上健1, 三宅芳男1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 921-921, 2019. |
|---|
|
|
P0575-3-AM. Efforts and evaluation of the hospitalization and release support room in our hospital 加藤幸三1, 山垣貴士1, 清水豊子1, 岡本卓也1, 島村圭二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 922-922, 2019. |
|---|
|
|
P0577-3-AM. Usefulness evaluation of the pharmacist outpatient department intervention in the Lenvatinib therapy for the hepatocellular carcinoma 高橋克之1, 高橋正也1, 打田佐和子2, 周防舞仁2, 小田桐直志2, 吉田香奈子2, 小谷晃平2, 元山宏行2, 萩原淳司2, 藤井英樹2, 森川浩安2, 榎本大2, 田守昭博2, 河田則文2, 永山勝也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 922-922, 2019. |
|---|
|
|
P0579-3-AM. The role of the pharmacist in the diabetes dialysis prevention outpatient department and future problem 佐藤淳子1, 田杭直哉1, 菅谷量俊1, 高瀬久光1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 923-923, 2019. |
|---|
|
|
P0581-3-AM. The need of the continuation instruction in the pharmacist diabetes instruction outpatient department 中村敏史1, 大屋有夏2, 福岡一貴2, 高橋典男2, 吉田昌則2, 池上信昭1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 923-923, 2019. |
|---|
|
|
P0583-3-AM. Treatment support in the pharmacist outpatient department and the effect on patients with inflammatory bowel disease 中村健志1, 平町隆明1, 石原慎之1, 西村信弘2, 玉木宏樹1, 矢野貴久1, 直良浩司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 924-924, 2019. |
|---|
|
|
P0585-3-AM. Efforts for the prevention of nausea post-operative, vomiting by the collaboration of an anesthesiologist and the pharmacist 西村瑞紀1, 高橋真理1, 武田康平1, 今浦将治1, 永瀬怜司1, 菅規久子2, 佐藤智行2, 澤柳ユカリ3, 谷口英喜3, 菅野浩1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 924-924, 2019. |
|---|
|
|
P0587-3-AM. The change of hospitalization and release support center duties 小宅典子1, 井口恵美子1, 猪股克彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 925-925, 2019. |
|---|
|
|
P0589-3-AM. Investigation of the inoculation situation of the influenza vaccine of the patients whom antiinfluenza medicine was prescribed for at Qol drugstore and the disease severity 池貴幸1,2,3, 高橋渉2, 板垣幸太郎2, 笹原侑祐3, 長沼未加2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 926-926, 2019. |
|---|
|
|
P0591-3-AM. Result of the management that we continued a balun strike scorecard in the Yokohama General Hospital and used 高田啓介1, 廣瀬直樹1,2, 倉田武徳1, 稲垣和幸1, 仙内光子1, 小町和樹1, 長屋美香子1, 佐村優1, 関根寿一1, 金田昌之2, 佐藤透3, 赤瀬朋秀4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 927-927, 2019. |
|---|
|
|
P0593-3-AM. Of the drug information for data-processing it 奥野真里絵1, 松本泰子1, 大谷優希1, 蛭谷一彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 928-928, 2019. |
|---|
|
|
P0595-3-AM. Pulse-taking of the number of generic name prescription accompanied with the prescription order system update 松山真範1, 河崎尚史1, 北島正大1, 名村隆2, 金桂洙3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 929-929, 2019. |
|---|
|
|
P0597-3-AM. The relative examination of α 1 receptor blockade and the faint using FAERS: Difference due to concurrent disease 大山勝宏1, 堀祐輔1, 杉浦宗敏1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 930-930, 2019. |
|---|
|
|
P0599-3-AM. Evaluation of the tendency to adverse event expression of the D-VRd therapy using the correspondence analysis 堀口悠太1, 向井淳治1,2, 坂本竜平1, 小竹優希1, 竹原涼子1, 奥田広志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 931-931, 2019. |
|---|
|
|
P0601-3-AM. 2 cases that a pharmacist was associated with about a tuberculosis therapeutic drug prescribed abroad 白川敦規1,2, 米田奈美1, 末松直幸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 931-931, 2019. |
|---|
|
|
P0603-3-AM. Examination of the new antiepileptic drug utilizing big data 定作奈津美1, 高橋志門2,3, 武智研志4, 中馬真幸4, 合田光寛3, 座間味義人2,3, 石澤有紀5,6, 堀ノ内裕也6, 池田康将6, 土屋浩一郎7, 石澤啓介2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 932-932, 2019. |
|---|
|
|
P0605-3-AM. About formula remaking being aware of emergency correspondence in the municipal hospital 岡田七津子1, 森田徹1, 市田千佳1, 高橋賢成1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 932-932, 2019. |
|---|
|
|
P0607-3-AM. Efforts and the use of antimicrobial situation investigation for antimicrobial proper use in our hospital 古賀みゆ1, 山村梨菜1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 933-933, 2019. |
|---|
|
|
P0609-3-AM. Comparison about the long-term use situation and the patients background factor of the sitagliptin in the outpatient and the linagliptin 安藤暢彦1, 近藤真由1, 上前里香1, 岩武幹乃1, 木本秀樹1, 三村英恵1, 大石丸美1, 上地純子1, 白石貴寿1, 中村泰士1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 934-934, 2019. |
|---|
|
|
P0611-3-AM. The use situation investigation for the non-cancerous pain of the opioid analgesic patch in our hospital 澁谷恵美子1, 石田詞子1, 小野達也1, 西田英之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 934-934, 2019. |
|---|
|
|
P0613-3-AM. Use of opioid preparation fact-finding for dyspnea in patients with terminal heart failure 中村眞梨1, 芝崎由美子1, 中村智弘2, 野村淳1, 石田岳史2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 935-935, 2019. |
|---|
|
|
P0615-3-AM. Use fact-finding (the second report) of the pain therapeutic drug of patients with amyotrophic lateral sclerosis 北川莉穂1, 石田奈津子1, 八田裕之2, 座光寺伸幸3, 蛭谷牧子3, 山本吉章4, 鈴木亮平5, 花満裕6, 菅幸生1, 石崎純子1, 松下良1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 935-935, 2019. |
|---|
|
|
P0617-3-AM. About the use actual situation of the morphine hydrochloride note for patients with heart failure in our hospital 榊原洋一1, 伊藤実優1, 平野貴志1, 吉川直利1, 永松秀紹1, 横田学1, 村上照幸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 936-936, 2019. |
|---|
|
|
P0619-3-AM. Risk factor analysis of the inhalational maneuver error in patients with bronchial asthma 大隅智之1, 小室治孝1, 田中大1, 西川正憲2, 喜古康博1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 936-936, 2019. |
|---|
|
|
P0621-3-AM. Use experience of hepatitis C therapeutic drug Glecaprevir/Pibrentasvir combination drug in our hospital 江原美里1, 宮城和代1, 宮部貴識1, 佐光留美1, 山内一恭1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 937-937, 2019. |
|---|
|
|
P0623-3-AM. The use situation investigation of DOAC for the venous thromboembolism 洲山佳寛1, 菅原隆文1, 吉川明良1, 開浩一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 937-937, 2019. |
|---|
|
|
P0625-3-AM. It is ... through way - health Festival of the pharmacist whom we saw from the attitude survey of local inhabitants 長谷川雅紀1, 芦川春菜1, 福本康之1, 川上典子1, 近藤昌子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 938-938, 2019. |
|---|
|
|
P0627-3-AM. It is ... for construction of the drug protocol that a risk in effect - Tomigusuku center Hospital of the sleeping drug in a fall, the fall patients was considered 平識善彦1, 宮良遥奈1, 赤嶺千秋1, 國分千代1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 938-938, 2019. |
|---|
|
|
P0629-3-AM. Sex differences in the association with an oral anticoagulant drug and the osteoporosis 横山聡1, 長野未来1, 岩瀬真1, 細見光一1, 高田充隆1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 939-939, 2019. |
|---|
|
|
P0631-3-AM. Fact-finding of the combination drug rate of use that planned drug costs reduction 浜園龍1, 岩下佳敬1, 薗田晃弘1, 中尾承司1, 兒玉麻代1, 高田侑那1, 久永あゆみ1, 森永知沙1, 上堀正博1, 柴田奨1, 岩下裕美1, 石田和久1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 940-940, 2019. |
|---|
|
|
P0633-3-AM. Effect to give medical expenses reduction effect and institution profit by DVO 橋本浩季1, 村上通康1, 宮崎実千芸1, 山口恭平1, 仙波昌三1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 940-940, 2019. |
|---|
|
|
P0635-3-AM. The medication situation of patients with stroke that we examined from on admission bringing medicine 押尾洋佑1, 高橋美咲2, 有山智博2, 田中博之2, 山本加奈子1, 深山歩美1, 亀田大介1, 矢吹優圭1, 羽山紗樹乃1, 鈴木知佳1, 本多佳也1, 朝生弓実1, 高橋佐和士1, 石井敏浩2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 941-941, 2019. |
|---|
|
|
P0637-3-AM. The back direction multicenter study of the prescription background associated with the polypharmacy in elderly people 早川裕二1, 溝神文博1, 鈴木亮平2, 平野淳3, 間瀬広樹4, 平野隆司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 942-942, 2019. |
|---|
|
|
P0639-3-AM. Efforts to the safe medical treatment that conducted bringing medicine differentiation in the hospitalization and release support center 浦更紗1, 小迫晶寛1, 上村豪1, 植村隆1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 942-942, 2019. |
|---|
|
|
P0641-3-AM. Effect on protective efficacy of the high hardness deep-ocean water for the inflammatory bowel disease and gut flora 長澤一樹1, 河本実季1, 浅田あゆみ1, 大嶋廉之1, 宮永佳代1, 鈴木杏1, 安川岳志2, 森本博俊2, 魚住嘉伸2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 943-943, 2019. |
|---|
|
|
P0643-3-AM. Elderly people purchasing trend of the sleep improvement medicine using the ID-POS data of the drugstore and the problems 小林華奈1, 菊池千草1,2, 渡邊崇2,3, 鈴木匡1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 944-944, 2019. |
|---|
|
|
P0645-3-AM. Safe comparison between starting pharmaceutical products and generic medicine in the docetaxel 川原裕1, 山下千草1, 佐野雅昭1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 945-945, 2019. |
|---|
|
|
P0647-3-AM. Consideration - from attenuation - elution behavior of the effect of treatment by changes from the starting pharmaceutical products of mesalazine tablets to generic medicine 原田恭江1, 細川宜嗣1, 軸原温2, 平岡憲侍3, 羽山薗泉3, 五郎丸剛3, 前田頼伸3, 江藤精二3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 946-946, 2019. |
|---|
|
|
P0649-3-AM. Examination about the effectiveness and the safety of the filgrastim bio follower product in patients with recurrence, intractable malignant lymphoma 奥野護1,2, 関菜摘子2, 五百蔵武士2, 丹田雅明2, 西岡達也2, 久米学2, 槇本博雄2, 矢野育子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 947-947, 2019. |
|---|
|
|
P0651-3-AM. The improvement of vascular pain measures at the dacarbazine administration and the effect 緑川智代1, 白石童子1, 福地祐司2, 竹下光弘1, 早乙女浩之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 948-948, 2019. |
|---|
|
|
P0653-3-AM. About the expression situation and a risk factor of immune-mediated adverse event (irAE) by nivolumab and the Pembrolizumab 道貝優太1, 坂東香織1, 飯田美紅1, 友寄旬1, 坂本和央1, 棚谷貢1, 桂川みき1, 鈴木千波1, 小原秀治1, 小原郁司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 949-949, 2019. |
|---|
|
|
P0655-3-AM. One patient whom systemic erythema multiforme developed in during Abemaciclib administration 杉原弘記1, 樫野かおり2, 岡田昌浩1, 岡本伸也1, 村上史承1, 岡崎和子1, 田代操1, 川真田修3, 竹井英介1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 949-949, 2019. |
|---|
|
|
P0657-3-AM. The side effect expression of immune checkpoint inhibitor situation 森本奈緒美1, 星田唯史1, 藤原大一朗1, 眞下惠次1, 和田祥明1, 野田明宏1, 多喜和夫1, 阪口勝彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 950-950, 2019. |
|---|
|
|
P0659-3-AM. Analysis of the risk factor of the MTX excretion delay with the a large quantity of methotrexate (MTX) therapy for the central nervous system origin malignant lymphoma 今井雄介1, 田中雅幸1, 藤井良平1, 打谷和記1, 村中達也1, 岡崎和一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 950-950, 2019. |
|---|
|
|
P0661-3-AM. Example that caused serious hypomagnesemia during cisplatin for the intraarterial injection and the liver arterial infusion chemotherapy enforcement using 5-fluorouracil 山崎直希1, 佐藤圭吾1, 西和哉1, 藤坂泰之2, 赤羽武弘2, 佐賀利英1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 951-951, 2019. |
|---|
|
|
P0663-3-AM. The onset of adverse event situation in the immune checkpoint inhibitor 作山悠里1, 上森美和子1, 星野茂則2, 米田勉2, 杉浦孝司3, 黒川幸典4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 951-951, 2019. |
|---|
|
|
P0665-3-AM. Examination of the hyperuricaemia with pyrazinamide 小坂隆介1, 則松郁香1, 山崎貴史1, 三浦麻耶1, 桑原貴美子1, 鈴田浩孝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 952-952, 2019. |
|---|
|
|
P0667-3-AM. One case that caused drug-related renal failure in intra-medullary antibiotics perfusion (iMAP) using the gentamicin sulfate injection (GM) 宮内英俊1, 加賀正基1, 山内拓1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 952-952, 2019. |
|---|
|
|
P0669-3-AM. Examination of the inhibitory effect for the indometacin-induced gastric ulcer by the nutrient for intestinal administration 吉見猛1,2, 須田恵1, 金川一成1, 齊木玲1, 合田ひとみ1, 山岸喜彰1, 工藤敏之1, 伊藤清美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 953-953, 2019. |
|---|
|
|
P0671-3-AM. One case that vildagliptin caused pemphigoid 東里美1, 永松翔1, 岩下龍史2, 寺口記代2, 上山逹典2, 寺師守彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 953-953, 2019. |
|---|
|
|
P0673-3-AM. 1 case of the Gitelman syndrome which became the QT prolonged by clarithromycin 高橋雄也1, 森本健幹1, 竹内陽亮1, 宮脇洋平1, 長嶋裕樹1, 米田託成2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 954-954, 2019. |
|---|
|
|
P0675-3-AM. Risk factor analysis of the onset of acute renal failure by the Edaravone 松山淳史1,2, 八牟禮沙織1, 國師奈緒美1, 岩元美樹1, 木下大夢1, 橋本直美1, 帖佐弘子1, 神田直昭2, 鬼丸俊司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 954-954, 2019. |
|---|
|
|
P0677-3-AM. 1 case with suspected autoimmune hepatitis onset type I by isoniazid internal use 川原茉莉1, 脇田恵里1, 伊藤洋貴1, 佐藤賛治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 955-955, 2019. |
|---|
|
|
P0679-3-AM. About a risk factor of the deep vein thrombosis embolism in the artificial joint replacement 谷聡美1, 吉田昭昌1, 山本宏1, 宗政充2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 955-955, 2019. |
|---|
|
|
P0681-3-AM. Examination of the factor in the circadian rhythm of Xanthine oxidase and xanthine dehydrogenase 喜多智生1, 西村さとみ1, 田山剛崇1, 岡村友理香2, 大松秀明1, 覚前美希1, 前田志津子1, 佐和章弘1, 三宅勝志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 956-956, 2019. |
|---|
|
|
P0683-3-AM. Application to a search and the administration plan of the factor influencing an internal change of the levetiracetam 佐々木祐樹1, 荒井希文1, 大場延浩2, 福岡憲泰2, 菊池憲和1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 957-957, 2019. |
|---|
|
|
P0685-3-AM. Physiologic pharmacokinetics model analysis of the rise in Esomeprazole and blood proguanil levels by the vonoprazan combination 大久保健二郎1, 石本麻帆1, 中内佳奈1, 田中亜希実1, 中林勇1, 合田ひとみ1, 舟越亮寛2, 山岸喜彰1, 工藤敏之1, 伊藤清美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 958-958, 2019. |
|---|
|
|
P0687-3-AM. One case with suspected blood level change by the interaction of tacrolimus and the fat-containing enteral feeding product 手塚千裕1, 佐藤祐司1, 小林大典1, 前嶋隆弘1, 小倉次郎1, 佐藤真由美1, 前川正充1, 眞野成康1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 959-959, 2019. |
|---|
|
|
P0689-3-AM. 1 case that became able to be controlled by the adjustment of the concomitant drug for blood voriconazole levels abnormality high level 赤羽理也1, 平大樹1,2, 磯野哲一郎1, 森田真也1, 寺田智祐1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 959-959, 2019. |
|---|
|
|
P0693-3-AM. Examination of the effect with the concomitant drug on effect of the immune checkpoint inhibitor in the non-small cell lung cancer 三浦華歩1,3, 佐野慶行1, 川澄賢司1, 望月伸夫1, 仁保誠治2, 葉清隆2, 松本慎吾2, 善家義貴2, 宇田川響2, 桐田圭輔2, 池田喬哉2, 後藤功一2, 川崎敏克1, 花田和彦3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 960-960, 2019. |
|---|
|
|
P0695-3-AM. Examination about the factor affecting the NICU, the blood level of vancomycin in the GCU ward hospitalization case 星島祐美子1, 田頭尚士1, 平澤裕美子1, 上野杏菜1, 山本宏1, 影山操2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 961-961, 2019. |
|---|
|
|
P0697-3-AM. Initial administration plan analysis of the glycopeptide-based antimicrobial in the Kurume University Hospital 内藤哲哉1, 酒井義朗1, 七田和佳子1, 岩見修一1, 内田貴之1, 鈴木美佳1, 三輪涼子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 962-962, 2019. |
|---|
|
|
P0699-3-AM. Fact-finding of the loading dose method of the Teicoplanin in Juntendo Clinic attached to the Juntendo University faculty of medicine 岡村美里1, 笹野央1, 吉澤寿宏1, 松本博志1, 青嶋瑞樹1, 佐藤邦義1, 荒川隆太郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 962-962, 2019. |
|---|
|
|
P0701-3-AM. Examination of vancomycin doses in patients with blood-forming organ tumor 島田泉1, 小林敬裕1, 小林将文1, 鈴木直人1, 外山聡1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 963-963, 2019. |
|---|
|
|
P0703-3-AM. Is the nourishment evaluation useful in a VCM doses prediction? 北條文啓1, 太田口義智1, 菊田燎1, 中野洸大1, 宗田一記1, 猪狩政則1, 佐久間淳一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 963-963, 2019. |
|---|
|
|
P0705-3-AM. Examination of the effect on initial administration plan of the vancomycin note by the difference in different software 門脇督1, 小笠原綾香1, 能登数馬1, 亀井浩二郎1, 三本松泰孝1, 佐藤弘康1, 和泉秀明1, 田村広志1, 渡辺浩明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 964-964, 2019. |
|---|
|
|
P0707-3-AM. Participation of the pharmacist for the cumulative dose grasp of the anthracycline anticancer agent 松谷直樹1, 中山潤平1, 岡安伸晃1, 内田隆通1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 965-965, 2019. |
|---|
|
|
P0709-3-AM. Efforts of our hospital in the regimen management using the electronic medical chart system of the cancer medical therapy in childhood blood-forming organ tumor 薮内絵里加1, 西山徳人1, 今井雄介1, 藤井良平1, 田中雅幸1, 打谷和記1, 村中達也1, 岡崎和一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 966-966, 2019. |
|---|
|
|
P0711-3-AM. Examination of early detection of Oxaliplatin hypersensitivity and the initial correspondence 谷口潤1, 橋本雅司2, 尾之江剛樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 967-967, 2019. |
|---|
|
|
P0713-3-AM. Fact-finding of the tracing report operation situation in the cancer domain 川澄賢司1, 中嶌明香1, 佐藤信恵1, 久松大祐1, 松井礼子1, 川崎敏克1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 968-968, 2019. |
|---|
|
|
P0715-3-AM. About making of the representation input protocol of the examination of the cancer chemotherapy item in a digestive organ, the surgery ward 西村栄一1, 近藤智幸1, 簑島弓未子1, 荻野健吾1, 斎藤芳敬1, 鈴木正樹1, 牧瀬英知1, 白府敏弘1, 橋本光生1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 968-968, 2019. |
|---|
|
|
P0717-3-AM. It is introduction ... of ... closed system anesthesia administration route "BD F seal (TM) spikes set" for CSTD introduction to all anticancer medicine 横山敦1, 橋口宏司1, 平賀久仁子2, 佐伯朋哉1, 石田梨沙1, 佐藤佑美2, 木村真美2, 上原万里奈2, 神谷武伺1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 969-969, 2019. |
|---|
|
|
P0719-3-AM. Change of the injectable anticancer agent multiple consumption by the closed system anesthesia connection appliance introduction 若松俊希1, 鈴木由紀子1, 草野元1, 松田明宏1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 970-970, 2019. |
|---|
|
|
P0721-3-AM. Effect of the closed system anesthesia preparation appliance introduction to all anticancer agents in anticancer agent exposure measures 田頭尚士1, 田坂友紀1, 串田康弘1, 吉田昭昌1, 山本宏1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 970-970, 2019. |
|---|
|
|
P0723-3-AM. Examination of the actual situation of the Residual medicine destruction in the anticancer medicine preparation and the multiple use 守屋昭宏1, 宇佐美英績1, 廣瀬達也1, 竹中翔也1, 浅野裕紀1, 岡田和智1, 吉村知哲1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 971-971, 2019. |
|---|
|
|
P0725-3-AM. Closed system anesthesia connection appliance compatibility evaluation in the company anticancer medicine lineup 吉田智子1, 前澤早苗2, 戸田麗香2, 高橋史章1, 高野聡之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 971-971, 2019. |
|---|
|
|
P0727-3-AM. The total drug dose upper limit measures of the anthracycline anticancer agent 藤井友和1, 澤柳直樹1, 西川隆一1, 荒木寛也1, 坂柳悦章1, 鈴木宏2, 辻博幸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 972-972, 2019. |
|---|
|
|
P0729-3-AM. It is the investigation about the therapy choice of patients in the adjuvant chemotherapy after the colon cancer technique 木下英樹1, 藤田亜弓1, 平尾郁1, 尼崎正路1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 973-973, 2019. |
|---|
|
|
P0731-3-AM. About importance of the current situation and the pharmacist intervention of the Obinutuzumab + bendamustine therapy in our hospital 橋本直美1, 堀口大輔1, 帖佐弘子1, 鬼丸俊司1, 中野伸亮2, 伊藤能清2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 973-973, 2019. |
|---|
|
|
P0733-3-AM. Investigation of the use situation of the G-CSF preparation in our hospital 篠原美紀1, 赤堀真佑子1, 川合麻未1, 山内拓1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 974-974, 2019. |
|---|
|
|
P0735-3-AM. Pharmaceutical products proper use for the digestive organ symptom improvement effect of olanzapine 畑賢太1, 斉藤俊英1, 神垣輝美1, 藤村拓也1, 相馬まゆ子1, 今田愛也1,2, 佐々木洋一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 975-975, 2019. |
|---|
|
|
P0737-3-AM. An effect of aprepitant on chemotherapy-induced retching, vomiting in the CHASER therapy and safe examination 大橋邦央1, 眞弓健介2, 藤田強記2, 横田千明2, 松元俊博1, 大久保博史1, 三角紳博1, 中川義浩2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 975-975, 2019. |
|---|
|
|
P0739-3-AM. Examination of the expression situation and the risk factor of the hypersensitivity reaction with oxaliplatin 大森義朗1, 藤井佑実1, 國次葉月1, 佐藤真也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 976-976, 2019. |
|---|
|
|
P0741-3-AM. Hypothyroidism during lenalidomide therapy: Observational, prospective study 奥野雅樹1, 土手賢史1, 小林由佳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 977-977, 2019. |
|---|
|
|
P0743-3-AM. One case of the squamous cell carcinoma of lung which showed a rise of PT-INR by warfarin and the interaction of the Tegafur gimeracil oteracil potassium combination drug 間瀬広樹1, 有原大貴1, 新屋智之2, 北俊之2, 秋山哲平1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 977-977, 2019. |
|---|
|
|
P0745-3-AM. Fact-finding of the use of Palbociclib in the Shonan Kamakura General Hospital 星吉行1, 島愛美1, 長岡和徳1, 門谷靖裕1, 中村雅敏1, 下山ライ2, 永田好香3, 田中久美子3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 978-978, 2019. |
|---|
|
|
P0747-3-AM. Examination about drug instruction contents at EGFR-TKIswitching 中村俊之1, 大岡千寿子1, 野洌孝二1, 小室太郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 978-978, 2019. |
|---|
|
|
P0749-3-AM. Examination about the effectiveness of the S-1 imbalance administration in patients with colon cancer and the safety 岩田一史1, 合澤啓二1, 小野達昌1, 陣上祥子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 979-979, 2019. |
|---|
|
|
P0751-3-AM. Search of the factor predicting tolerability of the oxaliplatin combination chemotherapy for patients with elderly people gastric cancer 小池尚弘1, 奈良克彦1, 山本武人1,2, 高田龍平1, 鈴木洋史1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 979-979, 2019. |
|---|
|
|
P0753-3-AM. Examination of antibacterial in front of pharmaceutical affair prescription for the febrile neutropenia during adjuvant chemotherapy after in front of art, the operation and an usefulness evaluation and the proper use of the G-CSF preparation prophylaxis 野田祐紀子1, 鍛治園誠2, 北村佳久1,2, 千堂年昭2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 980-980, 2019. |
|---|
|
|
P0755-3-AM. The infusion reaction expression situation investigation in PER/HER combination therapy and examination of the expression risk factor 成岡里紗1,2, 中垣繁2, 中條倫成2, 内田亮2, 浅原慶徳1, 木村緑2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 980-980, 2019. |
|---|
|
|
P0757-3-AM. - that the check system utilizing efforts - PBPM in the study implementation for immune-mediated adverse event early detection provides safe chemotherapy 鈴木敦詞1, 伊東沙紀1, 福井悠美1, 村山まりこ1, 前田剛司1, 服部芳明1, 坂田洋1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 981-981, 2019. |
|---|
|
|
P0759-3-AM. Investigation of a volume of infusion and the use in cisplatin treated patients of furosemide injection 佐々木好美1, 樋口美奈子1, 児玉沙奈恵1, 和田依子1, 山口竜司1, 檜山智子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 981-981, 2019. |
|---|
|
|
P0761-3-AM. A serious neutropenia in the ramucirumab + paclitaxel combination therapy for the progress recurrence stomach cancer and prognostic association 川嵜真太郎1, 宇佐美英績2, 木村美智男2, 祖父江伸匡1, 堀敦雄1, 吉村知哲2, 西嶋長1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 982-982, 2019. |
|---|
|
|
P0763-3-AM. Cause by 1 case - literature documentation that anticholinergic drug administration to dysarthria with the FOLFIRINOX therapy was invalid and examination ... of measures 後藤敏也1, 高屋敷奈々1, 正木銀三1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 982-982, 2019. |
|---|
|
|
P0767-3-AM. Examination of the prescription actual situation of the allopurinol gargle water for stomatitis due to fluorouracil and the protective efficacy 東郁子1, 大塚亮1, 矢内貴子1, 橋本浩伸1, 関口昌利1, 近野健一1, 牧野好倫1, 山口正和1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 983-983, 2019. |
|---|
|
|
P0769-3-AM. One case that resulted in disturbance of consciousness due to the hyperammonemia after 5-FU + nedaplatin administration for patients with chronic renal failure merger cancer of the esophagus 山本泰大1, 原田雄太2, 大西克浩1, 櫻井愛菜1, 奥村允基1, 平井孝典2, 宮田章弘2, 戸田康裕1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 984-984, 2019. |
|---|
|
|
P0771-3-AM. Effective and safe evaluation of the dexamethasone with the Abiraterone ester acetate (ZYTIGA tablets) 立沢正臣1, 金城直樹1, 金素安1, 坂本善郎2, 住吉正孝1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 984-984, 2019. |
|---|
|
|
P0773-3-AM. Investigation about the side effect frequency of the immune checkpoint inhibitor in the Saint servant Mikatagahara Hospital 井口晴加1, 赤堀真佑子1, 川合麻未1, 山内拓1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 985-985, 2019. |
|---|
|
|
P0775-3-AM. The use situation investigation of the naldemedine for the use of mild cathartic guideline making, examination report 茂原圭佑1, 岡田悠美1, 中川隼一1, 櫻井彩乃1, 高橋真一2, 秋本純矢1, 皆川卓也1, 蔭山博之1, 平島徹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 986-986, 2019. |
|---|
|
|
P0777-3-AM. 1 case that tapentadol showed an effect for neuropathic pain 糸永昇平1, 小山田純治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 987-987, 2019. |
|---|
|
|
P0779-3-AM. Somnolence is an example with difficulties for pain control by a cause 堀敦雄1, 橋本拓郎1, 藪田翼1, 西嶋長1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 987-987, 2019. |
|---|
|
|
P0781-3-AM. A clinical benefit of hydromorphone for the respiratory symptom relaxation of patients with cancer: We look at the single institution rear and examine a mark 守作美咲1, 伊藤佳織1, 覚前有希子1, 牧原俊康1, 山田成樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 988-988, 2019. |
|---|
|
|
P0783-3-AM. Examination for the use situation of the hydromorphone hydrochloride parenteral injection and the usefulness 井上敦介1, 岡本明子2, 田中奈桜1, 杉山喜久1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 988-988, 2019. |
|---|
|
|
P0787-3-AM. About effect by the difference in dose at the anticancer agent initial administration in elderly people 澤柳直樹1, 坂柳悦章1, 荒木寛也1, 西川隆一1, 藤井友和1, 辻博幸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 990-990, 2019. |
|---|
|
|
P0789-3-AM. Investigation, examination of the onset of clot situation in anticancer medicine-treated patients 田島実弥1, 三角紳博1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 990-990, 2019. |
|---|
|
|
P0791-3-AM. Investigation about the dysfunction thyroid in the treatment with immune checkpoint inhibitor 小泉綾乃1,2, 藤堂真紀1, 蝦名彩也佳1, 中島理津子2, 石川詩帆1, 眞壁秀樹1, 栗原進2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 991-991, 2019. |
|---|
|
|
P0793-3-AM. Use of Olaparib situation in our hospital and adverse event expression investigation 高原悠子1, 吉田弘樹1, 鈴木雅人1, 牧原明秀1, 三屋良太1, 木全司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 991-991, 2019. |
|---|
|
|
P0795-3-AM. We look at the ramucirumab for patients with unresectable progress recurrence stomach cancer and neutropenia in the paclitaxel combination therapy and the rear about the effect of treatment and examine a mark 桂川健司1, 荒川裕貴1, 高取裕司2, 後藤美穂1, 遠山幸男1, 久田達也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 992-992, 2019. |
|---|
|
|
P0797-3-AM. Investigation about the injection site reaction with the azacitidine hypodermic injection 藤田強記1, 高武嘉道2, 鶴崎泰史1, 花田聖典1, 中川義浩1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 992-992, 2019. |
|---|
|
|
P0799-3-AM. Fact-finding of the immune-mediated adverse event with the immune checkpoint inhibitor in our hospital 嶋戸理子1, 渡瀬美登里1, 柏田匡広1, 大石貴裕1, 池田浩和1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 993-993, 2019. |
|---|
|
|
P0801-3-AM. Search of the predictor of the severity of anemia by the Olaparib 久保果央莉1, 黒田真希1, 玉木慎也1, 田中寛之1, 橋下浩紀1, 遠藤雅之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 993-993, 2019. |
|---|
|
|
P0803-3-AM. The use of Pembroliazumab situation in our hospital: Change after unifying an effect, an adverse event, routine examination items 石崎文子1, 相原敏彦1, 増尾昌則1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 994-994, 2019. |
|---|
|
|
P0805-3-AM. Analysis according to the mutation in the gene of the side effect of EGFR-TKI given to patients with EGFR mutation in the gene-positive lung cancer 有山智博1, 滝澤苑美1, 菅野裕一朗2, 磯部和順3, 石井敏浩1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 994-994, 2019. |
|---|
|
|
P0807-3-AM. Example that developed acute renal failure in the nivolumab administration first time that became the problem submission of measures of irAE in our hospital 杉崎涼子1,2,3,4, 種市亜澄2, 綾部由紀乃1, 但木太3, 清家和裕4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 995-995, 2019. |
|---|
|
|
P0809-3-AM. The case that produced serious myelosuppression with Tegafur/uracil combination drug 宮田智陽1, 篠原佳祐1, 関口展貴1, 吉池麻衣1, 杉山昌秀1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 995-995, 2019. |
|---|
|
|
P0811-3-AM. Analysis of the occurrence of adverse event in the Lenvatinib and the factor 中島隆良1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 996-996, 2019. |
|---|
|
|
P0813-3-AM. Examination of the cancer chemotherapy enforcement situation within 30th before death in patients with our hospital cancer 鈴木拓也1, 佐藤真生1, 石栗由佳2, 伊藤勇樹2, 西崎初美2, 篠原一宏1, 磯部宏3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 996-996, 2019. |
|---|
|
|
P0815-3-AM. The qualitative test of urine protein in patients receiving neovascularisation inhibitor and study on correlation of the protein urine/creatinine ratio 吉村仁志1, 横山雄一1, 篠原義剛1, 植木哲也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 997-997, 2019. |
|---|
|
|
P0817-3-AM. Examination of safety and the effectiveness of the killer cells-related anticancer medicine after the checkpoint inhibitor administration of immunity 相川晴彦1, 酒井鉄平1, 嶋田烈1, 上野正夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 997-997, 2019. |
|---|
|
|
P0819-3-AM. It is the examination about the nourishment evaluation about the prognosis at the beginning of the cancer chemotherapy 田村悟1, 中村智1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 998-998, 2019. |
|---|
|
|
P0821-3-AM. It is use fact-finding of adjuvant chemotherapy S-1 after the pancreas malignant tumor technique 上ノ山和弥1, 三宅麻文1, 河原宏之1, 石川弘子1, 尾上雅英1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 998-998, 2019. |
|---|
|
|
P0823-3-AM. Pharmacist led antimicrobial proper use support and patients outcome in the small and medium size Hospital not to be able to conduct specialist in infection absence, an examination of bacteria outside order, Gram stain 西海一生1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 999-999, 2019. |
|---|
|
|
P0825-3-AM. The effect that AS activity of the carbapenem-based antimicrobial in our hospital gives for use of antimicrobial surveillance of the wide area antimicrobial 田井達也1, 山口佳津騎1, 元木貴大1, 田中裕章1, 横田恭子2, 加地雅人1, 小坂信二1, 芳地一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1000-1000, 2019. |
|---|
|
|
P0827-3-AM. Operational - utilizing the template function of efforts - electronic medical chart to use dose adequacy of the carbapenem-based antimicrobial which cooperated with a ward pharmacist 山口佳津騎1, 田井達也1, 元木貴大1, 田中裕章1, 横田恭子2, 加地雅人1, 小坂信二1, 芳地一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1000-1000, 2019. |
|---|
|
|
P0829-3-AM. Investigation about the blood culture effective time in the use of wide area antimicrobial to patients with cholangitis and cholecystitis 秋本純矢1, 片山頌子1, 内藤淳嗣1, 大貫麻友美1, 渡邉あゆみ1, 中川隼一1, 鈴木祥江1, 奥津利晃1, 蔭山博之1, 平島徹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1001-1001, 2019. |
|---|
|
|
P0831-3-AM. As compared with the SSI incidence of efforts and evaluation - JANIS to perioperative antimicrobial proper use, the standardization infection ratio ... 田中真衣1, 池崎友明1, 村上真樹1, 坂東翔1, 片山聡子1, 北島比香里1, 竹内都子1, 北澤英徳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1001-1001, 2019. |
|---|
|
|
P0833-3-AM. An example of the syphilis Jarisch-Herxheimer response found out by the syphilis development situation and screening of our hospital 小池彩子1, 花房伸幸1, 大道淳二1, 河村茉衣1, 廣田あゆ子1, 山口麻里2, 森英樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1002-1002, 2019. |
|---|
|
|
P0835-3-AM. Antimicrobial investigation used for empiric therapy for the aspiration pneumonia in the time when sulbactam/ampicillin was unusable 池田久雄1, 平田貴宏1, 神原弘和1, 森岡浩子1, 足立充司1, 野村浩英1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1002-1002, 2019. |
|---|
|
|
P0837-3-AM. Problem of the AST activity judging from the use of carbapenem-based antimicrobial actual situation 古庄弘和1, 陣上祥子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1003-1003, 2019. |
|---|
|
|
P0839-3-AM. The use situation investigation of the peramivir in our hospital 後藤健志1, 立花京香1, 鎌田理紗子1, 竹尾恵理子1, 酒井欣嗣2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1003-1003, 2019. |
|---|
|
|
P0841-3-AM. To urge proper quantum rectum prescription on thing - physician who start AST, and noticed; ... 福本康之1, 深井幸恵1, 長山晃1, 森下和美1, 川上典子1, 近藤昌子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1004-1004, 2019. |
|---|
|
|
P0843-3-AM. Examination of the effect that Antimicrobial Stewardship Team (AST) activity gives for the antimicrobial choice of the clinician 上田覚1,2, 高橋有1,2, 小林和博1,2, 羽田敦子2,3, 尾上雅英1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1004-1004, 2019. |
|---|
|
|
P0845-3-AM. Efforts (the second report) for the proper use of the carbapenem-based antimicrobial in our center 田村直斗1, 加賀谷明日美1, 木村正行1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1005-1005, 2019. |
|---|
|
|
P0847-3-AM. Use turn of eventss by the early intervention to the use of carbapenem-based antimicrobial patients 吉川雅之1,2, 岡本まとか1,2, 内藤結花2,3, 前田真之4, 石野敬子4, 宇賀神和久5, 長友安弘6, 詫間隆博6, 時松一成6, 二木芳人6, 佐々木忠徳2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1005-1005, 2019. |
|---|
|
|
P0849-3-AM. AST activity and use of oral antimicrobial situation ... in promotion and current situation - our hospital of the antimicrobial proper use support program 芝田和輝1,2, 深川裕1,2, 篠田健一1, 井上清子2, 谷内隆浩2, 清水哲朗2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1006-1006, 2019. |
|---|
|
|
P0851-3-AM. 3 cases of cholelithiasis that it was thought that it was caused by administration of ceftriaxone (CTRX) for children 國遠孝斗1, 鬼頭佳子1, 小嶋俊輝1, 柴田大地1, 鈴木秀明1, 滝本典夫1, 足立守1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1006-1006, 2019. |
|---|
|
|
P0853-3-AM. Effect on use of MEPM trend by our hospital AST activity 城間盛彦1, 玉城哲子1, 浦崎清美1, 武富美貴子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1007-1007, 2019. |
|---|
|
|
P0855-3-AM. Examination about the procalcitonin measurement in Sapporo Medical University Hospital 伊部裕太1, 藤居賢1, 石郷友之1, 北川学1, 木明智子1, 中田浩雅1, 宮本篤1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1008-1008, 2019. |
|---|
|
|
P0857-3-AM. About AST activity in our hospital and the evaluation 宮崎美穂1, 桑村恒夫1, 坪内和哉1, 芳賀由美1, 森本麗華1, 末松文博1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1009-1009, 2019. |
|---|
|
|
P0859-3-AM. Efforts of antimicrobial proper use support team (AST) and future problem 木村博史1,2, 矢野賢明1,2, 越智史博2, 末盛浩一郎2, 飛鷹範明1, 田中守1, 田中亮裕1, 田内久道2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1009-1009, 2019. |
|---|
|
|
P0861-3-AM. The use of antimicrobial situation investigation of the carbapenem-resistant Pseudomonas aeruginosa detection patients 田中慎1, 寺本晴美1, 坂口朋美1, 湧上大介1, 馬瀬久宜1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1010-1010, 2019. |
|---|
|
|
P0863-3-AM. The efforts of the working full time pharmacist in AST and the evaluation 塩田智子1,2,3, 谷長美菜子1,2, 段林正明1,2, 村瀬大翔1,2, 高橋一栄1,3, 足立幸人2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1010-1010, 2019. |
|---|
|
|
P0865-3-AM. Effect to give to consumption of the antimicrobial by the AS (Antimicrobial Stewardship) activity and the rate of detection of resistant Pseudomonas aeruginosa 小林和博1, 高橋有1, 上田覚1, 尾上雅英1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1011-1011, 2019. |
|---|
|
|
P0867-3-AM. About a clinical investigation of the ESBL-producing infection in our hospital 大橋武司1, 伊藤嘉英1, 古川大樹1, 林房江2, 寺島恭子2, 菱田志乃3, 中尾彰宏4, 長谷川雅哉1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1011-1011, 2019. |
|---|
|
|
P0869-3-AM. Change of the use of injection antimicrobial before and after the antimicrobial proper use support team intervention in our hospital 坂口晋哉1, 福石和久1, 川俣洋生1, 高島伸也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1012-1012, 2019. |
|---|
|
|
P0871-3-AM. About effect of the electronic medical chart introduction in the AST activity 菅原浩介1, 山崎翔太1, 鈴木英則1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1012-1012, 2019. |
|---|
|
|
P0873-3-AM. The result of the antimicrobial proper use support activity in our hospital and future problem 樋口聖人1,2, 山崎信也1, 横山茂1, 小林翔2, 小山洋子2, 小口弘子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1013-1013, 2019. |
|---|
|
|
P0875-3-AM. Examination of the usefulness of the antimicrobial proper use support round that a pharmacist played a key role 大戸祐治1,4,5, 新井祐司2,4, 岡田壮令3,4, 田中克巳1,5, 佐々木忠徳5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1013-1013, 2019. |
|---|
|
|
P0877-3-AM. Effect of the use of antimicrobial situation and the antimicrobial proper use support in the care mix hospital 阿部慎太郎1, 村田唯1, 吉田桃子1, 細田あゆみ1, 八重樫渉1, 中島稔也1, 大森英樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1014-1014, 2019. |
|---|
|
|
P0879-3-AM. Unionization ... of the patients support for the expansion of the efforts (2) - person in charge of prescription possibility pharmacist for the outside Parliament shift containing the antiHIV medicine in our hospital 井手頌美1, 保戸塚里美1, 南谷奈々1, 朽木絵美1, 黒木あかね1, 前波麻里子1, 井戸澤弘美1, 山形亜紀子1, 林みどり1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1015-1015, 2019. |
|---|
|
|
P0883-3-AM. Development of the nourishment assessment tool in the pediatric domain 佐々木真理1, 笠原沙耶香1, 今泉仁美1, 文靖子1, 山谷明正1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1017-1017, 2019. |
|---|
|
|
P0885-3-AM. One case that resulted in electrolyte abnormality by lack of administration fluid volume at the semisolid liquid food administration 菊井伴美1, 木村香織1, 矢野絢子1, 伊藤有佳子1, 池田桂子1, 行本拓史1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1018-1018, 2019. |
|---|
|
|
P0887-3-AM. Examination of a clue of the delirium patients early detection for clinical application and the drug that it is 松尾待池1, 山口泰弘1, 野田圭吾1, 千代延桜子1, 中村敦士1, 浦本邦弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1019-1019, 2019. |
|---|
|
|
P0889-3-AM. Efforts of the TDM enforcement of vancomycin in the mental hospital 北侑未1, 南憲一1, 竹中克之1, 下川千賀子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1020-1020, 2019. |
|---|
|
|
P0891-3-AM. 1 case that responded to citicoline for patients with Lewy bodies type dementia which a cognitive function decreased by general cold preparation internal use 中村隆志1, 遠藤唯1, 広瀬和之2, 鈴木伸男1, 只野文基3, 太田章三4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1020-1020, 2019. |
|---|
|
|
P0893-3-AM. 1 case that Yokukansan was effective for a sleeplessness symptom of the bipolar disorder 川中理香子1, 亀井進太郎1, 佐藤雄己1, 釘宮毅2, 河野健太郎2, 寺尾岳2, 伊東弘樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1021-1021, 2019. |
|---|
|
|
P0897-3-AM. Efforts for the current situation investigation and the revision of the drug nursing advisability confirmation system 高木祥子1, 木村純子1, 立松あき2, 山形ルミ子2, 久保田由美2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1022-1022, 2019. |
|---|
|
|
P0899-3-AM. The antiepileptic drug prescription situation investigation in the epilepsy merger pregnancy patients 安達るい1, 木村萌美1, 山田裕理1, 西田初博1, 真鍋健一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1023-1023, 2019. |
|---|
|
|
P0901-3-AM. Fact-finding of the consultation situation about the glaucoma therapeutic drug in the pregnancy and the medicine information center 宇野千晶1,2, 八鍬奈穂1,2, 肥沼幸2, 後藤美賀子2,3, 鈴木朋2,4, 伊藤直樹2,5, 山谷明正1,2, 村島温子2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1023-1023, 2019. |
|---|
|
|
P0903-3-AM. Examination about the pregnancy-induced hypertension syndrome 木藤一美1, 橋本隆信1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1024-1024, 2019. |
|---|
|
|
P0905-3-AM. Search of the clinical factor of the cancellation by the adverse event of the torr recity 中山佳代子1, 佐藤夕紀1, 中川俊作1, 吉田優子1, 傳田将也1, 木全柾典1, 今井哲司1, 米澤淳1, 中川貴之1, 稲垣暢也2, 原田範雄2, 小倉雅仁2, 松原和夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1025-1025, 2019. |
|---|
|
|
P0907-3-AM. Examination of the factor affecting the use of insulin fact-finding and the blood glucose level in patients with gestational diabetes 真井雄規1, 渡辺浩明1, 田村広志1, 和泉秀明1, 佐藤弘康1, 三本松泰孝1, 津田雅大1, 石田陽美1, 晴山知拓1, 村上冴美1, 喜多力1, 荒井理乃1, 久保萌美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1026-1026, 2019. |
|---|
|
|
P0909-3-AM. Investigation of the onset of digestive organ symptom situation and the administration continuance rate with the Dulaglutide administration 福森あや1, 梅崎裕子1, 中垣春美1, 三輪涼子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1026-1026, 2019. |
|---|
|
|
P0911-3-AM. Effect of the Empagliflozin administration on decreased renal function patients 中尾なつみ1, 石橋真実1, 大森麻江1, 宮下雄博2, 森英樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1027-1027, 2019. |
|---|
|
|
P0913-3-AM. Evaluation including chronic administration of the once a week DPP-4 inhibitor Omarigliptin 葛葉守1, 野口景子1, 久嶋真紀子1, 中野玲子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1027-1027, 2019. |
|---|
|
|
P0915-3-AM. Examination of the VCM administration for the extensive decreased renal function patients 増田章秀1, 大林巧志1, 宮川由季1, 山本美智1, 舩越真理1, 津田正博1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1028-1028, 2019. |
|---|
|
|
P0917-3-AM. The acute interstitial nephritis that developed after VCM internal use and TEIC infusional combination 小出哲朗1, 加藤公人1, 川崎好人1, 不破朱里1, 原美由紀1, 池口麻由子1, 今西義紀1, 橋本陽1, 森実優1, 出口賀奈子1, 有松冴1, 桐生浩子1, 西川嘉広1, 西田順二2, 伊藤久美子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1029-1029, 2019. |
|---|
|
|
P0919-3-AM. Change by the actual situation and the hospitalization of the medical therapy in patients with dementia 白根達彦1, 大野能之1, 服部ゆかり2, 小島太郎2, 小久江伸介1, 長瀬幸恵1, 秋下雅弘2, 鈴木洋史1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1030-1030, 2019. |
|---|
|
|
P0921-3-AM. One patient who tried medicine, the adjustment that it decreased by it from polypharmacy in our hospital during rehabilitation length of stay 佐藤智功1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1031-1031, 2019. |
|---|
|
|
P0923-3-AM. 2 cases that the restless symptom of patients with dementia improved by the intervention of the pharmacist 淺井俊平1, 佐藤裕介1, 池上信昭1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1031-1031, 2019. |
|---|
|
|
P0925-3-AM. ... which thinks about importance of the drug adjustment for approach ... delirium, the dementia behavior to the appropriate medical therapy promotion to elderly people 柴田博子1, 塩田恵1, 兵頭純子1, 足立洋子2, 田中宏和3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1032-1032, 2019. |
|---|
|
|
P0927-3-AM. Treatment by prescription suggestion participation in planning of the pharmacist in the dementia care team 森光輝1, 宇佐美英績1, 吉田光代2, 鈴木弥生2, 富田顕旨3, 吉村知哲1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1032-1032, 2019. |
|---|
|
|
P0929-3-AM. Investigation about the blood zinc levels in patients with hospitalization pressure sore and the nutritional status 小松裕里1, 八城瑞穂1, 相澤政明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1033-1033, 2019. |
|---|
|
|
P0931-3-AM. Effect, safe comparison of the antiarrhythmic drug after the catheter ablation enforcement in patients with sustained or chronic atrial fibrillation 古野喬志1, 小林賢滋1, 泉麻祐子1, 村井いずみ1, 渡邊さくら1, 仲村佳典2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1034-1034, 2019. |
|---|
|
|
P0933-3-AM. Examination about the stability of the pharmaceutics of the tacrolimus slow-release preparation which we made a de-capsule 金聖暎1, 牛尾聡一郎1, 岩田直大1, 江角悟1, 小川敦1, 村川公央1, 北村佳久1, 千堂年昭1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1035-1035, 2019. |
|---|
|
|
P0935-3-AM. Examination of the effect of the number of the drugs to give the warfarin control in patients with atrial fibrillation 高本光次郎1,2, 坂本淳一2, 近藤純1, 志方敏幸1, 伊藤都裕3, 辻野健2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1035-1035, 2019. |
|---|
|
|
P0937-3-AM. Correlative ... with examination - nutritional status of the factor to influence effect of treatment of the tolvaptan 大矢智則1,4, 前澤佳代子1,3,4, 柳谷将俊3, 松本玄紀3, 宮崎紗愛3, 平尾蘭3, 杉山奈津子1,3, 伊東岳3, 加藤芳徳3, 倉本敬二3, 柴信行2, 武田守彦2, 百瀬泰行1,3,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1036-1036, 2019. |
|---|
|
|
P0939-3-AM. 1 case that symptom improvement was seen in by an erythromycin IV infusion for acute dilatation of stomach after the catheter ablation for the atrial fibrillation 千葉貴志1, 上村新吾1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1036-1036, 2019. |
|---|
|
|
P0943-3-AM. Study on constipation improvement effect of herbal medicinal products, the Mashiningan 能登啓介1, 平田敦士1, 太田涼介1, 松岡寛1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1037-1037, 2019. |
|---|
|
|
P0945-3-AM. Association of anticholinergic/sedative agonistic medication and body function improvement in the cerebrovascular rehabilitation 小川ゆかり1, 二瓶太志2, 田中惣治2, 伊藤憲次3, 佐藤裕太3, 酒向正春4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1038-1038, 2019. |
|---|
|
|
P0947-3-AM. One case that a change was able to be given from a buprenorphine patch to tramadol/acetaminophen combination tablets well by a simple schedule 峰村智子1, 小島正照1, 荒木良介1, 山田英紀1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1038-1038, 2019. |
|---|
|
|
P0949-3-AM. About the total drug dose of hospitalizations and the drug of patients with heart failure in our hospital 川上莉奈1, 原田桂作1, 村本眞由美1, 原田敬2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1039-1039, 2019. |
|---|
|
|
P0953-3-AM. The current situation of the information sharing of the hospital pharmacist in regional alliances to see for Japanese Society of Hospital Pharmacists "current situation investigation of the hospital pharmacy gate" 津山昌子1, 園田純一郎2, 河内明夫3, 下堂薗権洋2, 池田龍二4, 武田泰生5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1041-1041, 2019. |
|---|
|
|
P0957-3-AM. Examination of the specialty of "the family pharmacist" to the patients who introduced the division formulations and the outcome 清水紗弥香1, 佐藤秀昭2, 神隆浩1, 野口宣之1, 小田慎3, 今井博久4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1042-1042, 2019. |
|---|
|
|
P0961-3-AM. About the inflection of the tracing report at the Lenvatinib administration 武田なつか1, 藤井裕史1, 三上忠司1, 柿原圭佑1, 白石亘1, 野田聖奈子1, 松崎雄1, 原田智子1, 篠崎千尋1, 松本美紅1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1044-1044, 2019. |
|---|
|
|
P0963-3-AM. Attitude survey for the relation with patients with familial tumor 直井美萌1, 武井大輔1, 山田遥子2, 大塚公庸1, 中村益美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1044-1044, 2019. |
|---|
|
|
P0965-3-AM. The multicenter inhalational instruction medicine medicine cooperation that we worked on together in the neighbor 関口愛1, 内田裕之1, 黒須智博3, 柳澤友希3, 小長井あゆみ1, 伊藤優4, 平居義裕2, 山下敦志3, 中田吉則1, 河井良智1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1045-1045, 2019. |
|---|
|
|
P0967-3-AM. It is instruction ... at the discharge using the information contact book between 1 efforts - institutions to the patients information sharing with the health insurance pharmacy pharmacist 高橋由紀奈1, 角田菜緒1, 宮崎美穂1, 秋吉尚雄1, 阿部名月1, 釘原瑶子1, 矢川結香1, 末松文博1, 星野正俊2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1045-1045, 2019. |
|---|
|
|
P0969-3-AM. The effect that the inhalational instruction in the health insurance pharmacy using the inhalational instruction contact vote gives for the clinical response of patients with asthma 浦上勇也1, 山地康文2, 篠永浩3, 山本和幸5, 飯原なおみ4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1046-1046, 2019. |
|---|
|
|
P0971-3-AM. Illness medicine cooperation (the second report) of the inhalation therapy in the childhood bronchial asthma 平岡陽一1, 中尾明日香1, 竹内亜紀3, 中村奈巳2, 橋本隆信1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1046-1046, 2019. |
|---|
|
|
P0973-3-AM. It is practiced the community medical care cooperation with the medication reporting book for medical care trusted by patients 市川康子1, 濱田政司1, 上淵未来1, 藤井浩毅1, 守田尚史1, 古田洋一1, 大岡建太郎1, 藤井憲一郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1047-1047, 2019. |
|---|
|
|
P0975-3-AM. Pharmaceutical management information sharing in Tennoji-ku 5 Hospital and the Tennoji-ku health insurance pharmacy 森田智子1,2, 小林政彦3, 村田久枝4, 石倉久美子5, 真常美紀6, 津田宜志7,8, 堀越博一7,9, 村西泰法10, 但馬重俊11 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1047-1047, 2019. |
|---|
|
|
P0977-3-AM. Public health effort in the Japan Team for Disaster Relief medical care team medical care support activity for the cyclone damage in Mozambique 加藤あゆみ1, 宮本純子2, 青木正志3, 南島友和4, 神谷睦美5, 笹村晶紀6, 中込悠7, 斉藤忠男8, 伊勢雄也1, 中森知毅9 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1048-1048, 2019. |
|---|
|
|
P0979-3-AM. Examination of the new notification of network operational training means based on results urgent at a disaster 西山裕也1, 宮脇舞1, 中谷孝史1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1049-1049, 2019. |
|---|
|
|
P0983-3-AM. Search of the sleeping drug which can become the risk factor of the fall fall 岩田華奈1, 細谷龍一郎1, 鈴木統子1, 宗山真梨奈1, 芝裕美子1, 日野斉一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1051-1051, 2019. |
|---|
|
|
P0985-3-AM. Practice of the medication management during the medication period based on the pharmaceutical products risk management plan in the health insurance pharmacy 加藤正久1, 石橋久1, 井手純司1, 吉川学1, 園田正信1, 山野徹2, 田中泰三2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1051-1051, 2019. |
|---|
|
|
P0987-3-AM. Examination about the effect that the insomnia therapeutic drug gives on fall, fall incident/accident 矢野裕士1, 鈴木優司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1052-1052, 2019. |
|---|
|
|
P0989-3-AM. Examination ... of efforts - S zopiclone of the prevention of fall, fall by the change of the sleep inducing drug 樺山智一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1052-1052, 2019. |
|---|
|
|
P0991-3-AM. Hold the medical safe joint workshop with efforts (the second report) - neighborhood drugstore of the medical security in the medicine medicine cooperation; and - 飯田真弓1, 熱海幸恵1, 今井祐貴子1, 大川藍子1, 李娜1, 大野翔子1, 添田真司1, 渡邊昌之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1053-1053, 2019. |
|---|
|
|
P0993-3-AM. Efforts to analysis and the prevention of development of the incident about the drug for the medical care in our hospital 中村るみ1, 長井砂都美2, 尾上博隆1, 田邉徹1, 永浜良章1, 平川尚宏1, 南裕司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1053-1053, 2019. |
|---|
|
|
P0995-3-AM. Inspection of the medical expenses reduction effect by the TABSORT introduction 島津智行1, 佐藤弘康1, 和泉瑞恵1, 猪谷朱理1, 河端真以1, 越野早紀1, 金住麻子1, 田中悠季1, 三本松泰孝1, 和泉秀明1, 田村広志1, 渡辺浩明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1054-1054, 2019. |
|---|
|
|
P0997-3-AM. Trial of the ward training corresponding to revision core Cali 田村賢士1, 池田由美1, 田沼弥紅1, 角田結菜1, 櫻井美月1, 加藤さやか1, 川端康太1, 中屋優香1, 栗原直貴1, 野崎千暁1, 本木龍二1, 前田力丸1, 山野邉裕子1, 澤田唯美1, 下村香菜1, 金子智一1, 寺田伊知郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1055-1055, 2019. |
|---|
|
|
P0999-3-AM. Change - from the post-questionary survey - long term business training start that we conducted for pharmacy school life about hospital business training of 8 years 大久保正人1,2, 増田和司1,2, 小林由佳1,2, 中村貴子1, 鈴木貴明1,2, 石井伊都子1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1056-1056, 2019. |
|---|
|
|
P1001-3-AM. The construction of the business training program for upbringing of the clinical pharmacist and the evaluation 鎌田里紗1, 柴谷直樹1,2, 冨田秀明1, 山下花南恵1, 松岡勇作1, 奥貞智1, 室井延之1,2, 橋田亨1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1056-1056, 2019. |
|---|
|
|
P1003-3-AM. The attempt of the joint Small discussion with a hospital, the health insurance pharmacy in the Yao district and the usefulness 大里恭章1, 小川充恵2, 横山靖法1, 奥村隆司3, 木村玲子4, 篠原裕子5, 中野道雄6, 山崎肇2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1057-1057, 2019. |
|---|
|
|
P1005-3-AM. Consciousness change for patients, the family of the student before the business training by the patients with hepatitis B lecture in the clinical propaedeutic in the Setsunan University pharmacy school 岩崎綾乃1, 曽根知道1, 奥村秀二2, 牧亮太3, 河野武幸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1058-1058, 2019. |
|---|
|
|
P1007-3-AM. The present situation of the medical therapy workshop by University of Shizuoka, hospital, the community pharmacy cooperation 辻大樹1,2, 平井啓太1,2, 伊藤邦彦1,2, 伊藤譲2, 井上達秀2, 河西きよみ2, 北村修2, 木村緑2, 黒川絢子2, 櫻井健史2, 並木徳之2, 平野桂子2, 松山耐至2, 森本達也2, 山田静雄2, 山田浩2, 賀川義之2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1059-1059, 2019. |
|---|
|
|
P1009-3-AM. Construction of the initial educational program in the Tomigusuku center Hospital drug department 三田井菜菜子1, 小杉卓大1, 國分千代1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1060-1060, 2019. |
|---|
|
|
P1011-3-AM. Construction of the new face educational program from a business training curriculum 日比陽子1,2, 長水正也1, 神田光司1, 久田宜範1, 諸角一成1, 佐藤由美子1, 中村康夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1061-1061, 2019. |
|---|
|
|
P1013-3-AM. The improvement of the TDM duties using the PDCA cycle and future problem 酌井敏伸1, 淵田悠一郎1, 服部公紀1, 野口祥紀1, 三宅知宏1, 谷村学1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1062-1062, 2019. |
|---|
|
|
P1015-3-AM. Research of recognition, the interest of the healthcare worker in aromatherapy 増渕龍一郎1,2, 秋元美咲1, 佐藤忠章2, 百瀬泰行1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1063-1063, 2019. |
|---|
|
|
P1017-3-AM. Support pharmacist system utilized the local pharmacist, cooperation with the community pharmacy 川那邊佐和子1, 原直己1, 徳丸歩子1, 小池玲江1, 石田明子1, 内田佳菜子1, 山下敦志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1063-1063, 2019. |
|---|
|
|
P1018-4-AM. Examination of the representation correction contents by the pharmacist for the duties burden reduction of the physician and efficiency 深井駿成1, 山本涼子1, 枦秀樹1, 太田哲徳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1064-1064, 2019. |
|---|
|
|
P1019-4-AM. Fact-finding of the pharmaceutical products inspection that the bar code certification of the PTP at fraction formulations is not possible 後藤千寿1, 池上遼1, 小椋奈央子1, 勝野隼人1, 高井綾乃1, 森田美穂1, 梅田道1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1065-1065, 2019. |
|---|
|
|
P1020-4-AM. Fact-finding of doubt inquiry in the convalescent rehabilitation hospital 島児佳孝1, 佐藤晴彦1, 津波古晶子1, 西村洸之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1065-1065, 2019. |
|---|
|
|
P1021-4-AM. Examination of the pharmaceutical intervention situation before and after the ward drug duties enforcement addition calculation start in Tagawa-Shiritsubyoin 竹村知1, 麻生忠弘1, 長原功騎1, 久保田政二郎1, 重藤直哉1, 大須賀保人1, 松元康人1, 徳丸一郎1, 西原豊1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1066-1066, 2019. |
|---|
|
|
P1022-4-AM. Efforts to the medical therapy adequacy for the decreased renal function patients 前田和彦1, 西原誠子1, 岡本知子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1066-1066, 2019. |
|---|
|
|
P1023-4-AM. Efforts to urgent intubation drug set withdrawal operation 嘉数亜紀1, 平田やよい1, 浜元善仁1, 翁長真一郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1067-1067, 2019. |
|---|
|
|
P1024-4-AM. Efforts of the medical cost cut to reuse the cancellation pharmaceutical products of the inpatient 水谷麻希子1, 木全司1, 吉田弘樹1, 木下元一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1068-1068, 2019. |
|---|
|
|
P1025-4-AM. Evaluation of the usefulness of the cubic sushi stem through the chronic administration experience of the blood clotting factor preparation 岡村央1, 小池博文1, 古川大輔1, 佐橋幸子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1068-1068, 2019. |
|---|
|
|
P1026-4-AM. Examination about the effectiveness of the cubic sushi stem in the pharmaceutical products inventory control 中尾倫子1, 中川雅史1, 井出朋子1, 吉岡厚子1, 宮内実奈絵1, 狩谷佳寛1, 樫葉利人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1069-1069, 2019. |
|---|
|
|
P1027-4-AM. The development of the drug inventory control system using the machine learning and effective evaluation 福原直樹1, 齋藤智之1, 藤林和俊2, 高橋明大3, 大塩悠貴4, 橋爪康知3, 内藤俊夫2, 佐藤邦義1, 荒川隆太郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1069-1069, 2019. |
|---|
|
|
P1028-4-AM. Efficacy evaluation of the 0.2% minocycline drug for external use for the epidermis, the soft tissue MRSA infection 田村和彦1, 中村槙一郎1, 財津孝希1, 瀧内瑛輔1, 長澤欣弘1, 羽生智宏1, 尾形美絵1, 新関みどり1, 近藤和宏1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1070-1070, 2019. |
|---|
|
|
P1029-4-AM. Preparation of the methylcellulose solution which assumed acetaminophen preparation of various kinds of dosage form a principal ingredient 下山哲哉1, 上嶋麻葵1, 赤石結菜1, 伊藤邦彦1, 小林道也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1071-1071, 2019. |
|---|
|
|
P1030-4-AM. Efforts about the review of the regime of the hospital preparation 坂田光平1, 花田聖典1, 鶴崎泰史1, 中川義浩1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1071-1071, 2019. |
|---|
|
|
P1031-4-AM. It is the real condition investigation of ward drug duties contents in the present just after ward drug duties start 早舩美保子1, 島崎良知1, 瀧川正紀1, 衣笠芳1, 横井妙子1, 森淑子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1072-1072, 2019. |
|---|
|
|
P1032-4-AM. Prescription support of the pharmacist in the urologic ward 高橋恭平1, 竹田瞳1, 大山展弘1, 森川記道1, 西倉教子1, 原田靖子1, 西原昌幸2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1073-1073, 2019. |
|---|
|
|
P1033-4-AM. Introduction of the antithrombotic drug resumption protocol after the surgery 立石昂偲1, 山崎伯都1, 柏木麻紀1, 井無田優1, 吉原郁夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1073-1073, 2019. |
|---|
|
|
P1034-4-AM. Can the reporting that a pharmacist conducts by ward duties contribute to the medical security of other types of job? 瀬上直輝1, 石光一幾1, 此原美佐江2, 佐藤真也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1074-1074, 2019. |
|---|
|
|
P1035-4-AM. Introduction effect of the periodical prescription input support task by the pharmacist 鈴木寿樹1, 黒澤桂子1, 白木美香1, 田中雅樹1, 赤井文香1, 横枕史1, 赤坂和俊1, 眞野成康1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1074-1074, 2019. |
|---|
|
|
P1036-4-AM. About the efforts of the drug control instruction duties for patients who received ERCP (endoscopic retrograde cholangiopancreatography) 出口華子1, 渡邊裕子1, 益田聖1, 瀬戸洋行1, 阿部元昭1, 鈴木由佳1, 田中富美1, 出口佳奈美1, 山田佳代1, 佐野麻璃奈1, 高田恭子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1075-1075, 2019. |
|---|
|
|
P1037-4-AM. The effect that deletion of the internal use antimicrobial in the cataract surgery clinical path gives 加藤結1, 荒川泰代1, 高橋弘泰1, 大谷寧次郎1, 畔柳敏弥1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1075-1075, 2019. |
|---|
|
|
P1038-4-AM. Outcome evaluation of the pharmacist ward permanent residence in the convalescent rehabilitation ward 阪東芳則1, 武田元樹2, 稲村千尋2, 布施順子2, 菊池健2, 相馬貴史2, 宮田列寧1, 鶴山辰2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1076-1076, 2019. |
|---|
|
|
P1039-4-AM. Effect of the exclusive drug reporting book making in the clinical path 三浦幸太1, 北條文啓1, 岩上泰崇1, 猪狩政則1, 景山亮平1, 宗田一記1, 中野洸大1, 鈴木実1, 松本和1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1076-1076, 2019. |
|---|
|
|
P1040-4-AM. After the operation in the cardiovascular surgery ward one package for improvement in adherence of patients about the usefulness of formulations 波多江沙織1, 石躍華奈1, 友納保幸1, 前田朱香1, 富田敏章1, 入江利行1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1077-1077, 2019. |
|---|
|
|
P1041-4-AM. Pharmacist, oral medicine management method decision standard unification and fact-finding by the nurse collaboration 守谷有美1, 河村聡志1, 橋本晴香1, 薬師寺寿世1, 平松眞澄2, 森一生1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1077-1077, 2019. |
|---|
|
|
P1042-4-AM. Result of PBPM of the edoxaban by the pharmacist for the purpose of the VTE generating prevention in patients who underwent lower limbs orthopedics surgery 松木克仁1, 平野淳1, 松岡梨恵1, 藤巻伊織1, 相澤佑佳1, 林誠1, 竹内正紀1, 金子敦2, 中井正彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1078-1078, 2019. |
|---|
|
|
P1043-4-AM. Relations with the appropriateness doses by a side effect (bleeding, thrombogenesis) and the renal function evaluation of the antithrombotic drugs (edoxaban) after the lower limbs surgery 徳永晃1,2, 貞嶋栄司2, 前隆男3, 松永尚1, 佐野雅彦1, 田中康弘1, 植松大智1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1078-1078, 2019. |
|---|
|
|
P1044-4-AM. Example that the suggestion by the ward pharmacist who started from the bringing medicine's confirmation led to treatment decision 寺島純一1, 谷口俊洋1, 中村直人1, 山田哲也1, 長内宏之2, 味岡正純3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1079-1079, 2019. |
|---|
|
|
P1045-4-AM. Investigation of the effect that intervened about instructions as PBPM at sleeplessness in consideration for a fall, the delirium risk of elderly people, unrest time 井上卓治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1079-1079, 2019. |
|---|
|
|
P1046-4-AM. Revision of the pain-killer usage by the pharmacist intervention and effect to early ambulation 森谷康志1, 本田徹郎2, 亀井健人1, 赤木晋介1, 高柳和伸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1080-1080, 2019. |
|---|
|
|
P1047-4-AM. Efforts to improvement in quality of ward duties by the joint ownership of the clinical record items mentioned 中村久美1, 伊藤隆哉1, 鬼窪利英1, 三浦篤史1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1080-1080, 2019. |
|---|
|
|
P1048-4-AM. Establishment and content analysis of the continuous extracting method of the pharmaceutical intervention using DWH 倉橋基尚1, 松本涼1, 是枝哲平1, 土谷裕貴1, 羽鹿成人1, 浦川美採1, 小松万恵1, 菰池春奈1, 山岡真由美1, 柳川智子1, 卜部和美1, 三井秀紀1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1081-1081, 2019. |
|---|
|
|
P1049-4-AM. Efforts for the proper use of the dry concentration person prothrombin complex 坂口結斗1, 友利隆一郎2, 又吉美重4, 長嶺あずさ3, 喜多洋嗣1, 喜多幸子1, 村雲智久1, 北池祥子1, 有銘千賀子1, 生野夢子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1082-1082, 2019. |
|---|
|
|
P1050-4-AM. Making and introduction of the clinical ladder about operating room pharmacist duties 亀田皓介1, 石関華子1, 野本祐介1, 増田大輔1, 上野正夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1083-1083, 2019. |
|---|
|
|
P1051-4-AM. Evaluation by the cardiopulmonary resuscitation participation of the pharmacist in the critical care center and the questionary survey for a physician, the nurse 遠藤啓之1, 野上裕介1, 坂本亮1, 大塚潔1, 長谷部忠史1, 柏浦正広2, 海老原貴之2, 守谷俊2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1083-1083, 2019. |
|---|
|
|
P1052-4-AM. The field where it is useful that a pharmacist is concerned in an intensive care domain (ICU/HCU) to think about from the intervention example that led to change of prescription 長谷川裕矢1, 黒川恵理1, 黒宮浩嗣1, 竹村恵里奈1, 松本利恵1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1084-1084, 2019. |
|---|
|
|
P1053-4-AM. Patients death ratio investigation in the pharmaceutical intervention of the intensive care unit permanent residence pharmacist 並木孝哉1, 鈴木俊一郎1, 山本涼子1, 枦秀樹1, 太田哲徳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1084-1084, 2019. |
|---|
|
|
P1054-4-AM. Pharmaceutical intervention effect of the pharmacist to all patients team rounds in the ICU 種田靖久1, 松岡知子1, 堀田奈央1, 川地志緒里1, 宇佐美英績1, 吉村知哲1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1085-1085, 2019. |
|---|
|
|
P1055-4-AM. Is going to perform the operations that included the on admission support addition pertinence patients in; efforts of the in front of pharmacist technique outpatient department for the patients 澤村愼吾1, 安村吉彦1, 本藤真太郎1, 長島真洋1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1086-1086, 2019. |
|---|
|
|
P1056-4-AM. Efforts of the pharmacist in the hospitalization and release support center 藤井達郎1, 佐々木静香1, 下口谷貴1, 山川拓1, 川本康太郎1, 野田聖奈子1,2, 森本雅子1, 門村将太1, 井藤達也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1087-1087, 2019. |
|---|
|
|
P1057-4-AM. Development of the confidence measure of the medication counseling for patients with depression of the pharmacist and inspection of the validity 庄司雅紀1, 藤原篤子2, 恩田光子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1087-1087, 2019. |
|---|
|
|
P1058-4-AM. Intervention and role of the pharmacist to medicine management targeted for perioperative cancellation prepared one package in "medicine confirmation outpatient department" 川島佳恵1, 吉川里香1, 石本学司1, 奥野昌宏1, 田中詳二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1088-1088, 2019. |
|---|
|
|
P1059-4-AM. The establishment of the perioperative pharmacist outpatient in the middle scale hospital and the efforts 赤星璃1, 栗崎貴啓1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1088-1088, 2019. |
|---|
|
|
P1060-4-AM. Relation of the pharmacist to treatment with growth hormone in our hospital 梅村実希1, 岩田怜奈1, 脇田恵理1, 伊藤洋貴1, 佐藤賛冶1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1089-1089, 2019. |
|---|
|
|
P1061-4-AM. About the reconsideration of the drug release pattern from a dry powder inhaler and inhalational instruction 近藤哲理1, 増尾昌則1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1089-1089, 2019. |
|---|
|
|
P1062-4-AM. Pharmacist permanent residence system ... in importance - admitting department of patients intervening before a pharmacist is hospitalized 徳山洋子1, 西本好児1, 松本圭司1, 丸山美香2, 清水義博3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1090-1090, 2019. |
|---|
|
|
P1063-4-AM. Formula remaking ... of rebuilding - convalescent rehabilitation hospital of the RAS inhibitor in TMG formula reexamination WG 永瀬真理子1, 金井紀仁2, 佐藤光3, 宮崎美子4,5, 齋藤俊夫5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1091-1091, 2019. |
|---|
|
|
P1064-4-AM. Role of the pharmacist in dyschezia measures team "team Rodin" 堀川康裕1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1092-1092, 2019. |
|---|
|
|
P1065-4-AM. It is development ... of the stopping medicine management Web application during construction - preoperation of the stopping medicine management database during preoperation 江本晶子1, 木村早希子1,2, 吉村麻里子2, 有水弘太3, 末岡榮三朗4, 成澤寛1,5, 木村晋也2,6 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1093-1093, 2019. |
|---|
|
|
P1066-4-AM. The current situation of the in-hospital side effect report collection system and the future prospects 齋藤雅俊1, 左右田和枝1, 松原肇1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1094-1094, 2019. |
|---|
|
|
P1067-4-AM. The mention situation investigation of the clinical study information in the pharmaceutical products interview form 冨田隆志1, 畝井浩子1, 松尾裕彰1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1094-1094, 2019. |
|---|
|
|
P1068-4-AM. Investigation of the discontinuation situation by the confirmation of a use drug before examination of the pancreatic outer secretion test bentiromide (PFD) study vote making 寺口敦1, 関口陽子1, 貝瀬眞由美1, 須田剛士2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1095-1095, 2019. |
|---|
|
|
P1069-4-AM. The cognitive function in local elderly people and the relations with the anticholinergic agent: The making of the evaluation standard based on the Nakajimacho study - package insert information and the evaluation 橋本恵幸1, 吉川由華1, 丸一泰雅1, 石田奈津子1, 菅幸生1, 松下良1, 石崎純子1, 篠原もえ子2, 駒井清暢3, 山田正仁2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1095-1095, 2019. |
|---|
|
|
P1070-4-AM. Consideration - judging from the occupation years of experience of evaluation - nurse for the simple suspension method introduction in the acute phase hospital 伊賀正典1, 齋藤彩子1, 高野温志1, 町田充1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1096-1096, 2019. |
|---|
|
|
P1071-4-AM. eGFR change ten years after the staff of a school clinical survey 守内匡1, 松井ひろみ1, 守内典子1, 西恵子1, 木南今日子1, 冨岡未悠1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1097-1097, 2019. |
|---|
|
|
P1072-4-AM. Investigation about the effect to give discontinuation and blood pressure of ACE inhibitor/ARB in the perioperative period 中村水紀1, 猪田宏美2, 錦織淳美2, 井川祐輔2, 北村佳久1,2, 千堂年昭2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1097-1097, 2019. |
|---|
|
|
P1073-4-AM. Questionary survey about the polypharmacy to a medical practitioner cooperating with our hospital 鷲尾浩司1, 太田しおぢ1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1098-1098, 2019. |
|---|
|
|
P1074-4-AM. Fact-finding of the Chinese medicine prescription in our hospital 坂本亮1, 大塚潔1, 遠藤啓之1, 長谷部忠史1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1098-1098, 2019. |
|---|
|
|
P1075-4-AM. Recognition, understanding degree investigation of the term which a pharmacist uses for patients in clinical settings 兼古絵里菜1, 市原航1, 福井宗憲1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1099-1099, 2019. |
|---|
|
|
P1076-4-AM. A successive change of the number of oral third generation cephem system antimicrobial prescription: Case series study 金沢有希1,2, 山越萌1, 藤原帆波1, 藤井哲英1, 北川誠子1, 勝村登美子1, 小林美代子1, 庵谷千恵子2, 桑原篤憲2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1099-1099, 2019. |
|---|
|
|
P1077-4-AM. The use situation investigation of the constipation therapeutic drug 清水誉志1, 福島将友1, 前田朱香1, 北島聖也1, 友納保幸1, 木原慶子1, 入江利行1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1100-1100, 2019. |
|---|
|
|
P1078-4-AM. Investigation of the medication situation of our hospital Parkinson's disease patients judging from on admission bringing medicine's confirmation 北浦円1,2, 佐々木萌1, 大竹将司1, 齊藤勇二2, 渡辺章功1, 高崎雅彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1100-1100, 2019. |
|---|
|
|
P1079-4-AM. The investigation about the clinical studies of the pharmacist working in local base Hospital: Questionary survey 小野塚和人1, 吉廣尚大1, 只佐正嗣2, 堀川俊二3, 橋本佳浩1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1101-1101, 2019. |
|---|
|
|
P1080-4-AM. The use situation investigation of the antiemetic for the vomiting post-operative prevention in our hospital pediatric surgery 楠川侑吾1, 多留木崇志1, 村田龍宣1, 村岡淳二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1101-1101, 2019. |
|---|
|
|
P1082-4-AM. Examination of the drug which you should watch closely on delirium patients early detection 野田圭吾1, 山口泰弘1, 松尾待池1, 千代延桜子1, 中村敦士1, 浦本邦弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1103-1103, 2019. |
|---|
|
|
P1083-4-AM. Cost effect analysis of the oral triptan preparation in migraine headache treatment 中川直人1, 今野瑞葉1, 井上忠夫1, Leanne Lai2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1103-1103, 2019. |
|---|
|
|
P1086-4-AM. Fact-finding of the Residual medicine which we saw from on admission bringing medicine and search of the development factor 高橋美咲1, 押尾洋佑2, 有山智博1, 田中博之1, 木下雅子1, 藤枝正輝1, 高橋佐和士2, 石井敏浩1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1105-1105, 2019. |
|---|
|
|
P1087-4-AM. 1 case that a convulsive seizure was thought to be caused by the cefmetazole administration in patients on dialysis 吉田美奈1, 井上敬之1, 田中早紀1, 中城宏子1, 栗田聡2, 国府孝敏1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1106-1106, 2019. |
|---|
|
|
P1088-4-AM. Examination of the onset of metronidazole-induced peripheral neuropathy risk in the inflammatory bowel disease 高塚博一1, 平山友里1, 内田雅士1, 山崎伸吾1, 鈴木貴明1, 石井伊都子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1107-1107, 2019. |
|---|
|
|
P1089-4-AM. Example that we were able to guess about the cause of the side effect by the measurement of cystatin C 片桐光1, 内山真理子1, 堀寧1, 山田徹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1107-1107, 2019. |
|---|
|
|
P1090-4-AM. An example of the children whom an orbital pseudotumor developed in as an adverse event of the leuprorelin acetate 眞栄城安貴1, 金城雄一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1108-1108, 2019. |
|---|
|
|
P1091-4-AM. Efforts to proper use of the magnesium oxide preparation for the elderly people with the decreased renal function 井桁和佳菜1, 鶴崎大2, 森川莉沙2, 澤村典子2, 深滝利也2, 荒川基記1, 日高慎二1, 菊池憲和2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1108-1108, 2019. |
|---|
|
|
P1092-4-AM. Examination about the effect to give to the milk sugar intolerance patients of the milk sugar included in the preparation 草村把奈1, 丹沢彩乃2, 高田裕奈1, 安武夫1, 石川洋一1, 深水啓朗1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1109-1109, 2019. |
|---|
|
|
P1093-4-AM. Search of the factor about the onset of low blood pressure during the operation in the perioperative period 芦田郁実1, 田中玖実1, 柏宗伸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1109-1109, 2019. |
|---|
|
|
P1094-4-AM. Examination and the system construction of the Relief System for Sufferers from Adverse Drug Reactions application support procedure 杉尾由希子1, 津曲恭一1, 北島久義1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1110-1110, 2019. |
|---|
|
|
P1095-4-AM. 1 case that operated on the patients with the anaphylactic history for an anesthetic 大道淳二1, 笠原なつみ1, 奈良葵1, 石橋真実1, 小林浩之2, 山口麻里3, 妹尾明美3, 森山重治4, 森英樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1110-1110, 2019. |
|---|
|
|
P1097-4-AM. One case that was restored without introducing adrenocortical steroid therapy into fallen leaves form pemphigus 小園亜希1, 島田秀一3, 中島聡子2, 佐保正直1, 野上玲子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1111-1111, 2019. |
|---|
|
|
P1098-4-AM. Effect on adverse event accompanied with the quantification for the fixation of the nivolumab in our hospital 光家勉1, 上田豊実1, 吉田友紀2, 塘賢二郎3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1112-1112, 2019. |
|---|
|
|
P1099-4-AM. Example that disturbance of consciousness by the ceftriaxone was suspected during the infective endocarditis (IE) treatment of the decreased renal function patients and improved by cancellation 高橋淳一1,2, 田中克幸3, 羽田彩萌1, 田邊恭彦5, 田邊嘉也2,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1112-1112, 2019. |
|---|
|
|
P1100-4-AM. About the administration situation and the onset of side effect situation of the levetiracetam in the Kasugai Municipal Hospital 大岩拓馬1, 竹内健吾1, 加藤麻理乃1, 水草博希1, 浅野嘉之1, 伊東和真1, 服部芳明1, 前田剛司1, 坂田洋2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1113-1113, 2019. |
|---|
|
|
P1101-4-AM. One case with suspected antiHMGCR antibody-positive necrotic line symptom with the statin administration 山本飛翔1, 櫻井恵一2, 前田幹広1, 有木宏宗1, 坂上逸孝1, 鈴木豪2, 川畑仁人2, 田中恒明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1113-1113, 2019. |
|---|
|
|
P1102-4-AM. Investigation about the association of warfarin and serum albumin and the nutritional status 森下怜美1, 武田元樹2, 渡邊英樹2, 菊池健2, 川瀬亜希子2, 佐々木啓2, 郡淳二3, 鶴山辰2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1114-1114, 2019. |
|---|
|
|
P1103-4-AM. Effect on blood pressure by the drug interaction of rifampicin and amlodipine 佐藤誠一1, 中島勝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1115-1115, 2019. |
|---|
|
|
P1104-4-AM. Effect (the fourth report) that combination of tramadol in the warfarin remedy patients gives to INR 花井誠1, 細野智美1, 青沼和隆2, 住田孝之2, 平松祐司2, 山崎正志2, 関堂充2, 神林泰行1, 本間真人1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1115-1115, 2019. |
|---|
|
|
P1105-4-AM. Examination IV isosorbide dinitrate of the interaction with the commercial denture adhesive and ethical drug, consideration in the mechanism of the interaction in the nitroglycerine 梅村雅之1, 伊藤友一1, 松葉圭祐1, 池上雄貴1, 吉田彩乃2, 柳原保3, 脇屋義文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1116-1116, 2019. |
|---|
|
|
P1106-4-AM. The present situation investigation about the tazobactam piperacillin combination during warfarin administration 土井啓員1, 井澤香1, 増田雅行1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1116-1116, 2019. |
|---|
|
|
P1107-4-AM. The current situation of the vancomycin loading dose to elderly people 橋本浩之1, 行縄文彦1, 小野村直紀1, 田邉智行1, 金杉真也1, 佐藤大希1, 今井慎也1, 西哲弘1, 江口善美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1117-1117, 2019. |
|---|
|
|
P1108-4-AM. Comparison between LC-MS/MS and sirolimus levels out of the whole blood with ACMIA in patients with lymph vessels myoma symptom 重田健介1, 菊地正史1,2, 大石久3, 佐渡哲3, 松田安史3, 野田雅史3, 岡田克典3, 眞野成康1,2, 山口浩明1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1118-1118, 2019. |
|---|
|
|
P1109-4-AM. Development and evaluation of the analytical procedure using the antiepileptic drug simultaneous analysis kit for the LC-MS/MS 池村真弓1, 石橋美紀1, 池村健治1, 岩本卓也1, 奥田真弘2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1118-1118, 2019. |
|---|
|
|
P1110-4-AM. One case that was given medical treatment by the linezolid based on consideration from literatures for a pregnant woman of the bacterial meningitis with suspected the Augmented renal clearance phenomenon 田中遼大1, 岩男元志1, 佐藤雄己1, 伊東弘樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1119-1119, 2019. |
|---|
|
|
P1111-4-AM. Examination of optimum doses based on the blood level measurement of the amikacin in respiratory illness 神戸宏憲1, 石井英俊1, 須山由佳子1, 杉山恭平1, 伊藤健太2, 袴田康弘3, 木村緑1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1119-1119, 2019. |
|---|
|
|
P1112-4-AM. Population pharmacokinetics analysis of the daptomycin in patients with renal failure and examination of the optimal administration method 榎木裕紀1, 山本理紗子1, 佐村優1,2, 伊藤勇人1, 高田啓介2, 倉田武徳2, 南雲史雄2, 内田仁樹2, 田口和明1, 関根寿一2, 松元一明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1120-1120, 2019. |
|---|
|
|
P1113-4-AM. Relation of the immune checkpoint inhibitor side effect measures team "KIT" setup and pharmacist in our hospital 古田祐美子1, 塩飽英二1, 藤村晋也2, 森井淳子2, 山口大介3, 西村尚志4, 土井章一3,5, 土手賢史1, 小林由佳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1121-1121, 2019. |
|---|
|
|
P1114-4-AM. The role of the multi-type of job cooperation and the pharmacist in the cancer genomic medicine and problem 平出耕石1,3,4, 宮本義浩1,3, 加藤武司1, 石原哲2,3,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1122-1122, 2019. |
|---|
|
|
P1115-4-AM. With mild measures of the going to hospital treatment room with consecutive holidays long-term in 2019, as a result 六波羅孝1,4, 工藤亜紀子2,4, 白鳥伊久代2,4, 高砂敬一郎3,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1122-1122, 2019. |
|---|
|
|
P1116-4-AM. The enforcement situation of the foreign nourishment diet advice which a foreign chemotherapy room asks for and the effect 野口善久1,2, 高橋真純1,2, 小池あい子1,3, 坂元有紀1,3, 川尻成美1,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1123-1123, 2019. |
|---|
|
|
P1117-4-AM. Fact-finding of the occupational exposure measures in the anticancer agent preparation duties in 29, Rousaibyoin institutions of the whole country 柳澤友希1, 黒須智博1, 山下敦志1, 夏目義明2, 清野敏一3, 伊佐間和郎3, 西村哲治3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1124-1124, 2019. |
|---|
|
|
P1118-4-AM. Fact-finding (additional investigation) of the anticancer agent exposure 宮川貴行1, 古谷幸子1, 井筒理子1, 梶井孝洋1, 水口敦子1, 西澤修一1, 大倉裕祐1, 小嶋麻衣子2, 山本伸弥2, 近森研一3, 武良卓哉4, 松久哲章4, 中川麻子5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1125-1125, 2019. |
|---|
|
|
P1119-4-AM. Role of the pharmacist in occupational exposure to oral anticancer medicine measures 福永千佳子1, 河野えみ子1, 鍜治谷玲子1, 三箇山宏樹1, 馬場綾2, 關壽人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1125-1125, 2019. |
|---|
|
|
P1120-4-AM. Examination about the change of the quantity of duties and anticancer medicine exposure to anticancer medicine preparation measures of the pharmacist before and after the anticancer medicine preparation support equipment DARWIN-Chemo operation 入佐俊弘1, 秦晃二郎1, 辻敏和1, 渡邊裕之1, 江頭伸昭1, 増田智先1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1126-1126, 2019. |
|---|
|
|
P1121-4-AM. Exposure measures in the safety cabinet by three kinds of cleaning methods 土橋俊文1, 今井陽介1, 石川星1, 箱島基貴1, 服部多映子1, 松林和幸1, 佐伯潤1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1126-1126, 2019. |
|---|
|
|
P1122-4-AM. The effect that discontinuation, weight loss of TAS102 in elderly people and overall status delinquent patients gives an effect 吉池麻衣1, 杉山昌秀1, 篠原佳祐1, 関口展貴1, 宮田智陽1, 渡邉将隆1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1127-1127, 2019. |
|---|
|
|
P1123-4-AM. Making and evaluation of the record template for standardization, the efficiency of cancer chemotherapy medication counseling duties 堀智貴1, 中川智章1, 武知理菜子1, 三宅純子1, 樽井静香1, 吉岡奈津恵1, 福森洋之1, 生島繁樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1128-1128, 2019. |
|---|
|
|
P1124-4-AM. The questionary survey for the health insurance pharmacy pharmacist in the cancer medical therapy and examination of the usefulness of the anticancer medicine instruction contents information report 今川未紀1, 有田仁紀1, 菅井瞳1, 川上達也1, 渡辺和美1, 坂本真紀1, 西澤健司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1128-1128, 2019. |
|---|
|
|
P1125-4-AM. Correspondence ... based on efforts - PBPM of the medicine medicine cooperation in the anticancer agent prescription 秋葉由華1, 長谷川晃司2, 武田智子2, 春名康裕2, 中村暢彦3, 佐野由美子4, 佐村頼寿5, 蓑輪圭一郎6, 小林篤史7 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1129-1129, 2019. |
|---|
|
|
P1126-4-AM. Examination of 5 mg of olanzapine to three-drug antiemesis therapy (dex 1) additional effect on CINV in the AC regimen of the breast cancer 末廣真理維1, 計良貴之1, 竹端琴美1, 池川貴和子1, 湊川紘子1, 田中恒明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1130-1130, 2019. |
|---|
|
|
P1127-4-AM. Fact-finding of retching, vomiting in the Carboplatin (AUC >= 4)-containing regimen 富士芳美1, 植田有希2, 和田宜久1, 友井理恵子1, 木村貴1, 木澤成美1, 金銅葉子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1131-1131, 2019. |
|---|
|
|
P1128-4-AM. Examination of the antiemesis effect of palonosetron on Carboplatin 植木大介1, 青野智恵美2, 稲生和彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1131-1131, 2019. |
|---|
|
|
P1129-4-AM. Usefulness investigation of the Goshajinkigan for peripheral neuropathy in patients with Weekly PTX + Bev application breast cancer 東野友貴1, 岩西雄大1, 立川奈保美1, 足立茜子1, 津幡あつ実1, 木村美甫1, 金澤真里1, 寺嶋香奈1, 迫田由佳梨1, 角川幸男1, 高木麻里1, 吉田智江1, 金銅葉子2, 藤田敬子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1132-1132, 2019. |
|---|
|
|
P1130-4-AM. 1 case of the gastric cancer which developed nephrotic syndrome by Ramcirumab 藤林遼1, 鈴木直哉1, 朝倉幹己1, 藤田果那1, 木下愛1, 庄崎沙耶1, 田中耕太1, 山本翔太1, 前川英輝1, 山田将悟1, 菊地義明1, 高橋誠1, 青田忠博1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1133-1133, 2019. |
|---|
|
|
P1131-4-AM. Effect of the side effect on treatment continuation of the IRd therapy in the multiple myeloma 森秋子1, 石田耕太2, 加藤淳平2, 立田真也2, 廣澤伊織1, 渡部一宏1, 廣原正宜1, 鈴木憲史3, 細谷治2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1133-1133, 2019. |
|---|
|
|
P1132-4-AM. Effect of the infusion increase in quantity on vascular pain at the oxaliplatin periphery intravenous administration 伊藤実里1, 阪田安彦1, 妹尾啓司1, 岡崎夏実1, 水上皓喜1, 吉川明良1, 宮森伸一1, 開浩一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1134-1134, 2019. |
|---|
|
|
P1133-4-AM. Making ... of education and duties support ... "tool that a side effect is removed" to a pharmacist engaged in cancer chemotherapy 高木麻衣1,2, 伊藤文香2, 鵜飼麻由2, 神谷幸江2, 切畑麻那2, 嶋洋将2, 鈴木大介2, 玉置彩奈2, 冨田庸介2, 川合甲祐2, 山田清文1, 板倉由縁2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1134-1134, 2019. |
|---|
|
|
P1134-4-AM. Elucidation of the onset of phlebitis mechanism by the interaction of Fosaprepitant and the epirubicin 山崎美保1, 和泉寿紀1, 水口真利江1, 前田頼伸2, 小田啓祐3, 森信博3, 村上照夫3, 面田恵1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1135-1135, 2019. |
|---|
|
|
P1135-4-AM. Examination of the expression situation and the risk factor of the neutropenia in the lung cancer nab-paclitaxel + Carboplatin therapy 米山大志1, 岡本美穂2, 佐々木寿子1, 菅原充広1, 佐々木治一郎3, 猶木克彦4, 厚田幸一郎1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1135-1135, 2019. |
|---|
|
|
P1136-4-AM. Examination about the effect that low blood pressure gives to renal failure by the cisplatin 近野祐里1, 中島彰信1, 八尾尚樹1, 大辻貴司1, 中村直美1, 塩田哲広2, 北居千明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1136-1136, 2019. |
|---|
|
|
P1137-4-AM. Search of the nephropathic progress prediction at the cisplatin repeated treatment and effect factor 堀田拓海1, 井澤春香1, 福島恵造1, 池村舞1, 安藤基純1, 富井啓介3, 池末裕明2, 橋田亨2, 杉岡信幸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1136-1136, 2019. |
|---|
|
|
P1138-4-AM. Investigation of the effect that administration of anticholinergic drug atropine gives to neutropenia of irinotecan 田中広大1, 胎中博行1, 中井梨郁1, 市川知加子1, 段松雅弘1, 田中聡1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1137-1137, 2019. |
|---|
|
|
P1139-4-AM. Relative investigation with the hand-and-foot syndrome incidence of docetaxel treated patients and disease severity and the indoor environment 内田敬1, 土屋雅美1, 猪岡京子1, 村川康子2, 高村千津子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1137-1137, 2019. |
|---|
|
|
P1140-4-AM. Analysis - from background investigation - PMDA adverse drug reaction database (JADER) of the patients who developed peripheral neuropathy by Oxaliplatin 橋本竜1,2, 前澤佳代子1,2,3, 三浦遥花3, 本多珠里都3, 車田聡美3, 櫻井梨那3, 佐藤晴香3, 杉山奈津子1,3, 伊東岳2,3, 加藤芳徳3, 倉本敬二2,3, 百瀬泰行1,2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1138-1138, 2019. |
|---|
|
|
P1141-4-AM. Examination about HBV reactivation measures in the cancer chemotherapy 稲葉真実1, 彦坂麻美1, 田代匠1, 市川竜太郎1, 鬼木紘実1, 滝久司1, 高木亮1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1138-1138, 2019. |
|---|
|
|
P1142-4-AM. About an approach of our hospital for the hand-and-foot syndrome in the side effect management team of the liver cancer treatment molecules target medicine 田中智啓1, 近藤理絵1, 太田あづさ1, 河原香織1, 日生下美紀1, 西窪奈津子1, 吉田直恵1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1139-1139, 2019. |
|---|
|
|
P1143-4-AM. Factor to have an influence on the serum lipid after the goserelin administration in men with prostate cancer 桐生浩子1, 有松冴1, 池口麻由子1, 近藤加奈子1, 原美由紀1, 不破朱里1, 今西義紀1, 橋本陽1, 小出哲朗1, 堀田康広2, 木瀬英明3, 伊藤久美子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1139-1139, 2019. |
|---|
|
|
P1144-4-AM. Neutropenia with the FP therapy in patients with cancer of the esophagus, investigation about the FN onset 熊澤里美1, 松岡宏2, 平岡佳子1, 村松直幸1, 山田成樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1140-1140, 2019. |
|---|
|
|
P1145-4-AM. Effect on peripheral blood humans immune system of Chinese medicine - supplementary agent - used for patients with cancer and comparison of the characteristic between the preparation maker 清海杏奈1, 松田彩花1, 今井志乃ぶ1, 杉浦宗敏1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1140-1140, 2019. |
|---|
|
|
P1146-4-AM. Bowel control intervention effect of the ward pharmacist in the CHOP and THP - COP therapy 水岡大策1, 山口佳津騎1, 高橋功一1, 元木貴大1, 鈴木聖1, 田中裕章1, 加地雅人1, 小坂信二1, 芳地一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1141-1141, 2019. |
|---|
|
|
P1147-4-AM. The expression situation investigation of the dermatopathy in the liver, the pancreas domain gemcitabine and examination of the risk factor 永松秀紹1, 三島江津子1, 榊原洋一1, 小林明日美1, 中野里佳2, 村上照幸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1141-1141, 2019. |
|---|
|
|
P1148-4-AM. Association between hypothyroidism and neutrophilic/lymphocytes ratio (NLR) by the nivolumab 元日田阿子1, 中澤佑介1, 影山明1, 川久保孝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1142-1142, 2019. |
|---|
|
|
P1149-4-AM. The use situation of pregabalin duloxetine in patients with cancer 下村真代1, 濱野麻子1, 廣田紘子2, 吉野裕統1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1143-1143, 2019. |
|---|
|
|
P1150-4-AM. Examination about the association with the blood test value of patients with end-stage cancer and a painful symptom and the prognosis 小山菜々子1,2,3,4, 松村千佳子1, 佐古守人2, 黒沢秀夫2, 野村剛久2, 江口由紀3, 矢野義孝1, 大場一輝4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1144-1144, 2019. |
|---|
|
|
P1151-4-AM. Use situation investigation of the antimicrobial for the cancer terminally ill patients which discontinued the active treatment with the anticancer agent aiming at antimicrobial proper use promotion 城山亮輔1,2, 山口諒1, 山本武人1,3, 長瀬幸恵1, 高田龍平1, 鈴木洋史1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1144-1144, 2019. |
|---|
|
|
P1152-4-AM. The current situation of the heart failure palliative care screening in our hospital and future problem 舟木ひかる1,2, 鈴木澪1,2, 佐々木美理1,2, 山崎幸子1,2, 柏原千草1,2, 平山道乃1,2, 江原晶子1,2, 木村尚子1,2, 嶋中ますみ1,2, 加藤一郎1,2, 土井千春1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1145-1145, 2019. |
|---|
|
|
P1153-4-AM. Effect of the pharmacist education by a problem and the practical skill seminar of the use of Patient-Controlled Analgesia pump in the at-home relaxation medical care 山田正実1,2, 地丸裕美1, 鳥井小莉1, 松村千佳子1,2, 高橋一栄1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1145-1145, 2019. |
|---|
|
|
P1154-4-AM. About the efforts to the palliative care unit system in the drug department in our hospital and the role 矢嶋美樹1, 安田麻美1, 松木浩子1, 高橋優香1, 杉浦健一1, 藤岡敬子1, 西関由梨子1, 小林健太郎1, 小関崇文1, 鈴木由佳1, 笠井洋輝1, 加藤由紀1, 安西美咲1, 小杉英恵1, 伊藤早紀1, 横山翔一1, 大橋香菜子1, 鐘司侑希1, 大貫敏明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1146-1146, 2019. |
|---|
|
|
P1155-4-AM. Before and after exploratory single group controlled trial of the improvement effect on lassitude of patients with end-stage cancer with the L-carnitine preparation 中西順子1, 片桐将志1, 篠永浩1, 原田典和1, 加地努1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1146-1146, 2019. |
|---|
|
|
P1156-4-AM. One case of the small-cell lung cancer given VP-16+CBDCA therapy under the haemodialysis 三好孝法1, 松尾尚美1, 鶴田南奈子1, 福山誠一2, 平木洋一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1147-1147, 2019. |
|---|
|
|
P1157-4-AM. We look at the rear of the factor associated with the effectiveness of the immune checkpoint inhibitor and examine a mark 長井宏文1, 戸塚弘幸1, 高橋喜統1, 政氏藤玄1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1148-1148, 2019. |
|---|
|
|
P1158-4-AM. Competitive review of the paclitaxel administration method + ramucirumab therapy a week and the albumin suspension type paclitaxel + ramucirumab therapy for the gastric cancer 西和哉1, 川田彰彦1, 高橋舞1, 佐々木崇1, 安田勝洋2, 大堀久詔2, 佐賀利英1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1148-1148, 2019. |
|---|
|
|
P1159-4-AM. About the effectiveness of the Cetuximab administration method a week and the every other week administration method and safety 木村祐子1,2, 市村丈典1,2, 市倉大輔1,2, 縄田修一1,2, 澤田成彦3, 峯村純子1,2, 佐々木忠徳2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1149-1149, 2019. |
|---|
|
|
P1160-4-AM. Use experience of the tolvaptan for the SIADH of patients with lung cancer 桑山果織1, 伊佐治麻里子1, 白井博1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1149-1149, 2019. |
|---|
|
|
P1161-4-AM. Efforts for the prescription trend of the CDK4/6 inhibitor and the side effect management 越智良明1, 石井弘幸1, 大渕徹2, 雨宮厚2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1150-1150, 2019. |
|---|
|
|
P1162-4-AM. Promotion of the treatment with safe anticancer agent using the anticancer agent test value list 羽生智宏1, 中村槙一郎1, 財津孝希1, 瀧内瑛輔1, 長澤欣弘1, 田村亜矢子1, 尾形美絵1, 田村和彦1, 新関みどり1, 近藤和宏1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1150-1150, 2019. |
|---|
|
|
P1163-4-AM. Construction of the Olaparib administration system in consideration for a genetic information 原田智子1, 柿原圭佑1, 三上忠司1, 野田聖奈子1, 白石亘1, 松崎雄1, 武田なつか1, 篠崎千尋1, 松本美紅1, 藤井裕史1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1151-1151, 2019. |
|---|
|
|
P1164-4-AM. Efforts and usefulness evaluation of "the clinical academic working group" 徳留章1,2, 齋藤靖弘1,2, 齋藤駿太1, 金崎修治1, 出内秀樹1, 木曽陽一1, 木明貴幸1, 武田清孝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1151-1151, 2019. |
|---|
|
|
P1165-4-AM. The current situation investigation about the HBV reactivation measures in patients who received chemotherapy 水嶋萌美1, 塚本絢子1, 渡辺麻里子1, 草信晴美1, 滝波昇悟1, 監物英男1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1152-1152, 2019. |
|---|
|
|
P1166-4-AM. Metabolic loam analysis of the metabolite out of the renal carcinoma tissue 高崎新也1, 佐藤友紀2, 川崎芳英2, 前川正充1, 三枝大輔1,3, 伊藤明宏2, 眞野成康1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1152-1152, 2019. |
|---|
|
|
P1167-4-AM. Investigation about the factor enabling long-term continuation of the unresectable progress pancreatic cancer GEM + nabPTX therapy 小竹正晃1, 坂井由紀1, 新木貴大1, 鈴木直人1, 外山聡1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1153-1153, 2019. |
|---|
|
|
P1168-4-AM. Cytotoxic comparison for F11 cells derived from sensory nerve with oxaliplatin and fluorouracil 山下郁太1, 入江圭一1, 山口愛貴1, 池帆花1, 下川拓郎1, 松尾宏一2, 林稔展2, 高瀬友美2, 三島健一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1153-1153, 2019. |
|---|
|
|
P1169-4-AM. Examination of the factor that a pharmacist racks the brains about in the communication between patients with cancer - pharmacists 亀田祥代1, 北村佳久1,2, 正岡康幸2, 藤本みなみ1, 千堂年昭1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1154-1154, 2019. |
|---|
|
|
P1170-4-AM. A treatment result of Nivolumab for progress, the recurrent gastric cancer in our hospital and examination of the effect predictor 小山加奈世1, 阿部史誉1, 中山英夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1154-1154, 2019. |
|---|
|
|
P1171-4-AM. Examination of the effect that a history of cigarette smoking gives for an effect of the antiPD-1 antibody medicine 小中健1,2, 斉藤辰彦1,2, 宮森弘子1,2, 森剛志1, 森本美由樹2, 柿内聡司3, 伏谷秀治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1155-1155, 2019. |
|---|
|
|
P1172-4-AM. Efforts of the appearance care team pharmacist 小林華南子1, 岡部真実1, 向井さや香2, 山本智子2, 玉井恭子2, 三好真由子2, 仙波昌三1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1155-1155, 2019. |
|---|
|
|
P1173-4-AM. Recognition investigation for the pharmacist specialized in cancer in the cancer special hospital 藤田行代志1, 新井隆広1, 三島八重子1, 齊藤妙子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1156-1156, 2019. |
|---|
|
|
P1174-4-AM. A preparation comparison of the vascular pain by the gemcitabine and examination of the risk factor 田路章博1, 田中麻理子1, 八瀬恵理子1, 西村真美1, 南山啓吾1, 砂金秀美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1156-1156, 2019. |
|---|
|
|
P1175-4-AM. Fact-finding about the quantity of duties of a cancer chemotherapy preparation room and the cancer chemotherapy center 稲野寛1, 森元能仁2, 佐々木寿子1, 長澤知徳3, 臼井浩明3, 吉田正3, 渡部一宏3, 廣原正宜3, 篠原高雄3, 厚田幸一郎1,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1157-1157, 2019. |
|---|
|
|
P1176-4-AM. Examination of the renal function improvement effect accompanied with the chemotherapy enforcement for patients with first multiple myeloma 中川隼一1, 大場理恵2, 岡田悠美1, 安藤尚美1, 桝茂典1, 高橋苑子1, 茂原圭佑1, 皆川卓也1, 蔭山博之1, 土橋史明2, 平島徹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1157-1157, 2019. |
|---|
|
|
P1177-4-AM. 1 case with suspected drug fever with the antimicrobial 渡貫悠1,2,3,4, 霍間尚樹2, 岩田昌英3, 山本剛4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1158-1158, 2019. |
|---|
|
|
P1178-4-AM. About efforts and the evaluation of the antimicrobial proper use support team activity 管田彩乃1, 下向井唯希1, 神谷真悟1, 岡村智文1, 梅野尚生1, 小川丈彦1, 田口みどり1, 船越幸代1, 田代紀陸2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1159-1159, 2019. |
|---|
|
|
P1179-4-AM. An approach and the effect that we applied to adequacy of the infection prophylaxis antimicrobial after the operation in our hospital 中川綾1, 伊藤智一1, 阪上貴子1, 鈴木信也1, 林誠一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1159-1159, 2019. |
|---|
|
|
P1180-4-AM. Efforts to proper use of the oral antimicrobial in the association of government official cooperative association society Rokko Hospital 宮川裕子1,2, 安保博文2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1160-1160, 2019. |
|---|
|
|
P1181-4-AM. Efforts to proper use of the oral third cephem-based antimicrobial 横田学1, 片岡万里奈1, 榊原洋一1, 村上照幸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1160-1160, 2019. |
|---|
|
|
P1182-4-AM. Investigation of the use of oral antimicrobial situation of the Anjo rebirth hospital for the AMR measures action plan 神谷祥世1, 奥平正美1, 伊藤友恵1, 澤田和久1, 土井裕一1, 鵜飼茜1, 小野内拓也1, 杉浦洋二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1161-1161, 2019. |
|---|
|
|
P1183-4-AM. Effect on marker HMGB1 examination of the thrombomodulin derived from sepsis using QCM 中野貴文1,2,3, 松山清4, 安村真子2, 西上知佐2, 野田尚子2, 入江圭一2, 山下郁太2, 仲村佳彦5, 兼重晋3, 神村英利1,3, 三島健一2, 江川孝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1161-1161, 2019. |
|---|
|
|
P1184-4-AM. Examination about the effectiveness of the antiMRSA medicine in the perioperative period of the artificial joint reimplantation for the delayed-action artificial joint neighborhood infection 高田昂輔1,2, 染谷梨沙1,2, 六鹿和子3, 田中佐知子3, 詫間章俊1,2, 内倉健1, 縄田修一1,2, 前田昭彦4, 川崎恵吉4, 木村聡5, 峯村純子1,2, 佐々木忠徳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1162-1162, 2019. |
|---|
|
|
P1185-4-AM. One patient who experienced treatment with voriconazole for Scedosporium apiospermum infection 元木貴大1, 松永圭司2, 山口佳津騎1, 山下紗矢佳1, 水岡大策1, 田井達也1, 加地雅人1, 小坂信二1, 南野哲男2, 芳地一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1162-1162, 2019. |
|---|
|
|
P1186-4-AM. Efforts for the current situation investigation and the antimicrobial adequacy of the perioperative clinical path 上田秀親1, 嶋俊弥1, 高橋麻衣子1, 政井恵1, 小林和正1, 若田達朗1, 和田泰明1, 小島圭太郎2, 石塚恭平3, 高橋洋城4, 白子順子5, 西尾優5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1163-1163, 2019. |
|---|
|
|
P1187-4-AM. Clostridioides difficile infection (CDI) treatment algorithm making and the evaluation 久田瑛吉1, 加藤洋介1, 前田直樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1163-1163, 2019. |
|---|
|
|
P1189-4-AM. The organized activity by the ICT including the promotion of the antimicrobial proper use can improve chemosensitivity of Pseudomonas aeruginosa 山本稔1,2, 中野紗央里1,2, 峯麻紀子1,5, 山口誠1,3, 北原美江1,3, 松原祐一1,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1164-1164, 2019. |
|---|
|
|
P1190-4-AM. Examination about the use of daptomycin for the methicillin-resistant Staphylococcus epidermidis (MRSE) bacteremia 平山忍1,2, 太田登志子1,2, 白根尚子1,2, 松尾和廣3, 中山晴雄2, 日浦寿美子1, 松瀬厚人2, 小林秀樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1165-1165, 2019. |
|---|
|
|
P1191-4-AM. Effective evaluation of the cefmetazole for ESBL-producing bacteria 門野健二1, 天野祐太1, 齊藤彩子1, 武田龍馬1, 本間和加子1, 山澤裕司1, 中村博彦2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1165-1165, 2019. |
|---|
|
|
P1192-4-AM. It is made the infection prophylaxis antimicrobial adequate after the operation of the ward pharmacist-led clinical path 平野美優1, 巽弥生1, 奥野昌宏1, 田中詳二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1166-1166, 2019. |
|---|
|
|
P1193-4-AM. Examination about the epidemiological clinical features and prognostic factor of the Candida bloodstream infection 塚本仁1, 東高士1, 新谷智則1, 末廣陽子1, 五十嵐敏明1, 古俵孝明1, 上谷幸男1, 渡邉享平1,2, 矢野良一1, 飛田征男3, 岩崎博道4, 後藤伸之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1167-1167, 2019. |
|---|
|
|
P1194-4-AM. The effect on antimicrobial choice of the acute biliary tract infection based on a protocol and clinical outcome evaluation 杢保貴幸1, 大西優里1, 石井康友2, 植田宏治3, 松岡裕士4, 徳竹裕貴1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1167-1167, 2019. |
|---|
|
|
P1195-4-AM. Making and evaluation of the vomit processing set manual in the pharmacy service under health insurance drugstore which aimed at the appropriate vomit processing and the education tool 石原義久1, 竹内正幸2, 石原知香枝1, 柏木宏仁2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1168-1168, 2019. |
|---|
|
|
P1196-4-AM. Investigation of the use of antimicrobial situation after the antimicrobial proper use support team activity start in our hospital 吉田愛1, 山口泰弘1, 中嶋浩太郎1, 中村敦士1, 浦本邦弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1168-1168, 2019. |
|---|
|
|
P1197-4-AM. Efforts of the AST activity using the balun strike scorecard 遠藤修司1, 吉田ミチル1, 斎藤菜穂子1, 冨樫真澄1, 高山芙実子1, 青山寿美香1, 平岩知子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1169-1169, 2019. |
|---|
|
|
P1198-4-AM. 2 cases of the adult Still disease that led to early diagnosis with the consultation to the antimicrobial proper use support team 天野哲史1,2, 生田幸江1,3, 太田晃成1,4, 稲塚信郎1,5, 大橋禎史1,6, 服部晃左1,7, 板倉由縁2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1169-1169, 2019. |
|---|
|
|
P1199-4-AM. An effect after the AS activity start and future problem 久保智士1, 芦澤穂波1, 土本寛子1, 鶴崎亮1, 木村真策1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1170-1170, 2019. |
|---|
|
|
P1200-4-AM. Antimicrobial Stewardship led by the ward pharmacist 杉沢拓磨1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1170-1170, 2019. |
|---|
|
|
P1201-4-AM. About an activity of antimicrobial proper use support team (AST) in the Osaka acute phase, comprehensive medical care center 岩崎瑛子1, 濱名哲大1, 奥村直生1, 綛谷哲也1, 村井千恵1, 坂上嘉浩1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1171-1171, 2019. |
|---|
|
|
P1202-4-AM. Chemosensitive tendency and trend of Staphylococcus lugdunensis isolates 小林宇太郎1, 金内弘志2, 後藤彰公2, 小山田純治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1171-1171, 2019. |
|---|
|
|
P1203-4-AM. Examination of the perioperative prophylactic antimicrobial of the urologic domain by the cefazolin supply difficulty 根上朋子1, 吉岡睦展1, 杉生雅和1, 石津智司1, 古倉浩次2, 福井浩二2, 大嶋浩一2, 赤木直紀2, 小林敦子3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1172-1172, 2019. |
|---|
|
|
P1204-4-AM. It is ... for adequacy of the Antimicrobial Stewardship activity ... oral antimicrobial of our hospital 石津智司1, 吉岡睦展1, 若松雄太1, 小澤拓1, 杉生雅和1, 高子優子1, 小林敦子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1172-1172, 2019. |
|---|
|
|
P1205-4-AM. The HIV merger product womb pregnant woman case's experience 二星知紗1, 門倉史枝1, 大谷美奈子1, 見上千昭1, 本間久美子1, 西尾孝1, 國東ゆかり1, 松尾裕央2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1173-1173, 2019. |
|---|
|
|
P1206-4-AM. It is the experience using the zidovudine injection drug for the fetomaternal infection prevention of the HIV product womb pregnant woman 門倉史枝1, 二星知紗1, 大谷美奈子1, 見上千昭1, 本間久美子1, 西尾孝1, 國東ゆかり1, 松尾裕央2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1174-1174, 2019. |
|---|
|
|
P1207-4-AM. The current situation investigation of the polypharmacy in the HIV infected person 治田匡平1, 青井博志1, 川崎裕貴1, 古西満2, 辻力夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1174-1174, 2019. |
|---|
|
|
P1208-4-AM. A dose choice of central venous hyperalimentation and the amino acid preparation in the small and medium size hospital and effect on PT-INR 清水忠洋1, 城綾香1, 浅川真由美1, 斎藤安昌1, 曽根原亘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1175-1175, 2019. |
|---|
|
|
P1209-4-AM. Nourishment management of the gastrointestinal carcinoma perioperative period: Effect of the nutrient preparation containing the fatty acid of n-3 origin 鈴木彰人1, 白尾一定2, 本吉佳世3, 武田朋子3, 花牟禮富美雄4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1176-1176, 2019. |
|---|
|
|
P1210-4-AM. Look at the rear of the hypozincaemia-induced possibility drug remedy situation for the blood zinc low level patients; mark investigation 大塚愛美1, 河村聡志1, 森一生1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1176-1176, 2019. |
|---|
|
|
P1211-4-AM. About practice and the effect of the medication self-care module 佐合絵里1, 川崎早容1, 川崎智弘2, 西川満里子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1177-1177, 2019. |
|---|
|
|
P1212-4-AM. Prescription pulse-taking of the aperient for the antipsychotics-induced gastrointestinal disorder in our hospital 谷口美紘1, 波多野正和1,2, 松崎遥菜1, 深谷麻実1, 山田成樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1178-1178, 2019. |
|---|
|
|
P1213-4-AM. Population pharmacokinetics analysis of Clozapine and the active metabolite: Hospitalization, foreign effect 小岸かれん1,2, 大村友博1,3, 山本将太1, 中川俊作1, 米澤淳1,2, 糸原光太郎1,2, 竹内理人1,2, 松尾研志1,2, 橋本凱朝1,2, 諏訪太朗4, 佐藤夕紀1, 今井哲司1, 中川貴之1, 村井俊哉4, 矢野育子1,3, 松原和夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1178-1178, 2019. |
|---|
|
|
P1214-4-AM. The night delirium case that quetiapine succeeded 谷口結基1, 白水将憲1, 森智世1, 田中美帆1, 太田達也1, 田中章郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1179-1179, 2019. |
|---|
|
|
P1216-4-AM. Analysis of the factor to require iron medicine, folic acid combined treatment in anemia of the pregnancy treatment of the early or threatened labour patients needing ritodrine intravenous feeding 長谷川京子1, 神田紘介1, 長谷川ゆり1, 三浦清徳1, 橋詰淳哉1, 兒玉幸修1, 中村忠博1, 佐々木均1, 室高広1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1180-1180, 2019. |
|---|
|
|
P1217-4-AM. It is a 1 case using tacrolimus for autoimmune disease during pregnancy 加島朱梨1, 藤川郁世1, 永井絵里子1, 松原侑紀1, 庵森靖弘1, 三島芳枝1, 大津由美子1, 望月千枝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1181-1181, 2019. |
|---|
|
|
P1218-4-AM. One case of the heparin calcium self injection for the obstructive venous thrombosis merger pregnancy patients 廣田あゆ子1, 出宮千聖1, 新城唯1, 河村茉衣1, 松本和也1, 渋川昇平2, 田中正道3, 福家聡一郎3, 森英樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1181-1181, 2019. |
|---|
|
|
P1219-4-AM. Relations with an effect factor and the nicardipine cumulative dose of the postpartum hypertension emergency symptom onset 野木山史恭1, 大谷弥生1, 山崎布美子1, 相馬まゆ子1, 佐々木洋一1, 今田愛也2, 猪爪信夫2, 永井匠3, 能代究3, 藤枝聡子3, 計良光昭3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1182-1182, 2019. |
|---|
|
|
P1220-4-AM. Examination of the kidney protection according to the CKD classification in the dapagliflozin 西村功史1, 花井雄貴1, 山西由里子1, 松尾和廣2, 坂本真紀1, 西澤健司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1183-1183, 2019. |
|---|
|
|
P1221-4-AM. The effectiveness of change cases from the DPP-4 inhibitor in patients with type 2 diabetes to Dulaglutide and safe examination 吉野さつき1, 早川伸樹1,2, 津川透1,3, 福井愛子1, 亀井浩行1, 牧野真樹2, 良元亮2, 鈴木敦詞2, 山田成樹3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1184-1184, 2019. |
|---|
|
|
P1222-4-AM. Examination of the lipid improvement effect of the SGLT2 inhibitor on patients with type 2 diabetes 田中壮周1, 大橋史嵩1, 臼窪一平1, 丸山卓哉1, 及川華代1, 田畑裕和1, 稲垣育宏1, 小寺隆二1, 柴波明男1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1184-1184, 2019. |
|---|
|
|
P1223-4-AM. The usefulness of the SGLT2 inhibitor in patients with type 2 diabetes and safe examination 小林雅弘1, 早川伸樹1,2, 津川透1,3, 福井愛子1, 亀井浩行1, 吉野寧維2, 岡本慧子2, 鈴木敦詞2, 山田成樹3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1185-1185, 2019. |
|---|
|
|
P1224-4-AM. Dispatch to the area that it merged on efforts world diabetes day in our hospital for diabetes 河村紳介1, 那須田沙織3, 丸井志織3, 原田雅子3, 中村正光5, 芝原裕和5, 岡本貴美子6, 鈴木聡史4, 安江誠人4, 槇野裕也2, 大石祐子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1185-1185, 2019. |
|---|
|
|
P1225-4-AM. The attitude survey about the hypoglycemia measures of patients with diabetes and future problem 岸孝行1, 中尾倫子1, 間宮知子1, 吉岡厚子1, 山田初美2, 森下加惠3, 政次健3, 樫葉利人1, 花岡郁子3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1186-1186, 2019. |
|---|
|
|
P1226-4-AM. Relation of the pharmacist to the patients whom an insulin ball developed in by long-term insulin administration 古川佳子1, 西村信弘1,2, 玉井杏奈1, 倉永勇希1, 古家紗希1, 山口亜里沙1, 宗像千恵1,2, 塚本真大3, 和泉賢一3, 小野恭裕3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1186-1186, 2019. |
|---|
|
|
P1227-4-AM. Efforts of the pharmacist in the dementia care team 中野剛志1, 安井友佳子1, 階堂三砂子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1187-1187, 2019. |
|---|
|
|
P1228-4-AM. About the effect that the anticholinergic agent in the polypharmacy patients, medicine decreasing by it of the benzodiazepine system medicine give for rehabilitation outcome 高田恵司1, 鬼木健太郎2, 松本庄平3, 横田美有1, 畑田雄一1, 猿渡淳二2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1188-1188, 2019. |
|---|
|
|
P1229-4-AM. Taking benzodiazepine drugs in the femur fracture inpatient and the current situation of the polypharmacy 小原朋也1, 片原憂斗1, 瀧川美和1, 島崎良知1, 森淑子1, 石川讓治2, 岩切理歌3, 時村文秋4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1188-1188, 2019. |
|---|
|
|
P1230-4-AM. Examination about the renal function evaluation in elderly people less than serum creatinine level 0.6 mg/dL 田畑貴康1, 福田もえ1, 宮本晃輔1, 岸本千絵1, 山口伸二1, 原圭子1, 山下秀之1, 中村徹志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1189-1189, 2019. |
|---|
|
|
P1231-4-AM. Of the bone fracture protective efficacy after the teriparatide administration actually arrive 城戸美恵子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1190-1190, 2019. |
|---|
|
|
P1233-4-AM. It is a 2 case using Apixaban after the transcatheter aortic valve replacement enforcement 水野稜子1, 谷口仁孝1, 山本彩佳1, 千葉恵美子1, 渡邉美樹1, 前川知子1, 坂井愛実1, 前田典子1, 小原祐子1, 徳村博子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1191-1191, 2019. |
|---|
|
|
P1234-4-AM. Examination of the clinical response of the Hochuekkito after the pneumonectomy 廣瀬達也1, 黒田彩夏1, 篠田康孝1,2, 三岡麻千子1, 森光輝1, 川地雄基1, 守屋昭宏1, 田中孝治1, 竹田亜子1, 宇佐美英績1, 杉山正2, 吉村知哲1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1192-1192, 2019. |
|---|
|
|
P1235-4-AM. Factor examination, analysis of the cerebrovascular spasm onset under the cilostazol administration in patients with subarachnoid hemorrhage 天野祐太1, 門野健二1, 吉田美咲1, 武田龍馬1, 山澤裕司2, 本間和加子1, 上山憲司3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1192-1192, 2019. |
|---|
|
|
P1236-4-AM. Examination about the predictive index of the weight and the BNP decrease in tolvaptan introduction case for the heart failure 篠田梨恵1, 篠田康孝1, 森卓之1, 吉村知哲1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1193-1193, 2019. |
|---|
|
|
P1237-4-AM. About the relation of the pharmacist to proximal thighbone bone fracture re-bone fracture prevention support service in our hospital 富樫博敬1, 河原香織1, 日生下美紀1, 西窪奈津子1, 吉田直恵1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1193-1193, 2019. |
|---|
|
|
P1238-4-AM. After the operation with participation - perioperative care of the pharmacist in the anesthesia management of the atrial fibrillation ablation effect on awakening - 黒岩亮平1,3, 平尾龍彦2, 井口恵美子1, 加藤裕久3, 猪股克彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1194-1194, 2019. |
|---|
|
|
P1239-4-AM. A report and examination of the minocycline infusion sclerotherapy through the drainage tube in the huge hepatic cyst 竹野孝慶1, 本田博樹2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1194-1194, 2019. |
|---|
|
|
P1240-4-AM. Usefulness of the morphine injection drug in patients with terminal heart failure, - including the investigation - impaired renal function merger case about the safety 西村健二1, 小林晃子1, 亀井健人1, 高柳和伸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1195-1195, 2019. |
|---|
|
|
P1241-4-AM. Efforts in the area for the local inclusion care systems construction 伊東健一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1196-1196, 2019. |
|---|
|
|
P1242-4-AM. Pharmacist dispatch from a university hospital aiming at community medical care cooperation to the community hospital 龍田涼佑1, 炭本隆宏1, 田中遼大1, 中原良介1, 佐藤雄己1, 伊東弘樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1197-1197, 2019. |
|---|
|
|
P1243-4-AM. It is ... through discharge support in thing - NICU/GCU which is made to connect to the treatment at home 大西知絵1, 勝弘毅1, 溝口和代1, 阿部康治1, 内薗広匡2, 栗本淳子3, 林眞砂子4, 寺田幸司5, 小林竜也5, 石垣孝5, 服部文乃5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1197-1197, 2019. |
|---|
|
|
P1244-4-AM. Questionary survey about the infection measures for drugstore pharmacists 中山雅裕1, 安田恵1, 天野学1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1198-1198, 2019. |
|---|
|
|
P1245-4-AM. The number of doubt inquiries after the prior agreement protocol operation of the outside Parliament prescription 矢野涼子1, 間瀬広樹1, 室谷理沙1, 杉村勇人1, 河崎文洋1, 坂野由宇希2, 村田世里子2, 齋藤讓一1, 秋山哲平1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1199-1199, 2019. |
|---|
|
|
P1246-4-AM. Effect on health insurance pharmacy duties of the outside Parliament prescription inquiry simplification protocol 村川公央1, 猪田宏美1, 西原茂樹1, 北村佳久1, 千堂年昭1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1200-1200, 2019. |
|---|
|
|
P1247-4-AM. Comparison of the medication reporting book in the community-acquired acute phase hospital 小川充恵1, 大里恭章3, 井上麻衣1, 小枝伸行2, 山崎肇1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1200-1200, 2019. |
|---|
|
|
P1248-4-AM. Efforts (the second report) of the medicine medicine cooperation in the Komaki Municipal Hospital 水谷貴樹1,2, 山本泰大1,2, 山本将司1,2, 戸田康裕1,2, 仲井伸子2,3, 松山苑未2,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1201-1201, 2019. |
|---|
|
|
P1249-4-AM. Efforts of the medicine medicine cooperation through the prescription analysis in the Soka medical therapy workshop 村社計寿1,10,11, 森田元2,10,11, 山崎あすか3,10,11, 増田怜平1,10, 青木悠一4,10,11, 大石卓也5,10,11, 葉山智恵6,10,11, 岸岡奈実7,10,11, 鮎澤道代8,10,11, 木村直也1,10,11, 須鴨一正9,10,11, 源川良一1,10,11 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1201-1201, 2019. |
|---|
|
|
P1250-4-AM. About the improvement of duties by the protocol making of doubt inquiry 豊田悠希1, 小松沙妃1, 加藤あゆみ1, 武方みなみ1, 松本大輝1, 篠原正樹1, 星加寿子1, 矢野琢也1, 谷崎文彦1, 福岡竜逸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1202-1202, 2019. |
|---|
|
|
P1251-4-AM. About the doubt inquiry protocol making in the outside Parliament prescription 鈴山直人1, 高島伸也2, 湊本康則1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1202-1202, 2019. |
|---|
|
|
P1252-4-AM. About outside Parliament prescription doubt inquiry simplification protocol introduction in the Kyoritsu Kanbara General Hospital and the effect 渡辺俊輔1, 竹下秀司1, 久保田倫代1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1203-1203, 2019. |
|---|
|
|
P1253-4-AM. Role of the issue of Residual medicine and the hospital pharmacist whom an outpatient has 松田一駿1, 堀絵理1, 中村雄太郎1, 眞木秀子1, 板垣有紀1, 羽太光範1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1203-1203, 2019. |
|---|
|
|
P1254-4-AM. How did doubt inquiry change by the test value printing of the outside Parliament prescription? 小島一晃1, 松永富美代2, 山村裕佳子1, 森川智子1, 林愛華1, 濱武清範1, 野間敏也1, 酒井ちひろ1, 松本弘誠1, 中西輝1, 小西史子1, 仲忠士1, 美和孝之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1204-1204, 2019. |
|---|
|
|
P1255-4-AM. Efforts for the proper use of the potassium preparation in our hospital 丘龍祥1,2, 稲毛あずさ1, 金野昇1, 山口浩明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1205-1205, 2019. |
|---|
|
|
P1257-4-AM. Efforts of the potentially serious medical errors recurrent prevention in our hospital pharmacy 佐倉小百合1, 大前隆広1, 上田里恵1, 國東ゆかり2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1206-1206, 2019. |
|---|
|
|
P1258-4-AM. Search of the factor factor of the potentially serious medical errors in the health insurance pharmacy 佐々木善信1, 羽田明浩2, 平山武司1,3, 厚田幸一郎1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1207-1207, 2019. |
|---|
|
|
P1259-4-AM. Efforts about the management of the use of pharmaceutical products such as nonrecognition, and the like in Kanazawa University Hospital 板井進悟1, 山本奈歩1, 川岸篤史1, 原祐輔1, 増江俊子1,2, 嶋田努1, 崔吉道1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1207-1207, 2019. |
|---|
|
|
P1261-4-AM. Participation of the medical drug incident report example and pharmacist in the palliative care hospital 椎崎正秀1,2, 原口勝3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1208-1208, 2019. |
|---|
|
|
P1262-4-AM. Investigation about the result of a doubt inquiry for the prescription of the resident in the emergency visit and the efforts of the pharmacy 向山直樹1, 向山麻衣子1, 成瀬徳彦1, 黒野康正1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1209-1209, 2019. |
|---|
|
|
P1263-4-AM. The learning effect using the monitoring sheet of 8 representative diseases in the ward training and evaluation of the satisfaction 安藤久美子1, 島忠光1, 河島雄大1, 浅木知子1, 中島圭佑1, 榎本弘美1, 渡部多真紀1,2, 河村剛至1,2, 安野伸浩1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1210-1210, 2019. |
|---|
|
|
P1264-4-AM. Because when the business training in the new core curriculum begins, ... student participates in team approach in medical care, by all means from a visit to an experience 渡邉正教1, 中沢修司1, 日比徹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1211-1211, 2019. |
|---|
|
|
P1265-4-AM. Establishment of the system of the outline evaluation based on the diachronic instruction record of person in charge of ward training patients 新井亘1, 土屋裕伴1, 増田裕一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1211-1211, 2019. |
|---|
|
|
P1266-4-AM. The effect that the number of the experience of 8 representative diseases in the pharmacy business training gives for an outline evaluation 清宮啓介1, 池淵由香1, 津田壮一郎1, 別府紀子1, 青森達1,2, 鈴木小夜3, 地引綾3, 横山雄太3, 河添仁3, 岩田紘樹3, 小林典子3, 藤本和子3, 早川智久1, 山浦克典3, 中村智徳3, 村松博1, 望月眞弓2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1212-1212, 2019. |
|---|
|
|
P1267-4-AM. The effect that the early clinical experience in the hospital gives to the occupational interest of the first annual student 永田実沙1, 串畑太郎1, 上田昌宏1, 栗尾和佐子1, 安原智久1, 曽根知道1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1213-1213, 2019. |
|---|
|
|
P1268-4-AM. The effect that the communication education utilizing the simulated patient gives in a skill, the manner in the practice curriculum of the pharmacy student in 4 annual 福井愛子1, 半谷眞七子1, 伊東亜紀雄1, 黒野俊介1, 野田幸裕1, 吉見陽1, 亀井浩行1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1214-1214, 2019. |
|---|
|
|
P1269-4-AM. Significance of the anti-doping education utilizing the active learning for the pharmacy school student 杉山育美1, 佐塚泰之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1214-1214, 2019. |
|---|
|
|
P1270-4-AM. It is ... including the duties cooperation with ... nursing department about the review of the duties contents by the change of the injection drug withdrawal device 小山晃生1, 谷口朝香1, 前北章衣1, 江藤恭子1, 木村泰巳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1215-1215, 2019. |
|---|
|
|
P1271-4-AM. In examination - construction fourth year of new face education system in our hospital, we were able to see it from reflection 樋本繭子1, 日原章詔1, 木村有子1, 新免徹1, 高瀬尚武1, 三木育子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1216-1216, 2019. |
|---|
|
|
P1272-4-AM. It is ... about a qualification and the staff education of efforts ... staff of the pharmacy for the JCI certification 田中博和1, 山下大貴1, 馬島礼1, 立石裕樹1, 後藤貴央1, 與田賢作1, 秋吉正貴1, 宮津大輔1, 井上幸子1, 平川雅章1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1216-1216, 2019. |
|---|
